date generated: 2020-07-14

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

##                rna       meth
## A2M      0.6662719 -1.9577707
## A3GALT2 -0.7307640  0.6904985
## A4GALT   1.5792346 -0.6623122
## AAAS     1.2886140  0.1999249
## AACS    -1.1333351 -0.4966348
## AAED1    0.9638579  0.3271153

Here are some metrics about the input data profile:

Profile metrics
Profile metrics
num_genes_in_profile 10950
duplicated_genes_present 0
num_profile_genes_in_sets 6266
num_profile_genes_not_in_sets 4684
profile_pearson_correl -0.01047
profile_spearman_correl -0.0044

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt

Gene sets metrics
Gene sets metrics
num_genesets 2400
num_genesets_excluded 1155
num_genesets_included 1245

Gene sets by quadrant


Number of significant gene sets (FDR<0.05)= 333

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

set setSize pMANOVA p.adjustMANOVA s.dist s.rna s.meth p.rna p.meth
Leading Strand Synthesis 12 1.02e-05 9.80e-05 0.799 0.795 0.081100 1.87e-06 0.62700
Polymerase switching 12 1.02e-05 9.80e-05 0.799 0.795 0.081100 1.87e-06 0.62700
DNA strand elongation 23 3.42e-10 1.52e-08 0.795 0.792 -0.069100 4.70e-11 0.56600
Lagging Strand Synthesis 16 6.65e-07 8.44e-06 0.770 0.766 0.076100 1.13e-07 0.59800
Inhibition of replication initiation of damaged DNA by RB1/E2F1 12 3.25e-05 2.77e-04 0.757 0.670 0.351000 5.81e-05 0.03540
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 12 4.04e-05 3.29e-04 0.749 0.728 0.177000 1.26e-05 0.28800
Processive synthesis on the lagging strand 12 4.89e-05 3.76e-04 0.742 0.740 0.061000 9.04e-06 0.71500
Removal of the Flap Intermediate 11 1.21e-04 8.51e-04 0.740 0.739 -0.016100 2.17e-05 0.92600
GP1b-IX-V activation signalling 10 4.99e-04 2.86e-03 0.712 -0.710 0.063800 1.02e-04 0.72700
E2F mediated regulation of DNA replication 18 1.50e-06 1.76e-05 0.703 0.550 0.438000 5.32e-05 0.00129
PCNA-Dependent Long Patch Base Excision Repair 15 2.47e-05 2.24e-04 0.686 0.660 0.187000 9.52e-06 0.21100
Translesion Synthesis by POLH 10 8.83e-04 4.64e-03 0.684 0.634 0.255000 5.14e-04 0.16200
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 12 2.91e-04 1.84e-03 0.672 0.651 0.168000 9.53e-05 0.31300
Heme biosynthesis 11 6.77e-04 3.68e-03 0.664 0.615 0.252000 4.16e-04 0.14800
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 12 3.69e-04 2.24e-03 0.661 0.522 0.406000 1.73e-03 0.01500
Mismatch Repair 13 3.06e-04 1.91e-03 0.644 0.612 0.200000 1.34e-04 0.21300
Condensation of Prophase Chromosomes 10 2.07e-03 1.01e-02 0.641 0.414 0.489000 2.34e-02 0.00744
G1/S-Specific Transcription 23 7.67e-07 9.65e-06 0.639 0.619 0.155000 2.72e-07 0.19700
Initiation of Nuclear Envelope (NE) Reformation 14 1.91e-04 1.29e-03 0.638 0.579 0.268000 1.77e-04 0.08320
Gap-filling DNA repair synthesis and ligation in GG-NER 17 4.62e-05 3.64e-04 0.625 0.610 0.139000 1.34e-05 0.32300
Formation of the ternary complex, and subsequently, the 43S complex 17 4.66e-05 3.65e-04 0.625 0.610 0.136000 1.33e-05 0.33200
cGMP effects 13 5.26e-04 2.98e-03 0.622 -0.615 -0.095800 1.25e-04 0.55000
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 21 5.22e-06 5.51e-05 0.621 0.579 0.225000 4.44e-06 0.07450
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 33 6.76e-09 1.56e-07 0.617 0.617 0.005820 8.60e-10 0.95400
p53-Independent DNA Damage Response 33 6.76e-09 1.56e-07 0.617 0.617 0.005820 8.60e-10 0.95400
p53-Independent G1/S DNA damage checkpoint 33 6.76e-09 1.56e-07 0.617 0.617 0.005820 8.60e-10 0.95400
Ribosomal scanning and start codon recognition 20 1.32e-05 1.23e-04 0.611 0.573 0.214000 9.23e-06 0.09770
Translation initiation complex formation 20 1.32e-05 1.23e-04 0.611 0.573 0.214000 9.23e-06 0.09770
Cross-presentation of soluble exogenous antigens (endosomes) 36 2.09e-09 6.50e-08 0.609 0.602 -0.092200 4.01e-10 0.33900
Recognition of DNA damage by PCNA-containing replication complex 18 4.75e-05 3.68e-04 0.607 0.596 0.114000 1.19e-05 0.40400
Cyclin A/B1/B2 associated events during G2/M transition 12 1.36e-03 6.81e-03 0.605 0.524 0.301000 1.67e-03 0.07090
Assembly of the pre-replicative complex 46 1.49e-11 9.77e-10 0.602 0.601 0.030400 1.78e-12 0.72200
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 17 9.68e-05 7.01e-04 0.602 0.573 0.183000 4.29e-05 0.19300
DNA Replication Pre-Initiation 58 3.00e-14 2.66e-12 0.599 0.597 0.046900 3.70e-15 0.53700
Formation of a pool of free 40S subunits 34 1.41e-08 2.83e-07 0.595 0.575 0.155000 6.72e-09 0.11700
SCF-beta-TrCP mediated degradation of Emi1 37 3.85e-09 9.60e-08 0.591 0.591 0.012700 4.88e-10 0.89300
Ubiquitin-dependent degradation of Cyclin D 35 1.64e-08 3.25e-07 0.585 0.584 0.025500 2.22e-09 0.79400
L13a-mediated translational silencing of Ceruloplasmin expression 38 3.58e-09 9.10e-08 0.584 0.552 0.190000 3.93e-09 0.04240
Regulation of activated PAK-2p34 by proteasome mediated degradation 33 5.07e-08 7.99e-07 0.583 0.583 0.020400 6.97e-09 0.84000
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 13 1.39e-03 6.90e-03 0.580 0.552 0.179000 5.71e-04 0.26300
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD 35 2.31e-08 4.28e-07 0.579 0.579 -0.003400 3.03e-09 0.97200
CDT1 association with the CDC6:ORC:origin complex 39 3.13e-09 8.22e-08 0.579 0.578 0.026200 4.08e-10 0.77700
Regulation of ornithine decarboxylase (ODC) 35 2.34e-08 4.28e-07 0.579 0.579 -0.000584 3.07e-09 0.99500
Activation of the pre-replicative complex 23 9.82e-06 9.76e-05 0.578 0.575 0.057400 1.78e-06 0.63400
Telomere C-strand (Lagging Strand) Synthesis 25 3.65e-06 3.88e-05 0.578 0.578 0.024200 5.77e-07 0.83400
Metabolism of polyamines 40 2.19e-09 6.64e-08 0.577 0.577 -0.011500 2.71e-10 0.90000
Phase 2 - plateau phase 17 2.13e-04 1.38e-03 0.575 -0.535 -0.213000 1.36e-04 0.12900
Digestion 11 4.37e-03 2.01e-02 0.574 -0.572 0.054600 1.03e-03 0.75400
Cap-dependent Translation Initiation 45 2.26e-10 1.08e-08 0.574 0.557 0.139000 1.05e-10 0.10800
Eukaryotic Translation Initiation 45 2.26e-10 1.08e-08 0.574 0.557 0.139000 1.05e-10 0.10800


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.rna s.meth p.rna p.meth
Leading Strand Synthesis 12 1.02e-05 9.80e-05 0.79900 7.95e-01 8.11e-02 1.87e-06 0.627000
Polymerase switching 12 1.02e-05 9.80e-05 0.79900 7.95e-01 8.11e-02 1.87e-06 0.627000
DNA strand elongation 23 3.42e-10 1.52e-08 0.79500 7.92e-01 -6.91e-02 4.70e-11 0.566000
Lagging Strand Synthesis 16 6.65e-07 8.44e-06 0.77000 7.66e-01 7.61e-02 1.13e-07 0.598000
Inhibition of replication initiation of damaged DNA by RB1/E2F1 12 3.25e-05 2.77e-04 0.75700 6.70e-01 3.51e-01 5.81e-05 0.035400
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 12 4.04e-05 3.29e-04 0.74900 7.28e-01 1.77e-01 1.26e-05 0.288000
Processive synthesis on the lagging strand 12 4.89e-05 3.76e-04 0.74200 7.40e-01 6.10e-02 9.04e-06 0.715000
Removal of the Flap Intermediate 11 1.21e-04 8.51e-04 0.74000 7.39e-01 -1.61e-02 2.17e-05 0.926000
GP1b-IX-V activation signalling 10 4.99e-04 2.86e-03 0.71200 -7.10e-01 6.38e-02 1.02e-04 0.727000
E2F mediated regulation of DNA replication 18 1.50e-06 1.76e-05 0.70300 5.50e-01 4.38e-01 5.32e-05 0.001290
PCNA-Dependent Long Patch Base Excision Repair 15 2.47e-05 2.24e-04 0.68600 6.60e-01 1.87e-01 9.52e-06 0.211000
Translesion Synthesis by POLH 10 8.83e-04 4.64e-03 0.68400 6.34e-01 2.55e-01 5.14e-04 0.162000
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 12 2.91e-04 1.84e-03 0.67200 6.51e-01 1.68e-01 9.53e-05 0.313000
Heme biosynthesis 11 6.77e-04 3.68e-03 0.66400 6.15e-01 2.52e-01 4.16e-04 0.148000
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 12 3.69e-04 2.24e-03 0.66100 5.22e-01 4.06e-01 1.73e-03 0.015000
Mismatch Repair 13 3.06e-04 1.91e-03 0.64400 6.12e-01 2.00e-01 1.34e-04 0.213000
Condensation of Prophase Chromosomes 10 2.07e-03 1.01e-02 0.64100 4.14e-01 4.89e-01 2.34e-02 0.007440
G1/S-Specific Transcription 23 7.67e-07 9.65e-06 0.63900 6.19e-01 1.55e-01 2.72e-07 0.197000
Initiation of Nuclear Envelope (NE) Reformation 14 1.91e-04 1.29e-03 0.63800 5.79e-01 2.68e-01 1.77e-04 0.083200
Gap-filling DNA repair synthesis and ligation in GG-NER 17 4.62e-05 3.64e-04 0.62500 6.10e-01 1.39e-01 1.34e-05 0.323000
Formation of the ternary complex, and subsequently, the 43S complex 17 4.66e-05 3.65e-04 0.62500 6.10e-01 1.36e-01 1.33e-05 0.332000
cGMP effects 13 5.26e-04 2.98e-03 0.62200 -6.15e-01 -9.58e-02 1.25e-04 0.550000
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 21 5.22e-06 5.51e-05 0.62100 5.79e-01 2.25e-01 4.44e-06 0.074500
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 33 6.76e-09 1.56e-07 0.61700 6.17e-01 5.82e-03 8.60e-10 0.954000
p53-Independent DNA Damage Response 33 6.76e-09 1.56e-07 0.61700 6.17e-01 5.82e-03 8.60e-10 0.954000
p53-Independent G1/S DNA damage checkpoint 33 6.76e-09 1.56e-07 0.61700 6.17e-01 5.82e-03 8.60e-10 0.954000
Ribosomal scanning and start codon recognition 20 1.32e-05 1.23e-04 0.61100 5.73e-01 2.14e-01 9.23e-06 0.097700
Translation initiation complex formation 20 1.32e-05 1.23e-04 0.61100 5.73e-01 2.14e-01 9.23e-06 0.097700
Cross-presentation of soluble exogenous antigens (endosomes) 36 2.09e-09 6.50e-08 0.60900 6.02e-01 -9.22e-02 4.01e-10 0.339000
Recognition of DNA damage by PCNA-containing replication complex 18 4.75e-05 3.68e-04 0.60700 5.96e-01 1.14e-01 1.19e-05 0.404000
Cyclin A/B1/B2 associated events during G2/M transition 12 1.36e-03 6.81e-03 0.60500 5.24e-01 3.01e-01 1.67e-03 0.070900
Assembly of the pre-replicative complex 46 1.49e-11 9.77e-10 0.60200 6.01e-01 3.04e-02 1.78e-12 0.722000
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 17 9.68e-05 7.01e-04 0.60200 5.73e-01 1.83e-01 4.29e-05 0.193000
DNA Replication Pre-Initiation 58 3.00e-14 2.66e-12 0.59900 5.97e-01 4.69e-02 3.70e-15 0.537000
Formation of a pool of free 40S subunits 34 1.41e-08 2.83e-07 0.59500 5.75e-01 1.55e-01 6.72e-09 0.117000
SCF-beta-TrCP mediated degradation of Emi1 37 3.85e-09 9.60e-08 0.59100 5.91e-01 1.27e-02 4.88e-10 0.893000
Ubiquitin-dependent degradation of Cyclin D 35 1.64e-08 3.25e-07 0.58500 5.84e-01 2.55e-02 2.22e-09 0.794000
L13a-mediated translational silencing of Ceruloplasmin expression 38 3.58e-09 9.10e-08 0.58400 5.52e-01 1.90e-01 3.93e-09 0.042400
Regulation of activated PAK-2p34 by proteasome mediated degradation 33 5.07e-08 7.99e-07 0.58300 5.83e-01 2.04e-02 6.97e-09 0.840000
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 13 1.39e-03 6.90e-03 0.58000 5.52e-01 1.79e-01 5.71e-04 0.263000
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD 35 2.31e-08 4.28e-07 0.57900 5.79e-01 -3.40e-03 3.03e-09 0.972000
CDT1 association with the CDC6:ORC:origin complex 39 3.13e-09 8.22e-08 0.57900 5.78e-01 2.62e-02 4.08e-10 0.777000
Regulation of ornithine decarboxylase (ODC) 35 2.34e-08 4.28e-07 0.57900 5.79e-01 -5.84e-04 3.07e-09 0.995000
Activation of the pre-replicative complex 23 9.82e-06 9.76e-05 0.57800 5.75e-01 5.74e-02 1.78e-06 0.634000
Telomere C-strand (Lagging Strand) Synthesis 25 3.65e-06 3.88e-05 0.57800 5.78e-01 2.42e-02 5.77e-07 0.834000
Metabolism of polyamines 40 2.19e-09 6.64e-08 0.57700 5.77e-01 -1.15e-02 2.71e-10 0.900000
Phase 2 - plateau phase 17 2.13e-04 1.38e-03 0.57500 -5.35e-01 -2.13e-01 1.36e-04 0.129000
Digestion 11 4.37e-03 2.01e-02 0.57400 -5.72e-01 5.46e-02 1.03e-03 0.754000
Cap-dependent Translation Initiation 45 2.26e-10 1.08e-08 0.57400 5.57e-01 1.39e-01 1.05e-10 0.108000
Eukaryotic Translation Initiation 45 2.26e-10 1.08e-08 0.57400 5.57e-01 1.39e-01 1.05e-10 0.108000
Vif-mediated degradation of APOBEC3G 34 5.60e-08 8.71e-07 0.57300 5.72e-01 2.35e-02 7.78e-09 0.813000
Orc1 removal from chromatin 47 1.01e-10 5.59e-09 0.57200 5.71e-01 3.28e-02 1.28e-11 0.698000
Autodegradation of the E3 ubiquitin ligase COP1 35 4.42e-08 7.19e-07 0.56900 5.67e-01 -4.07e-02 6.37e-09 0.677000
Deposition of new CENPA-containing nucleosomes at the centromere 16 4.41e-04 2.58e-03 0.56800 5.68e-01 -1.44e-02 8.49e-05 0.920000
Nucleosome assembly 16 4.41e-04 2.58e-03 0.56800 5.68e-01 -1.44e-02 8.49e-05 0.920000
AUF1 (hnRNP D0) binds and destabilizes mRNA 36 3.30e-08 5.78e-07 0.56500 5.65e-01 -2.07e-02 4.44e-09 0.830000
GTP hydrolysis and joining of the 60S ribosomal subunit 39 8.03e-09 1.79e-07 0.56400 5.35e-01 1.80e-01 7.45e-09 0.052600
Defective CFTR causes cystic fibrosis 38 1.36e-08 2.78e-07 0.56400 5.64e-01 2.09e-02 1.81e-09 0.823000
Hh mutants abrogate ligand secretion 37 2.37e-08 4.28e-07 0.56300 5.63e-01 -4.31e-03 3.11e-09 0.964000
Metabolism of porphyrins 21 4.76e-05 3.68e-04 0.56100 4.73e-01 3.02e-01 1.75e-04 0.016600
Termination of translesion DNA synthesis 21 4.95e-05 3.78e-04 0.56100 5.57e-01 6.50e-02 9.84e-06 0.606000
Translesion synthesis by POLI 11 5.60e-03 2.45e-02 0.56100 5.60e-01 2.72e-02 1.30e-03 0.876000
Peptide chain elongation 28 1.86e-06 2.15e-05 0.56000 5.21e-01 2.05e-01 1.82e-06 0.060400
Polymerase switching on the C-strand of the telomere 21 5.51e-05 4.15e-04 0.55800 5.58e-01 1.72e-02 9.59e-06 0.892000
G1/S Transition 92 2.74e-19 4.26e-17 0.55700 5.47e-01 1.09e-01 1.33e-19 0.070800
Heme degradation 11 6.04e-03 2.59e-02 0.55600 3.75e-01 4.10e-01 3.12e-02 0.018700
Cholesterol biosynthesis 16 6.33e-04 3.50e-03 0.55400 -5.41e-01 -1.18e-01 1.80e-04 0.413000
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 37 4.66e-08 7.43e-07 0.55200 5.52e-01 2.08e-02 6.41e-09 0.827000
Synthesis of DNA 86 1.34e-17 1.52e-15 0.55000 5.50e-01 -6.87e-03 1.20e-18 0.913000
Striated Muscle Contraction 30 1.23e-06 1.46e-05 0.55000 -5.12e-01 -2.00e-01 1.21e-06 0.058700
SCF(Skp2)-mediated degradation of p27/p21 39 2.31e-08 4.28e-07 0.54900 5.48e-01 3.01e-02 3.23e-09 0.745000
Regulation of Apoptosis 35 1.49e-07 2.18e-06 0.54800 5.48e-01 -8.87e-04 2.05e-08 0.993000
DNA Replication 93 8.70e-19 1.08e-16 0.54700 5.47e-01 1.13e-02 7.71e-20 0.851000
The role of GTSE1 in G2/M progression after G2 checkpoint 40 1.86e-08 3.56e-07 0.54500 5.38e-01 8.96e-02 4.07e-09 0.327000
Transcription of E2F targets under negative control by DREAM complex 16 8.38e-04 4.46e-03 0.54300 5.15e-01 1.72e-01 3.62e-04 0.234000
Vpu mediated degradation of CD4 34 3.49e-07 4.94e-06 0.54100 5.40e-01 -1.20e-02 4.97e-08 0.904000
Autodegradation of Cdh1 by Cdh1:APC/C 45 7.19e-09 1.63e-07 0.52800 5.23e-01 -6.98e-02 1.25e-09 0.418000
Extension of Telomeres 35 4.49e-07 6.01e-06 0.52800 5.20e-01 8.97e-02 1.01e-07 0.359000
VLDLR internalisation and degradation 10 1.53e-02 5.61e-02 0.52800 5.13e-01 1.23e-01 4.95e-03 0.502000
Negative regulation of NOTCH4 signaling 37 2.25e-07 3.26e-06 0.52600 5.26e-01 1.11e-02 3.18e-08 0.907000
Translesion synthesis by REV1 10 1.62e-02 5.87e-02 0.52400 5.23e-01 3.52e-02 4.19e-03 0.847000
Mitotic G1 phase and G1/S transition 104 3.32e-19 4.59e-17 0.52300 5.15e-01 9.33e-02 1.19e-19 0.101000
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 19 4.39e-04 2.58e-03 0.52200 4.85e-01 -1.93e-01 2.54e-04 0.145000
Eukaryotic Translation Elongation 31 3.12e-06 3.43e-05 0.52200 4.82e-01 2.01e-01 3.47e-06 0.053400
RUNX1 regulates transcription of genes involved in differentiation of HSCs 49 2.59e-09 7.33e-08 0.52000 5.14e-01 -7.59e-02 4.82e-10 0.359000
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 30 5.28e-06 5.52e-05 0.51900 4.73e-01 2.14e-01 7.30e-06 0.042800
G0 and Early G1 21 2.07e-04 1.36e-03 0.51900 5.06e-01 1.16e-01 6.08e-05 0.356000
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 53 6.65e-10 2.43e-08 0.51600 5.16e-01 -6.92e-03 7.98e-11 0.931000
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 52 1.03e-09 3.48e-08 0.51600 5.16e-01 6.67e-03 1.26e-10 0.934000
Platelet Adhesion to exposed collagen 11 1.27e-02 4.75e-02 0.51500 -4.75e-01 2.01e-01 6.40e-03 0.249000
Laminin interactions 22 1.68e-04 1.15e-03 0.51300 -5.04e-01 -9.45e-02 4.23e-05 0.443000
Hedgehog ligand biogenesis 41 1.02e-07 1.55e-06 0.51200 5.11e-01 -3.70e-02 1.50e-08 0.682000
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 54 6.37e-10 2.40e-08 0.51200 5.12e-01 -1.95e-02 7.82e-11 0.805000
APC/C:Cdc20 mediated degradation of mitotic proteins 55 4.33e-10 1.75e-08 0.51200 5.12e-01 9.91e-03 5.20e-11 0.899000
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 55 4.33e-10 1.75e-08 0.51200 5.12e-01 9.91e-03 5.20e-11 0.899000
Homologous DNA Pairing and Strand Exchange 28 1.77e-05 1.63e-04 0.51200 4.79e-01 -1.80e-01 1.17e-05 0.098800
Degradation of DVL 38 3.86e-07 5.27e-06 0.51000 5.09e-01 2.56e-02 5.74e-08 0.785000
Generation of second messenger molecules 22 2.03e-04 1.35e-03 0.50900 -4.88e-01 1.45e-01 7.57e-05 0.239000
CDK-mediated phosphorylation and removal of Cdc6 51 3.14e-09 8.22e-08 0.50700 5.02e-01 -6.73e-02 5.45e-10 0.406000
Eukaryotic Translation Termination 30 9.98e-06 9.78e-05 0.50600 4.90e-01 1.27e-01 3.47e-06 0.230000
Cyclin A:Cdk2-associated events at S phase entry 58 2.51e-10 1.16e-08 0.50500 5.03e-01 4.18e-02 3.50e-11 0.582000
Cyclin E associated events during G1/S transition 56 5.43e-10 2.11e-08 0.50500 5.02e-01 5.17e-02 8.31e-11 0.504000
APC/C-mediated degradation of cell cycle proteins 64 2.69e-11 1.59e-09 0.50400 5.01e-01 5.33e-02 4.07e-12 0.462000
Regulation of mitotic cell cycle 64 2.69e-11 1.59e-09 0.50400 5.01e-01 5.33e-02 4.07e-12 0.462000
Regulation of APC/C activators between G1/S and early anaphase 57 4.36e-10 1.75e-08 0.50300 5.02e-01 3.30e-02 5.78e-11 0.667000
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 12 1.07e-02 4.15e-02 0.50300 -4.91e-01 1.08e-01 3.24e-03 0.518000
Diseases of hemostasis 12 1.07e-02 4.15e-02 0.50300 -4.91e-01 1.08e-01 3.24e-03 0.518000
SRP-dependent cotranslational protein targeting to membrane 43 8.82e-08 1.36e-06 0.50200 4.80e-01 1.46e-01 5.11e-08 0.098700
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway 12 1.14e-02 4.34e-02 0.50000 -4.22e-01 2.68e-01 1.14e-02 0.108000
Presynaptic phase of homologous DNA pairing and strand exchange 25 9.17e-05 6.67e-04 0.49900 4.55e-01 -2.04e-01 8.14e-05 0.077000
Viral mRNA Translation 28 2.95e-05 2.59e-04 0.49800 4.72e-01 1.59e-01 1.54e-05 0.146000
Degradation of GLI1 by the proteasome 39 6.06e-07 7.94e-06 0.49500 4.95e-01 -2.48e-03 8.74e-08 0.979000
APC/C:Cdc20 mediated degradation of Securin 49 1.75e-08 3.41e-07 0.49400 4.92e-01 -4.42e-02 2.60e-09 0.593000
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 16 3.05e-03 1.44e-02 0.49100 4.85e-01 7.64e-02 7.79e-04 0.597000
Postmitotic nuclear pore complex (NPC) reformation 20 7.19e-04 3.86e-03 0.49100 4.72e-01 1.37e-01 2.62e-04 0.290000
Switching of origins to a post-replicative state 64 1.03e-10 5.59e-09 0.49000 4.90e-01 -1.83e-02 1.22e-11 0.801000
Activation of ATR in response to replication stress 23 2.75e-04 1.75e-03 0.48800 4.86e-01 3.81e-02 5.45e-05 0.752000
Mitochondrial translation elongation 56 2.51e-09 7.33e-08 0.48600 4.86e-01 2.44e-02 3.29e-10 0.752000
Chromosome Maintenance 56 2.89e-09 8.00e-08 0.48500 4.84e-01 1.86e-02 3.73e-10 0.810000
GLI3 is processed to GLI3R by the proteasome 39 1.12e-06 1.35e-05 0.48500 4.84e-01 2.05e-02 1.70e-07 0.824000
HDR through Homologous Recombination (HRR) 42 4.09e-07 5.53e-06 0.48400 4.78e-01 -7.72e-02 8.40e-08 0.387000
Resolution of D-loop Structures through Holliday Junction Intermediates 22 4.63e-04 2.67e-03 0.48300 4.46e-01 -1.86e-01 2.92e-04 0.131000
NIK-->noncanonical NF-kB signaling 38 1.95e-06 2.23e-05 0.48100 4.74e-01 -8.02e-02 4.20e-07 0.393000
Purine catabolism 14 7.81e-03 3.16e-02 0.48100 4.79e-01 3.57e-02 1.90e-03 0.817000
TP53 Regulates Transcription of Death Receptors and Ligands 10 3.20e-02 1.05e-01 0.48000 -3.74e-01 3.01e-01 4.05e-02 0.099300
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 26 1.24e-04 8.64e-04 0.48000 4.67e-01 1.12e-01 3.80e-05 0.322000
Translocation of ZAP-70 to Immunological synapse 11 2.26e-02 7.78e-02 0.48000 -4.73e-01 8.15e-02 6.61e-03 0.640000
ABC transporter disorders 46 1.34e-07 1.99e-06 0.48000 4.79e-01 -1.33e-02 1.87e-08 0.876000
Translesion synthesis by POLK 11 2.25e-02 7.78e-02 0.48000 4.75e-01 6.38e-02 6.35e-03 0.714000
Degradation of GLI2 by the proteasome 40 1.11e-06 1.35e-05 0.47900 4.78e-01 2.15e-02 1.70e-07 0.814000
Resolution of D-Loop Structures 23 3.90e-04 2.35e-03 0.47800 4.47e-01 -1.69e-01 2.05e-04 0.161000
Presynaptic depolarization and calcium channel opening 11 2.30e-02 7.92e-02 0.47800 -4.75e-01 -5.46e-02 6.40e-03 0.754000
Mitochondrial translation termination 56 5.15e-09 1.26e-07 0.47700 4.77e-01 1.37e-02 6.62e-10 0.860000
Selenocysteine synthesis 30 3.81e-05 3.14e-04 0.47500 4.32e-01 1.97e-01 4.17e-05 0.061900
FCGR activation 15 6.33e-03 2.66e-02 0.47500 4.63e-01 -1.08e-01 1.93e-03 0.468000
Digestion and absorption 12 1.77e-02 6.35e-02 0.47400 -4.61e-01 1.10e-01 5.69e-03 0.510000
Degradation of AXIN 36 6.03e-06 6.26e-05 0.47200 4.71e-01 -3.39e-02 1.00e-06 0.725000
Dectin-1 mediated noncanonical NF-kB signaling 40 1.63e-06 1.89e-05 0.47200 4.65e-01 -8.32e-02 3.65e-07 0.363000
Stabilization of p53 38 3.22e-06 3.47e-05 0.47200 4.70e-01 -3.58e-02 5.26e-07 0.702000
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 43 6.44e-07 8.27e-06 0.47000 4.65e-01 7.29e-02 1.35e-07 0.409000
Retrograde neurotrophin signalling 12 1.88e-02 6.66e-02 0.47000 4.63e-01 7.90e-02 5.48e-03 0.636000
Telomere Maintenance 42 9.67e-07 1.19e-05 0.46900 4.65e-01 6.33e-02 1.87e-07 0.478000
Apoptotic factor-mediated response 11 2.73e-02 9.17e-02 0.46700 4.66e-01 2.86e-02 7.42e-03 0.870000
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects 13 1.49e-02 5.48e-02 0.46400 3.51e-01 3.03e-01 2.86e-02 0.058300
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) 13 1.49e-02 5.48e-02 0.46400 3.51e-01 3.03e-01 2.86e-02 0.058300
S Phase 118 3.98e-17 4.13e-15 0.46300 4.61e-01 4.35e-02 5.22e-18 0.416000
DNA Damage Bypass 31 5.00e-05 3.79e-04 0.46100 4.43e-01 1.29e-01 1.98e-05 0.213000
SUMOylation of DNA replication proteins 32 3.84e-05 3.15e-04 0.46000 4.36e-01 1.48e-01 2.00e-05 0.149000
G2/M Checkpoints 90 6.08e-13 5.05e-11 0.45800 4.56e-01 4.04e-02 8.13e-14 0.509000
Common Pathway of Fibrin Clot Formation 12 2.31e-02 7.92e-02 0.45700 -4.01e-01 -2.18e-01 1.61e-02 0.190000
Phosphorylation of CD3 and TCR zeta chains 13 1.76e-02 6.32e-02 0.45500 -4.46e-01 -8.96e-02 5.37e-03 0.576000
Translation 150 1.06e-20 3.31e-18 0.45400 4.53e-01 3.52e-02 1.19e-21 0.458000
Mitochondrial translation initiation 56 3.46e-08 5.90e-07 0.45300 4.51e-01 4.16e-02 5.39e-09 0.590000
Processive synthesis on the C-strand of the telomere 13 1.83e-02 6.52e-02 0.45300 4.48e-01 6.30e-02 5.13e-03 0.694000
HDMs demethylate histones 15 1.03e-02 4.02e-02 0.45200 -3.95e-01 2.19e-01 8.04e-03 0.142000
GABA synthesis, release, reuptake and degradation 11 3.45e-02 1.12e-01 0.45200 -4.51e-01 -3.31e-02 9.67e-03 0.849000
Rev-mediated nuclear export of HIV RNA 24 6.66e-04 3.63e-03 0.45100 4.34e-01 1.21e-01 2.32e-04 0.306000
Surfactant metabolism 13 1.91e-02 6.75e-02 0.45100 -7.42e-02 -4.44e-01 6.43e-01 0.005540
Nuclear import of Rev protein 23 9.35e-04 4.89e-03 0.45000 4.44e-01 7.21e-02 2.30e-04 0.550000
Metabolism of folate and pterines 14 1.56e-02 5.73e-02 0.44500 4.41e-01 -6.27e-02 4.28e-03 0.685000
HDR through Single Strand Annealing (SSA) 26 4.57e-04 2.64e-03 0.44500 3.83e-01 -2.27e-01 7.28e-04 0.044900
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 68 1.75e-09 5.58e-08 0.44500 4.37e-01 8.57e-02 4.77e-10 0.222000
Amplification of signal from the kinetochores 68 1.75e-09 5.58e-08 0.44500 4.37e-01 8.57e-02 4.77e-10 0.222000
Defective EXT1 causes exostoses 1, TRPS2 and CHDS 10 5.22e-02 1.50e-01 0.44400 -8.79e-03 -4.44e-01 9.62e-01 0.015100
Defective EXT2 causes exostoses 2 10 5.22e-02 1.50e-01 0.44400 -8.79e-03 -4.44e-01 9.62e-01 0.015100
Interactions of Rev with host cellular proteins 25 6.25e-04 3.48e-03 0.44300 4.30e-01 1.08e-01 1.99e-04 0.348000
Nitric oxide stimulates guanylate cyclase 18 5.11e-03 2.30e-02 0.44200 -4.31e-01 -9.65e-02 1.54e-03 0.479000
Separation of Sister Chromatids 124 2.19e-16 2.10e-14 0.44200 4.40e-01 4.40e-02 3.02e-17 0.398000
Golgi Cisternae Pericentriolar Stack Reorganization 11 4.06e-02 1.27e-01 0.44000 2.72e-01 3.46e-01 1.19e-01 0.047000
Fanconi Anemia Pathway 22 1.72e-03 8.42e-03 0.44000 4.39e-01 -2.17e-02 3.64e-04 0.860000
Constitutive Signaling by NOTCH1 HD Domain Mutants 10 5.54e-02 1.58e-01 0.43900 -4.25e-01 -1.09e-01 1.99e-02 0.550000
Signaling by NOTCH1 HD Domain Mutants in Cancer 10 5.54e-02 1.58e-01 0.43900 -4.25e-01 -1.09e-01 1.99e-02 0.550000
Insulin processing 16 1.00e-02 3.93e-02 0.43900 -4.02e-01 1.75e-01 5.34e-03 0.225000
Assembly of collagen fibrils and other multimeric structures 37 2.65e-05 2.36e-04 0.43500 -3.65e-01 -2.38e-01 1.23e-04 0.012500
Hyaluronan metabolism 11 4.52e-02 1.36e-01 0.43400 3.57e-01 -2.47e-01 4.03e-02 0.156000
Regulation of RUNX3 expression and activity 37 3.13e-05 2.69e-04 0.43300 4.22e-01 -1.00e-01 9.22e-06 0.291000
Mitochondrial translation 62 3.55e-08 5.98e-07 0.43000 4.30e-01 4.37e-03 4.73e-09 0.953000
Incretin synthesis, secretion, and inactivation 10 6.38e-02 1.75e-01 0.42800 -4.03e-01 -1.43e-01 2.73e-02 0.433000
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 10 6.44e-02 1.75e-01 0.42800 2.67e-02 4.27e-01 8.84e-01 0.019400
alpha-linolenic acid (ALA) metabolism 10 6.44e-02 1.75e-01 0.42800 2.67e-02 4.27e-01 8.84e-01 0.019400
Mitotic Metaphase and Anaphase 166 2.74e-20 6.81e-18 0.42700 4.18e-01 8.91e-02 1.79e-20 0.048500
Resolution of Sister Chromatid Cohesion 77 7.37e-10 2.62e-08 0.42700 4.12e-01 1.15e-01 4.45e-10 0.080900
Nuclear Envelope (NE) Reassembly 51 8.66e-07 1.08e-05 0.42700 3.69e-01 2.16e-01 5.31e-06 0.007810
Elevation of cytosolic Ca2+ levels 10 6.50e-02 1.76e-01 0.42600 -3.32e-01 -2.68e-01 6.95e-02 0.143000
NEP/NS2 Interacts with the Cellular Export Machinery 22 2.58e-03 1.25e-02 0.42500 4.06e-01 1.24e-01 9.76e-04 0.313000
Mitotic Anaphase 165 6.76e-20 1.40e-17 0.42400 4.16e-01 8.59e-02 3.84e-20 0.057800
Removal of the Flap Intermediate from the C-strand 12 3.97e-02 1.25e-01 0.42400 4.24e-01 -7.48e-03 1.11e-02 0.964000
Initial triggering of complement 19 6.27e-03 2.65e-02 0.42300 4.11e-01 -9.65e-02 1.91e-03 0.467000
ER-Phagosome pathway 54 5.68e-07 7.52e-06 0.42200 4.17e-01 -6.96e-02 1.20e-07 0.377000
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 66 2.61e-08 4.65e-07 0.42100 4.19e-01 4.23e-02 4.18e-09 0.553000
Influenza Viral RNA Transcription and Replication 56 3.64e-07 5.09e-06 0.42100 4.12e-01 8.29e-02 9.60e-08 0.284000
Homology Directed Repair 70 1.00e-08 2.15e-07 0.42000 4.18e-01 4.04e-02 1.55e-09 0.560000
Diseases of DNA repair 10 7.10e-02 1.85e-01 0.41900 3.08e-01 2.84e-01 9.18e-02 0.120000
Regulation of expression of SLITs and ROBOs 80 7.68e-10 2.66e-08 0.41900 4.04e-01 1.11e-01 4.44e-10 0.085300
EML4 and NUDC in mitotic spindle formation 71 8.75e-09 1.91e-07 0.41800 4.13e-01 6.63e-02 1.85e-09 0.335000
Resolution of Abasic Sites (AP sites) 30 3.89e-04 2.35e-03 0.41800 4.10e-01 7.83e-02 1.00e-04 0.458000
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 20 5.36e-03 2.38e-02 0.41700 4.07e-01 9.19e-02 1.63e-03 0.477000
Regulation of Glucokinase by Glucokinase Regulatory Protein 20 5.36e-03 2.38e-02 0.41700 4.07e-01 9.19e-02 1.63e-03 0.477000
Vpr-mediated nuclear import of PICs 23 2.59e-03 1.25e-02 0.41500 3.98e-01 1.19e-01 9.59e-04 0.322000
SUMOylation of SUMOylation proteins 22 3.40e-03 1.59e-02 0.41500 3.96e-01 1.23e-01 1.30e-03 0.318000
MET activates PTK2 signaling 16 1.62e-02 5.87e-02 0.41400 -3.95e-01 -1.25e-01 6.25e-03 0.386000
Regulation of PTEN stability and activity 46 8.07e-06 8.24e-05 0.41300 4.13e-01 -1.99e-05 1.28e-06 1.000000
Receptor-type tyrosine-protein phosphatases 10 7.94e-02 1.99e-01 0.41100 -8.07e-02 -4.03e-01 6.59e-01 0.027400
Glutamate and glutamine metabolism 11 6.27e-02 1.73e-01 0.41000 3.82e-01 -1.51e-01 2.84e-02 0.387000
Regulation of necroptotic cell death 12 4.97e-02 1.45e-01 0.40900 -3.81e-01 1.48e-01 2.22e-02 0.375000
Mitochondrial protein import 44 1.78e-05 1.63e-04 0.40800 3.70e-01 -1.73e-01 2.19e-05 0.047500
Selenoamino acid metabolism 39 5.78e-05 4.31e-04 0.40800 3.82e-01 1.45e-01 3.72e-05 0.118000
Defective B4GALT7 causes EDS, progeroid type 14 3.06e-02 1.01e-01 0.40700 -1.22e-01 -3.88e-01 4.30e-01 0.011900
Antimicrobial peptides 21 5.62e-03 2.46e-02 0.40500 -3.14e-01 -2.56e-01 1.27e-02 0.042600
Budding and maturation of HIV virion 15 2.54e-02 8.58e-02 0.40500 3.62e-01 -1.82e-01 1.53e-02 0.223000
Asymmetric localization of PCP proteins 47 1.01e-05 9.78e-05 0.40500 4.05e-01 -1.35e-04 1.61e-06 0.999000
Activation of gene expression by SREBF (SREBP) 35 1.97e-04 1.32e-03 0.40400 -3.73e-01 1.56e-01 1.36e-04 0.110000
G1/S DNA Damage Checkpoints 45 1.75e-05 1.62e-04 0.40400 4.04e-01 -3.29e-03 2.86e-06 0.970000
Syndecan interactions 16 2.01e-02 7.04e-02 0.40300 -3.26e-01 -2.37e-01 2.40e-02 0.101000
FOXO-mediated transcription of cell death genes 13 4.19e-02 1.30e-01 0.40300 2.37e-01 3.26e-01 1.39e-01 0.042200
p53-Dependent G1 DNA Damage Response 44 2.52e-05 2.25e-04 0.40100 4.01e-01 -1.45e-02 4.22e-06 0.868000
p53-Dependent G1/S DNA damage checkpoint 44 2.52e-05 2.25e-04 0.40100 4.01e-01 -1.45e-02 4.22e-06 0.868000
Cell Cycle Checkpoints 183 1.15e-19 2.05e-17 0.40100 3.99e-01 4.30e-02 1.68e-20 0.318000
HCMV Late Events 37 1.41e-04 9.73e-04 0.40000 3.96e-01 5.63e-02 3.08e-05 0.554000
Intrinsic Pathway of Fibrin Clot Formation 14 3.51e-02 1.13e-01 0.40000 -3.99e-01 1.72e-02 9.69e-03 0.911000
Mitotic Spindle Checkpoint 83 2.55e-09 7.33e-08 0.40000 3.97e-01 4.60e-02 4.22e-10 0.470000
Nucleobase biosynthesis 13 4.46e-02 1.35e-01 0.40000 3.99e-01 1.32e-02 1.27e-02 0.935000
Activation of NF-kappaB in B cells 44 3.30e-05 2.78e-04 0.39600 3.92e-01 -5.56e-02 6.78e-06 0.524000
Platelet Aggregation (Plug Formation) 28 1.49e-03 7.37e-03 0.39500 -3.70e-01 1.37e-01 7.02e-04 0.211000
Response of EIF2AK4 (GCN2) to amino acid deficiency 33 4.51e-04 2.62e-03 0.39400 3.67e-01 1.44e-01 2.65e-04 0.152000
Metabolism of non-coding RNA 34 4.21e-04 2.49e-03 0.39000 3.66e-01 1.35e-01 2.21e-04 0.173000
snRNP Assembly 34 4.21e-04 2.49e-03 0.39000 3.66e-01 1.35e-01 2.21e-04 0.173000
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 44 4.34e-05 3.46e-04 0.39000 3.16e-01 2.28e-01 2.84e-04 0.008970
Nonsense-Mediated Decay (NMD) 44 4.34e-05 3.46e-04 0.39000 3.16e-01 2.28e-01 2.84e-04 0.008970
Cellular response to hypoxia 51 9.87e-06 9.76e-05 0.38900 3.84e-01 6.14e-02 2.16e-06 0.449000
Na+/Cl- dependent neurotransmitter transporters 10 1.05e-01 2.44e-01 0.38800 -7.29e-02 3.81e-01 6.90e-01 0.036800
Nucleobase catabolism 24 4.44e-03 2.03e-02 0.38800 3.87e-01 3.23e-02 1.04e-03 0.784000
Regulation of pyruvate dehydrogenase (PDH) complex 11 8.36e-02 2.06e-01 0.38700 -3.04e-01 -2.40e-01 8.11e-02 0.168000
Degradation of cysteine and homocysteine 10 1.06e-01 2.45e-01 0.38700 3.87e-01 7.59e-04 3.41e-02 0.997000
Sulfur amino acid metabolism 17 2.23e-02 7.75e-02 0.38700 3.79e-01 -7.53e-02 6.79e-03 0.591000
CLEC7A (Dectin-1) induces NFAT activation 10 1.07e-01 2.47e-01 0.38700 -3.71e-01 1.08e-01 4.21e-02 0.554000
PD-1 signaling 12 6.98e-02 1.83e-01 0.38400 -3.74e-01 -8.75e-02 2.48e-02 0.600000
MAP3K8 (TPL2)-dependent MAPK1/3 activation 10 1.11e-01 2.53e-01 0.38300 -3.78e-01 6.22e-02 3.83e-02 0.734000
Transport of Ribonucleoproteins into the Host Nucleus 22 7.82e-03 3.16e-02 0.38300 3.68e-01 1.07e-01 2.81e-03 0.386000
Dopamine Neurotransmitter Release Cycle 11 8.83e-02 2.15e-01 0.38300 -3.64e-01 -1.21e-01 3.68e-02 0.488000
RAS processing 12 7.06e-02 1.84e-01 0.38300 2.74e-01 2.68e-01 1.00e-01 0.109000
Mitotic G2-G2/M phases 129 6.63e-13 5.16e-11 0.38200 3.67e-01 1.05e-01 6.53e-13 0.039200
tRNA Aminoacylation 17 2.47e-02 8.37e-02 0.38200 3.42e-01 -1.70e-01 1.47e-02 0.225000
Transport of the SLBP Dependant Mature mRNA 24 5.27e-03 2.37e-02 0.38200 3.73e-01 8.25e-02 1.58e-03 0.484000
Influenza Infection 68 3.72e-07 5.15e-06 0.38200 3.72e-01 8.46e-02 1.15e-07 0.228000
Base Excision Repair 37 3.13e-04 1.95e-03 0.38100 3.61e-01 1.23e-01 1.48e-04 0.194000
HS-GAG biosynthesis 18 2.03e-02 7.09e-02 0.38100 1.32e-01 -3.57e-01 3.34e-01 0.008720
Depolymerisation of the Nuclear Lamina 12 7.34e-02 1.89e-01 0.38000 2.99e-01 2.35e-01 7.32e-02 0.158000
Cell Cycle, Mitotic 356 1.84e-33 2.28e-30 0.38000 3.69e-01 9.22e-02 1.22e-32 0.003030
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 18 1.99e-02 7.01e-02 0.38000 2.85e-01 2.52e-01 3.66e-02 0.064300
Antigen processing-Cross presentation 67 6.18e-07 8.01e-06 0.37900 3.56e-01 -1.30e-01 4.96e-07 0.065600
Cyclin D associated events in G1 31 1.26e-03 6.43e-03 0.37900 3.19e-01 2.04e-01 2.12e-03 0.049900
G1 Phase 31 1.26e-03 6.43e-03 0.37900 3.19e-01 2.04e-01 2.12e-03 0.049900
Non-integrin membrane-ECM interactions 35 5.42e-04 3.05e-03 0.37800 -3.43e-01 -1.59e-01 4.43e-04 0.104000
LGI-ADAM interactions 13 6.12e-02 1.70e-01 0.37800 -3.69e-01 -8.32e-02 2.12e-02 0.604000
Interferon alpha/beta signaling 37 3.61e-04 2.20e-03 0.37800 3.66e-01 9.31e-02 1.16e-04 0.327000
G2/M Transition 127 1.85e-12 1.28e-10 0.37800 3.65e-01 9.82e-02 1.34e-12 0.056700
Cytosolic sulfonation of small molecules 14 5.14e-02 1.49e-01 0.37600 3.76e-01 1.43e-02 1.49e-02 0.926000
Viral Messenger RNA Synthesis 25 5.29e-03 2.37e-02 0.37400 3.73e-01 2.93e-02 1.25e-03 0.800000
Mitotic Prophase 61 2.83e-06 3.21e-05 0.37400 3.24e-01 1.87e-01 1.27e-05 0.011500
Long-term potentiation 17 2.84e-02 9.47e-02 0.37400 -3.67e-01 -6.98e-02 8.80e-03 0.618000
tRNA processing in the nucleus 41 1.90e-04 1.29e-03 0.37400 3.71e-01 4.36e-02 3.97e-05 0.629000
Nuclear Pore Complex (NPC) Disassembly 25 5.35e-03 2.38e-02 0.37300 3.64e-01 8.54e-02 1.66e-03 0.460000
p130Cas linkage to MAPK signaling for integrins 10 1.24e-01 2.78e-01 0.37300 -3.53e-01 1.22e-01 5.33e-02 0.505000
Formation of Fibrin Clot (Clotting Cascade) 23 8.24e-03 3.32e-02 0.37300 -3.65e-01 -7.70e-02 2.46e-03 0.523000
PCP/CE pathway 66 1.14e-06 1.37e-05 0.37200 3.61e-01 8.94e-02 3.92e-07 0.210000
Diseases of carbohydrate metabolism 22 1.03e-02 4.02e-02 0.37200 3.55e-01 1.11e-01 3.91e-03 0.370000
Interactions of Vpr with host cellular proteins 25 5.59e-03 2.45e-02 0.37200 3.68e-01 5.73e-02 1.47e-03 0.620000
Processing of DNA double-strand break ends 41 2.19e-04 1.42e-03 0.37000 3.61e-01 8.10e-02 6.29e-05 0.370000
NS1 Mediated Effects on Host Pathways 25 6.07e-03 2.60e-02 0.36900 3.65e-01 5.20e-02 1.57e-03 0.653000
Transport of the SLBP independent Mature mRNA 23 9.45e-03 3.72e-02 0.36800 3.57e-01 8.66e-02 3.03e-03 0.473000
Host Interactions of HIV factors 91 1.08e-08 2.29e-07 0.36700 3.60e-01 7.60e-02 3.21e-09 0.211000
M Phase 256 8.20e-23 3.40e-20 0.36700 3.57e-01 8.58e-02 1.18e-22 0.018800
Collagen chain trimerization 33 1.35e-03 6.76e-03 0.36500 -3.38e-01 -1.38e-01 7.80e-04 0.169000
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 11 1.14e-01 2.60e-01 0.36300 -1.48e-01 3.32e-01 3.94e-01 0.056900
Activation of RAC1 10 1.41e-01 3.05e-01 0.36200 -2.98e-01 2.06e-01 1.03e-01 0.260000
Defective B3GALT6 causes EDSP2 and SEMDJL1 13 7.78e-02 1.96e-01 0.36200 -1.05e-01 -3.46e-01 5.11e-01 0.030800
Nuclear Envelope Breakdown 37 7.11e-04 3.83e-03 0.36200 3.50e-01 8.99e-02 2.29e-04 0.345000
Export of Viral Ribonucleoproteins from Nucleus 23 1.10e-02 4.22e-02 0.36100 3.47e-01 1.02e-01 4.01e-03 0.397000
Mitotic Prometaphase 140 1.55e-12 1.14e-10 0.36100 3.50e-01 8.81e-02 9.07e-13 0.072700
FCERI mediated Ca+2 mobilization 24 9.57e-03 3.76e-02 0.36000 -3.15e-01 1.76e-01 7.64e-03 0.137000
PECAM1 interactions 10 1.45e-01 3.08e-01 0.36000 -3.32e-01 1.39e-01 6.93e-02 0.446000
Downregulation of SMAD2/3:SMAD4 transcriptional activity 14 6.64e-02 1.78e-01 0.36000 -3.60e-01 1.57e-03 1.99e-02 0.992000
Transferrin endocytosis and recycling 17 3.69e-02 1.18e-01 0.35900 3.21e-01 1.61e-01 2.19e-02 0.251000
Transport of Mature mRNAs Derived from Intronless Transcripts 29 3.66e-03 1.69e-02 0.35900 3.41e-01 1.13e-01 1.49e-03 0.294000
Post-chaperonin tubulin folding pathway 16 4.50e-02 1.35e-01 0.35900 2.44e-01 2.63e-01 9.05e-02 0.068900
Purine ribonucleoside monophosphate biosynthesis 11 1.25e-01 2.80e-01 0.35500 3.44e-01 8.68e-02 4.83e-02 0.618000
Ras activation upon Ca2+ influx through NMDA receptor 16 4.94e-02 1.45e-01 0.35400 -3.54e-01 -1.38e-02 1.43e-02 0.924000
Hedgehog 'on' state 54 4.25e-05 3.44e-04 0.35400 3.45e-01 -7.83e-02 1.19e-05 0.320000
Dual Incision in GG-NER 31 3.02e-03 1.43e-02 0.35400 3.49e-01 5.36e-02 7.64e-04 0.606000
Carnitine metabolism 11 1.27e-01 2.83e-01 0.35300 -3.00e-01 -1.86e-01 8.49e-02 0.286000
Plasma lipoprotein clearance 25 9.45e-03 3.72e-02 0.35300 3.39e-01 9.72e-02 3.37e-03 0.400000
Diseases of programmed cell death 18 3.61e-02 1.16e-01 0.35000 2.98e-01 1.84e-01 2.87e-02 0.176000
AURKA Activation by TPX2 57 3.10e-05 2.68e-04 0.34900 3.34e-01 1.00e-01 1.30e-05 0.192000
Glutathione synthesis and recycling 10 1.63e-01 3.37e-01 0.34800 3.30e-02 -3.47e-01 8.57e-01 0.057700
Transport of Mature mRNA Derived from an Intronless Transcript 28 6.28e-03 2.65e-02 0.34700 3.27e-01 1.17e-01 2.75e-03 0.284000
Diseases associated with N-glycosylation of proteins 14 8.05e-02 2.01e-01 0.34700 3.43e-01 -5.11e-02 2.63e-02 0.741000
SUMOylation of ubiquitinylation proteins 26 9.33e-03 3.70e-02 0.34600 3.32e-01 9.95e-02 3.44e-03 0.380000
DNA Double-Strand Break Repair 90 1.12e-07 1.68e-06 0.34600 3.46e-01 3.48e-04 1.53e-08 0.995000
XBP1(S) activates chaperone genes 38 1.16e-03 5.99e-03 0.34600 3.18e-01 -1.35e-01 6.97e-04 0.150000
Telomere C-strand synthesis initiation 11 1.40e-01 3.02e-01 0.34500 3.41e-01 5.25e-02 5.01e-02 0.763000
ABC-family proteins mediated transport 65 9.60e-06 9.71e-05 0.34500 3.45e-01 8.77e-03 1.55e-06 0.903000
Creation of C4 and C2 activators 13 9.82e-02 2.31e-01 0.34500 3.44e-01 2.52e-02 3.17e-02 0.875000
Diseases associated with the TLR signaling cascade 18 4.25e-02 1.31e-01 0.34200 -5.74e-02 -3.37e-01 6.73e-01 0.013300
Diseases of Immune System 18 4.25e-02 1.31e-01 0.34200 -5.74e-02 -3.37e-01 6.73e-01 0.013300
Gap-filling DNA repair synthesis and ligation in TC-NER 42 6.40e-04 3.51e-03 0.34200 3.19e-01 1.24e-01 3.58e-04 0.165000
Detoxification of Reactive Oxygen Species 20 3.03e-02 1.00e-01 0.34200 3.41e-01 2.11e-02 8.32e-03 0.870000
UCH proteinases 60 3.05e-05 2.66e-04 0.34000 3.38e-01 4.49e-02 6.26e-06 0.548000
Cell Cycle 443 4.25e-33 2.64e-30 0.34000 3.33e-01 7.28e-02 9.97e-33 0.009290
Regulation of RUNX2 expression and activity 49 2.07e-04 1.36e-03 0.34000 3.40e-01 -4.69e-03 3.81e-05 0.955000
SARS-CoV-1 Infection 29 6.74e-03 2.80e-02 0.33900 3.04e-01 1.50e-01 4.63e-03 0.163000
Formation of the cornified envelope 21 2.74e-02 9.18e-02 0.33700 -2.35e-01 -2.43e-01 6.28e-02 0.054500
Transcriptional regulation by small RNAs 29 7.23e-03 2.99e-02 0.33700 3.24e-01 9.01e-02 2.51e-03 0.401000
Phase 0 - rapid depolarisation 29 7.52e-03 3.09e-02 0.33600 -3.33e-01 -3.91e-02 1.91e-03 0.716000
ECM proteoglycans 42 8.71e-04 4.59e-03 0.33400 -2.81e-01 -1.81e-01 1.62e-03 0.043100
Late endosomal microautophagy 18 5.03e-02 1.46e-01 0.33400 2.88e-01 -1.69e-01 3.45e-02 0.216000
VEGFR2 mediated cell proliferation 19 4.22e-02 1.30e-01 0.33400 -3.33e-01 2.59e-02 1.21e-02 0.845000
IRE1alpha activates chaperones 40 1.31e-03 6.65e-03 0.33400 3.17e-01 -1.03e-01 5.19e-04 0.262000
Glutamate Neurotransmitter Release Cycle 15 8.18e-02 2.03e-01 0.33300 -3.20e-01 -9.48e-02 3.21e-02 0.525000
Loss of Nlp from mitotic centrosomes 55 1.10e-04 7.86e-04 0.33300 3.22e-01 8.53e-02 3.76e-05 0.274000
Loss of proteins required for interphase microtubule organization from the centrosome 55 1.10e-04 7.86e-04 0.33300 3.22e-01 8.53e-02 3.76e-05 0.274000
Effects of PIP2 hydrolysis 19 4.26e-02 1.31e-01 0.33200 -2.91e-01 -1.60e-01 2.80e-02 0.226000
Telomere Extension By Telomerase 15 8.26e-02 2.05e-01 0.33200 2.46e-01 2.24e-01 9.93e-02 0.134000
TICAM1, RIP1-mediated IKK complex recruitment 12 1.42e-01 3.06e-01 0.33000 -3.17e-01 9.20e-02 5.77e-02 0.581000
Regulation of PLK1 Activity at G2/M Transition 62 4.41e-05 3.50e-04 0.32900 2.99e-01 1.35e-01 4.63e-05 0.065400
Glycogen breakdown (glycogenolysis) 12 1.44e-01 3.08e-01 0.32800 -3.24e-01 5.68e-02 5.24e-02 0.733000
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 53 1.97e-04 1.32e-03 0.32800 3.25e-01 4.61e-02 4.37e-05 0.562000
EGR2 and SOX10-mediated initiation of Schwann cell myelination 22 2.98e-02 9.90e-02 0.32700 -3.23e-01 5.02e-02 8.77e-03 0.684000
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 16 7.69e-02 1.94e-01 0.32700 1.10e-01 3.08e-01 4.47e-01 0.033200
Cleavage of the damaged purine 10 2.01e-01 3.85e-01 0.32700 1.93e-01 2.64e-01 2.92e-01 0.149000
Depurination 10 2.01e-01 3.85e-01 0.32700 1.93e-01 2.64e-01 2.92e-01 0.149000
Recognition and association of DNA glycosylase with site containing an affected purine 10 2.01e-01 3.85e-01 0.32700 1.93e-01 2.64e-01 2.92e-01 0.149000
Citric acid cycle (TCA cycle) 15 9.14e-02 2.18e-01 0.32700 -5.88e-02 3.21e-01 6.93e-01 0.031300
Regulation of beta-cell development 20 4.17e-02 1.30e-01 0.32600 -2.69e-01 1.84e-01 3.70e-02 0.154000
APC-Cdc20 mediated degradation of Nek2A 19 4.86e-02 1.43e-01 0.32600 3.20e-01 -6.43e-02 1.58e-02 0.628000
Assembly and cell surface presentation of NMDA receptors 16 7.75e-02 1.95e-01 0.32600 -3.07e-01 -1.10e-01 3.35e-02 0.447000
Ion homeostasis 37 2.86e-03 1.37e-02 0.32600 -3.01e-01 1.24e-01 1.53e-03 0.191000
Ca2+ pathway 48 5.12e-04 2.91e-03 0.32600 -3.01e-01 1.23e-01 3.08e-04 0.140000
Global Genome Nucleotide Excision Repair (GG-NER) 60 7.56e-05 5.61e-04 0.32500 3.22e-01 4.73e-02 1.65e-05 0.527000
Rap1 signalling 14 1.10e-01 2.52e-01 0.32500 -3.14e-01 8.41e-02 4.20e-02 0.586000
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 24 2.39e-02 8.18e-02 0.32300 -3.16e-01 6.39e-02 7.35e-03 0.588000
PI-3K cascade:FGFR4 11 1.79e-01 3.61e-01 0.32200 -2.26e-01 -2.30e-01 1.95e-01 0.187000
Degradation of beta-catenin by the destruction complex 61 9.00e-05 6.59e-04 0.32000 3.18e-01 3.14e-02 1.76e-05 0.671000
Endosomal Sorting Complex Required For Transport (ESCRT) 18 6.42e-02 1.75e-01 0.31900 3.19e-01 -9.46e-03 1.92e-02 0.945000
Regulation of RAS by GAPs 49 5.78e-04 3.23e-03 0.31900 3.10e-01 7.26e-02 1.72e-04 0.380000
TRAF6 mediated IRF7 activation 15 1.04e-01 2.41e-01 0.31800 -7.17e-02 3.10e-01 6.31e-01 0.037800
LDL clearance 13 1.39e-01 3.01e-01 0.31800 2.95e-01 1.19e-01 6.60e-02 0.456000
CASP8 activity is inhibited 10 2.21e-01 4.05e-01 0.31800 -3.00e-01 1.04e-01 1.00e-01 0.568000
Dimerization of procaspase-8 10 2.21e-01 4.05e-01 0.31800 -3.00e-01 1.04e-01 1.00e-01 0.568000
Regulation by c-FLIP 10 2.21e-01 4.05e-01 0.31800 -3.00e-01 1.04e-01 1.00e-01 0.568000
Uptake and actions of bacterial toxins 26 1.96e-02 6.93e-02 0.31700 -2.94e-01 -1.20e-01 9.55e-03 0.290000
FCERI mediated NF-kB activation 54 2.99e-04 1.88e-03 0.31700 3.17e-01 1.27e-03 5.62e-05 0.987000
Iron uptake and transport 36 4.62e-03 2.10e-02 0.31500 2.74e-01 1.57e-01 4.54e-03 0.103000
Recruitment of NuMA to mitotic centrosomes 64 8.36e-05 6.16e-04 0.31300 3.06e-01 6.67e-02 2.34e-05 0.357000
Hedgehog 'off' state 71 3.29e-05 2.78e-04 0.31200 3.09e-01 4.37e-02 6.92e-06 0.525000
Defective B3GALTL causes Peters-plus syndrome (PpS) 30 1.25e-02 4.70e-02 0.31200 -1.99e-01 -2.40e-01 5.88e-02 0.023300
RHO GTPases Activate Formins 88 2.96e-06 3.33e-05 0.31100 3.04e-01 6.88e-02 8.83e-07 0.266000
HCMV Infection 59 2.04e-04 1.35e-03 0.31100 3.10e-01 2.18e-02 3.93e-05 0.772000
O-glycosylation of TSR domain-containing proteins 31 1.13e-02 4.32e-02 0.31000 -1.84e-01 -2.50e-01 7.71e-02 0.016000
Inactivation of APC/C via direct inhibition of the APC/C complex 18 7.67e-02 1.94e-01 0.30900 3.07e-01 -2.83e-02 2.40e-02 0.835000
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 18 7.67e-02 1.94e-01 0.30900 3.07e-01 -2.83e-02 2.40e-02 0.835000
Nucleotide-like (purinergic) receptors 10 2.39e-01 4.25e-01 0.30900 -2.59e-02 -3.08e-01 8.87e-01 0.092100
HS-GAG degradation 15 1.18e-01 2.66e-01 0.30800 -1.08e-02 -3.08e-01 9.42e-01 0.038800
Translation of structural proteins 18 7.67e-02 1.94e-01 0.30800 2.55e-01 1.72e-01 6.08e-02 0.206000
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models 17 8.88e-02 2.15e-01 0.30800 2.62e-01 1.61e-01 6.11e-02 0.251000
Neurodegenerative Diseases 17 8.88e-02 2.15e-01 0.30800 2.62e-01 1.61e-01 6.11e-02 0.251000
Aberrant regulation of mitotic cell cycle due to RB1 defects 30 1.44e-02 5.35e-02 0.30700 2.99e-01 7.14e-02 4.68e-03 0.499000
Diseases of mitotic cell cycle 30 1.44e-02 5.35e-02 0.30700 2.99e-01 7.14e-02 4.68e-03 0.499000
G2/M DNA damage checkpoint 43 2.41e-03 1.17e-02 0.30600 3.03e-01 4.36e-02 5.94e-04 0.621000
Voltage gated Potassium channels 21 5.27e-02 1.51e-01 0.30600 -3.06e-01 8.23e-03 1.53e-02 0.948000
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 13 1.63e-01 3.37e-01 0.30600 1.80e-01 -2.47e-01 2.61e-01 0.123000
Mitochondrial tRNA aminoacylation 12 1.90e-01 3.74e-01 0.30500 2.37e-01 -1.91e-01 1.55e-01 0.252000
Collagen formation 61 2.08e-04 1.36e-03 0.30400 -2.38e-01 -1.90e-01 1.34e-03 0.010200
Neurexins and neuroligins 37 5.81e-03 2.51e-02 0.30400 -2.00e-01 -2.29e-01 3.51e-02 0.015900
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 19 7.22e-02 1.87e-01 0.30400 -3.00e-01 5.26e-02 2.38e-02 0.692000
Cardiac conduction 83 1.19e-05 1.13e-04 0.30300 -3.00e-01 4.41e-02 2.42e-06 0.488000
RIPK1-mediated regulated necrosis 14 1.48e-01 3.14e-01 0.30300 -2.69e-01 1.39e-01 8.20e-02 0.367000
Regulated Necrosis 14 1.48e-01 3.14e-01 0.30300 -2.69e-01 1.39e-01 8.20e-02 0.367000
Integrin cell surface interactions 52 8.56e-04 4.53e-03 0.30100 -2.73e-01 -1.28e-01 6.83e-04 0.111000
Unblocking of NMDA receptors, glutamate binding and activation 14 1.50e-01 3.18e-01 0.30100 -3.00e-01 -2.40e-02 5.24e-02 0.877000
Glutamate binding, activation of AMPA receptors and synaptic plasticity 23 4.45e-02 1.35e-01 0.30000 -2.94e-01 -6.19e-02 1.47e-02 0.607000
Trafficking of AMPA receptors 23 4.45e-02 1.35e-01 0.30000 -2.94e-01 -6.19e-02 1.47e-02 0.607000
APC/C:Cdc20 mediated degradation of Cyclin B 18 8.80e-02 2.15e-01 0.30000 2.98e-01 -3.80e-02 2.87e-02 0.780000
Platelet calcium homeostasis 20 6.76e-02 1.80e-01 0.30000 -2.87e-01 -8.55e-02 2.63e-02 0.508000
Regulation of IFNA signaling 10 2.60e-01 4.48e-01 0.29900 2.95e-01 5.19e-02 1.06e-01 0.777000
Regulation of cholesterol biosynthesis by SREBP (SREBF) 45 2.61e-03 1.25e-02 0.29800 -2.93e-01 5.16e-02 6.75e-04 0.550000
Fatty acyl-CoA biosynthesis 22 5.51e-02 1.58e-01 0.29700 -1.93e-01 2.26e-01 1.17e-01 0.066300
Glycogen metabolism 19 8.13e-02 2.02e-01 0.29700 -2.94e-01 3.99e-02 2.63e-02 0.763000
Anchoring of the basal body to the plasma membrane 75 5.57e-05 4.18e-04 0.29600 2.90e-01 6.03e-02 1.49e-05 0.368000
Dual incision in TC-NER 43 3.64e-03 1.69e-02 0.29500 2.89e-01 5.86e-02 1.03e-03 0.507000
Blood group systems biosynthesis 12 2.11e-01 3.99e-01 0.29500 2.69e-01 -1.20e-01 1.07e-01 0.471000
HIV Infection 152 3.17e-09 8.22e-08 0.29500 2.94e-01 1.78e-02 4.29e-10 0.706000
SUMOylation of DNA damage response and repair proteins 50 1.50e-03 7.37e-03 0.29500 2.64e-01 1.30e-01 1.25e-03 0.111000
Muscle contraction 134 3.35e-08 5.79e-07 0.29400 -2.93e-01 2.72e-02 5.08e-09 0.588000
Activated NOTCH1 Transmits Signal to the Nucleus 20 7.39e-02 1.90e-01 0.29400 -1.96e-01 -2.20e-01 1.30e-01 0.089100
eNOS activation 10 2.76e-01 4.65e-01 0.29300 -6.95e-02 -2.84e-01 7.04e-01 0.120000
Antiviral mechanism by IFN-stimulated genes 53 1.14e-03 5.92e-03 0.29200 2.53e-01 1.46e-01 1.44e-03 0.067100
Metabolism of nucleotides 72 1.08e-04 7.79e-04 0.29100 2.85e-01 6.07e-02 2.97e-05 0.374000
Aberrant regulation of mitotic exit in cancer due to RB1 defects 18 1.02e-01 2.39e-01 0.29100 2.85e-01 -5.97e-02 3.64e-02 0.661000
The role of Nef in HIV-1 replication and disease pathogenesis 23 5.39e-02 1.55e-01 0.29100 7.23e-02 2.82e-01 5.49e-01 0.019400
Deactivation of the beta-catenin transactivating complex 27 3.35e-02 1.10e-01 0.28900 -2.33e-01 -1.71e-01 3.60e-02 0.124000
Meiotic synapsis 24 4.89e-02 1.44e-01 0.28900 1.80e-01 2.26e-01 1.26e-01 0.055300
mTORC1-mediated signalling 17 1.18e-01 2.66e-01 0.28900 1.30e-01 2.58e-01 3.54e-01 0.065500
Synthesis of PIPs at the early endosome membrane 14 1.75e-01 3.56e-01 0.28800 -2.78e-01 7.73e-02 7.20e-02 0.617000
Spry regulation of FGF signaling 10 2.87e-01 4.76e-01 0.28800 1.68e-01 2.34e-01 3.57e-01 0.201000
Protein-protein interactions at synapses 53 1.39e-03 6.90e-03 0.28800 -1.76e-01 -2.28e-01 2.69e-02 0.004200
Synthesis of PC 19 9.48e-02 2.24e-01 0.28800 4.60e-02 2.84e-01 7.28e-01 0.032200
ISG15 antiviral mechanism 47 2.96e-03 1.41e-02 0.28700 2.46e-01 1.49e-01 3.55e-03 0.078300
Centrosome maturation 65 3.30e-04 2.03e-03 0.28700 2.79e-01 6.68e-02 1.00e-04 0.352000
Recruitment of mitotic centrosome proteins and complexes 65 3.30e-04 2.03e-03 0.28700 2.79e-01 6.68e-02 1.00e-04 0.352000
Regulation of KIT signaling 11 2.59e-01 4.47e-01 0.28700 -2.47e-01 1.46e-01 1.57e-01 0.402000
MAPK6/MAPK4 signaling 61 5.76e-04 3.23e-03 0.28600 2.77e-01 6.95e-02 1.82e-04 0.349000
PI3K Cascade 29 2.85e-02 9.47e-02 0.28600 -1.45e-01 -2.46e-01 1.76e-01 0.021900
Signaling by NOTCH4 61 6.38e-04 3.51e-03 0.28400 2.83e-01 2.49e-02 1.34e-04 0.737000
Platelet sensitization by LDL 14 1.85e-01 3.67e-01 0.28400 2.59e-01 -1.16e-01 9.30e-02 0.453000
Deadenylation of mRNA 17 1.31e-01 2.89e-01 0.28300 -1.24e-01 2.55e-01 3.78e-01 0.069200
FOXO-mediated transcription of cell cycle genes 13 2.12e-01 3.99e-01 0.28200 -2.82e-01 3.21e-03 7.82e-02 0.984000
Regulation of FZD by ubiquitination 11 2.73e-01 4.61e-01 0.28100 -2.67e-01 8.75e-02 1.25e-01 0.616000
NCAM1 interactions 26 4.58e-02 1.37e-01 0.28100 -1.77e-01 -2.18e-01 1.19e-01 0.054100
HIV elongation arrest and recovery 15 1.72e-01 3.50e-01 0.28100 2.10e-01 -1.85e-01 1.58e-01 0.214000
Pausing and recovery of HIV elongation 15 1.72e-01 3.50e-01 0.28100 2.10e-01 -1.85e-01 1.58e-01 0.214000
Pausing and recovery of Tat-mediated HIV elongation 15 1.72e-01 3.50e-01 0.28100 2.10e-01 -1.85e-01 1.58e-01 0.214000
Tat-mediated HIV elongation arrest and recovery 15 1.72e-01 3.50e-01 0.28100 2.10e-01 -1.85e-01 1.58e-01 0.214000
Formation of tubulin folding intermediates by CCT/TriC 15 1.71e-01 3.50e-01 0.28000 5.96e-02 2.74e-01 6.90e-01 0.066600
Regulation of TNFR1 signaling 24 6.15e-02 1.70e-01 0.27800 -2.74e-01 -5.14e-02 2.04e-02 0.663000
DNA Repair 197 1.64e-10 8.50e-09 0.27800 2.76e-01 3.32e-02 2.71e-11 0.424000
ER Quality Control Compartment (ERQC) 11 2.83e-01 4.73e-01 0.27700 1.22e-01 -2.49e-01 4.85e-01 0.152000
Signal regulatory protein family interactions 11 2.84e-01 4.74e-01 0.27600 2.76e-01 1.06e-02 1.13e-01 0.951000
NOD1/2 Signaling Pathway 24 6.47e-02 1.75e-01 0.27600 -2.76e-01 9.53e-03 1.93e-02 0.936000
NOTCH2 Activation and Transmission of Signal to the Nucleus 13 2.25e-01 4.08e-01 0.27600 -1.91e-01 -1.99e-01 2.33e-01 0.214000
Gap junction trafficking 13 2.26e-01 4.08e-01 0.27600 2.29e-01 1.54e-01 1.53e-01 0.336000
Signaling by FGFR4 in disease 10 3.22e-01 5.06e-01 0.27500 -2.69e-01 5.83e-02 1.41e-01 0.750000
FCERI mediated MAPK activation 25 6.02e-02 1.68e-01 0.27500 -1.55e-01 2.27e-01 1.80e-01 0.049800
Signaling by RAF1 mutants 27 4.91e-02 1.44e-01 0.27400 -2.33e-01 1.44e-01 3.66e-02 0.195000
TRAF3-dependent IRF activation pathway 13 2.34e-01 4.17e-01 0.27300 -3.85e-02 2.71e-01 8.10e-01 0.091200
MicroRNA (miRNA) biogenesis 13 2.36e-01 4.19e-01 0.27300 1.98e-01 -1.88e-01 2.16e-01 0.242000
A tetrasaccharide linker sequence is required for GAG synthesis 17 1.49e-01 3.17e-01 0.27300 -1.41e-01 -2.34e-01 3.15e-01 0.095500
Nonhomologous End-Joining (NHEJ) 24 6.96e-02 1.83e-01 0.27200 2.61e-01 7.59e-02 2.68e-02 0.520000
Regulation of mRNA stability by proteins that bind AU-rich elements 60 1.32e-03 6.66e-03 0.27200 2.70e-01 3.10e-02 2.99e-04 0.679000
Mitochondrial calcium ion transport 16 1.69e-01 3.47e-01 0.27200 1.65e-01 2.16e-01 2.52e-01 0.135000
CRMPs in Sema3A signaling 13 2.40e-01 4.25e-01 0.27100 -2.70e-01 2.03e-02 9.21e-02 0.899000
Defective B3GAT3 causes JDSSDHD 14 2.15e-01 4.02e-01 0.27000 -6.06e-02 -2.63e-01 6.95e-01 0.087900
Gluconeogenesis 22 8.95e-02 2.16e-01 0.27000 -2.17e-01 -1.61e-01 7.87e-02 0.191000
Metalloprotease DUBs 15 1.94e-01 3.80e-01 0.27000 8.68e-02 2.56e-01 5.61e-01 0.086600
Termination of O-glycan biosynthesis 12 2.71e-01 4.60e-01 0.27000 2.24e-01 -1.50e-01 1.79e-01 0.367000
Late Phase of HIV Life Cycle 84 1.13e-04 8.00e-04 0.27000 2.65e-01 -5.20e-02 2.83e-05 0.411000
Insulin receptor recycling 12 2.71e-01 4.60e-01 0.27000 2.20e-02 2.69e-01 8.95e-01 0.107000
Signaling by NTRK3 (TRKC) 15 1.96e-01 3.81e-01 0.26900 -2.69e-01 -4.33e-04 7.09e-02 0.998000
Signaling by NODAL 16 1.78e-01 3.59e-01 0.26900 1.64e-01 -2.13e-01 2.55e-01 0.140000
Phosphorylation of the APC/C 17 1.60e-01 3.33e-01 0.26800 2.66e-01 -3.48e-02 5.75e-02 0.804000
HCMV Early Events 44 8.88e-03 3.53e-02 0.26800 2.68e-01 -9.71e-03 2.12e-03 0.911000
Nucleotide Excision Repair 75 3.21e-04 1.99e-03 0.26800 2.59e-01 6.72e-02 1.05e-04 0.315000
MECP2 regulates neuronal receptors and channels 11 3.07e-01 4.94e-01 0.26700 -2.33e-01 -1.31e-01 1.82e-01 0.451000
Signaling by cytosolic FGFR1 fusion mutants 16 1.82e-01 3.65e-01 0.26700 -2.28e-01 1.40e-01 1.15e-01 0.333000
Interleukin-7 signaling 14 2.24e-01 4.06e-01 0.26700 -2.26e-01 -1.42e-01 1.44e-01 0.357000
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 25 6.98e-02 1.83e-01 0.26700 4.10e-02 2.63e-01 7.23e-01 0.022700
Regulation of Complement cascade 31 3.78e-02 1.20e-01 0.26600 1.96e-01 -1.80e-01 5.92e-02 0.082200
Diseases associated with O-glycosylation of proteins 46 7.71e-03 3.14e-02 0.26600 -1.42e-01 -2.24e-01 9.64e-02 0.008490
Signaling by Leptin 10 3.54e-01 5.37e-01 0.26400 -2.61e-01 3.47e-02 1.53e-01 0.849000
mRNA decay by 3' to 5' exoribonuclease 10 3.52e-01 5.37e-01 0.26300 2.26e-01 1.35e-01 2.16e-01 0.458000
Activation of Matrix Metalloproteinases 18 1.54e-01 3.24e-01 0.26300 -1.30e-01 -2.29e-01 3.41e-01 0.093200
Molecules associated with elastic fibres 26 6.78e-02 1.80e-01 0.26300 -2.58e-01 -5.02e-02 2.29e-02 0.658000
PI-3K cascade:FGFR2 12 2.91e-01 4.79e-01 0.26200 -2.47e-01 -8.59e-02 1.38e-01 0.607000
Reduction of cytosolic Ca++ levels 10 3.62e-01 5.46e-01 0.26100 -2.42e-01 9.69e-02 1.85e-01 0.596000
Tight junction interactions 12 2.93e-01 4.81e-01 0.26100 -1.70e-01 -1.97e-01 3.07e-01 0.236000
FRS-mediated FGFR4 signaling 11 3.26e-01 5.10e-01 0.26000 -2.14e-01 -1.48e-01 2.19e-01 0.395000
Transcriptional Regulation by E2F6 27 6.57e-02 1.77e-01 0.25900 2.31e-01 1.18e-01 3.83e-02 0.287000
IKK complex recruitment mediated by RIP1 15 2.23e-01 4.06e-01 0.25800 -2.58e-01 -2.13e-02 8.43e-02 0.886000
Sealing of the nuclear envelope (NE) by ESCRT-III 19 1.50e-01 3.18e-01 0.25800 1.05e-01 2.35e-01 4.26e-01 0.076000
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane 10 3.71e-01 5.56e-01 0.25700 8.31e-02 2.43e-01 6.49e-01 0.183000
Role of phospholipids in phagocytosis 25 8.67e-02 2.13e-01 0.25600 1.23e-01 -2.24e-01 2.85e-01 0.052200
ERKs are inactivated 11 3.38e-01 5.25e-01 0.25600 2.25e-01 1.22e-01 1.96e-01 0.484000
p38MAPK events 12 3.10e-01 4.96e-01 0.25600 -2.11e-01 1.45e-01 2.06e-01 0.385000
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 11 3.41e-01 5.28e-01 0.25600 2.56e-01 -6.91e-03 1.42e-01 0.968000
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 18 1.74e-01 3.54e-01 0.25500 2.43e-01 -7.72e-02 7.45e-02 0.571000
Netrin-1 signaling 40 2.07e-02 7.19e-02 0.25500 -2.54e-01 -1.29e-02 5.42e-03 0.888000
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 13 2.83e-01 4.73e-01 0.25400 2.52e-01 3.52e-02 1.16e-01 0.826000
EPHA-mediated growth cone collapse 11 3.47e-01 5.33e-01 0.25400 -1.74e-01 1.85e-01 3.17e-01 0.288000
Processing of SMDT1 11 3.46e-01 5.32e-01 0.25400 2.36e-01 9.16e-02 1.75e-01 0.599000
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 10 3.80e-01 5.65e-01 0.25400 -1.64e-01 -1.93e-01 3.68e-01 0.291000
DAG and IP3 signaling 33 4.21e-02 1.30e-01 0.25300 -2.52e-01 2.65e-02 1.23e-02 0.792000
Apoptotic cleavage of cellular proteins 30 5.74e-02 1.62e-01 0.25300 -1.63e-01 1.93e-01 1.22e-01 0.067100
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 25 9.47e-02 2.24e-01 0.25200 -2.05e-01 1.46e-01 7.65e-02 0.207000
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 12 3.24e-01 5.07e-01 0.25000 2.45e-01 4.95e-02 1.41e-01 0.767000
SARS-CoV Infections 55 5.72e-03 2.48e-02 0.25000 2.23e-01 1.14e-01 4.29e-03 0.144000
Collagen biosynthesis and modifying enzymes 47 1.25e-02 4.70e-02 0.24900 -1.88e-01 -1.63e-01 2.57e-02 0.052800
Signaling by FGFR3 in disease 13 3.01e-01 4.88e-01 0.24900 -2.46e-01 3.72e-02 1.25e-01 0.816000
Signaling by FGFR3 point mutants in cancer 13 3.01e-01 4.88e-01 0.24900 -2.46e-01 3.72e-02 1.25e-01 0.816000
RNA Polymerase I Transcription Termination 16 2.29e-01 4.12e-01 0.24900 1.25e-01 -2.15e-01 3.86e-01 0.137000
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 12 3.32e-01 5.17e-01 0.24800 -9.61e-02 2.29e-01 5.65e-01 0.170000
Downstream signaling of activated FGFR4 16 2.29e-01 4.12e-01 0.24800 -2.16e-01 -1.21e-01 1.34e-01 0.403000
Downstream signaling events of B Cell Receptor (BCR) 56 6.12e-03 2.60e-02 0.24700 2.44e-01 -3.66e-02 1.58e-03 0.636000
Class I peroxisomal membrane protein import 10 4.03e-01 5.86e-01 0.24700 1.53e-01 -1.94e-01 4.02e-01 0.289000
Chondroitin sulfate biosynthesis 16 2.31e-01 4.14e-01 0.24700 9.41e-02 2.28e-01 5.15e-01 0.114000
Gene Silencing by RNA 43 2.00e-02 7.02e-02 0.24700 2.45e-01 2.64e-02 5.44e-03 0.765000
RHO GTPases activate PKNs 27 8.68e-02 2.13e-01 0.24600 -1.57e-01 1.90e-01 1.57e-01 0.088100
Integrin signaling 20 1.64e-01 3.38e-01 0.24600 -2.45e-01 2.62e-02 5.84e-02 0.839000
HIV Life Cycle 92 2.56e-04 1.64e-03 0.24600 2.45e-01 -2.29e-02 5.09e-05 0.705000
Acyl chain remodelling of PS 14 2.83e-01 4.73e-01 0.24600 2.30e-02 -2.44e-01 8.82e-01 0.113000
Smooth Muscle Contraction 26 9.65e-02 2.27e-01 0.24500 -2.03e-02 2.44e-01 8.58e-01 0.031100
Apoptotic execution phase 37 3.68e-02 1.18e-01 0.24500 -1.33e-01 2.06e-01 1.62e-01 0.030600
IRS-mediated signalling 32 5.63e-02 1.60e-01 0.24500 -1.50e-01 -1.93e-01 1.42e-01 0.058500
DNA Damage Recognition in GG-NER 25 1.07e-01 2.47e-01 0.24400 2.44e-01 -1.43e-02 3.48e-02 0.901000
Interferon Signaling 116 3.38e-05 2.81e-04 0.24400 2.33e-01 7.33e-02 1.54e-05 0.174000
DNA Damage/Telomere Stress Induced Senescence 20 1.68e-01 3.47e-01 0.24400 2.29e-01 8.24e-02 7.59e-02 0.524000
Complex I biogenesis 35 4.48e-02 1.35e-01 0.24400 2.43e-01 1.53e-02 1.29e-02 0.876000
Meiotic recombination 19 1.86e-01 3.68e-01 0.24300 2.34e-01 6.49e-02 7.74e-02 0.624000
Myogenesis 22 1.42e-01 3.06e-01 0.24300 -1.58e-01 -1.84e-01 1.99e-01 0.135000
Amine ligand-binding receptors 14 2.92e-01 4.79e-01 0.24200 -2.02e-01 -1.33e-01 1.90e-01 0.391000
Dissolution of Fibrin Clot 11 3.82e-01 5.66e-01 0.24200 -5.53e-02 2.35e-01 7.51e-01 0.176000
Metabolism of amino acids and derivatives 197 4.45e-08 7.19e-07 0.24200 2.38e-01 -3.97e-02 9.28e-09 0.338000
DCC mediated attractive signaling 12 3.51e-01 5.36e-01 0.24100 -2.40e-01 2.32e-02 1.50e-01 0.889000
PERK regulates gene expression 19 1.90e-01 3.74e-01 0.24100 1.47e-01 1.91e-01 2.66e-01 0.150000
Negative epigenetic regulation of rRNA expression 28 8.84e-02 2.15e-01 0.24100 1.83e-01 -1.57e-01 9.44e-02 0.150000
Glyoxylate metabolism and glycine degradation 23 1.35e-01 2.94e-01 0.24100 -1.19e-01 -2.09e-01 3.23e-01 0.082400
Elastic fibre formation 31 6.80e-02 1.81e-01 0.24100 -2.40e-01 -1.67e-02 2.08e-02 0.872000
Formation of the Early Elongation Complex 19 1.93e-01 3.79e-01 0.24100 2.40e-01 9.74e-03 6.99e-02 0.941000
Formation of the HIV-1 Early Elongation Complex 19 1.93e-01 3.79e-01 0.24100 2.40e-01 9.74e-03 6.99e-02 0.941000
Transport of Mature Transcript to Cytoplasm 59 6.02e-03 2.59e-02 0.24100 2.02e-01 1.30e-01 7.28e-03 0.084300
Neurotransmitter release cycle 25 1.16e-01 2.62e-01 0.24000 -2.26e-01 -7.83e-02 5.01e-02 0.498000
MHC class II antigen presentation 84 7.92e-04 4.23e-03 0.23900 2.01e-01 -1.30e-01 1.47e-03 0.039900
TNFR1-induced NFkappaB signaling pathway 22 1.52e-01 3.19e-01 0.23900 -2.20e-01 -9.38e-02 7.45e-02 0.446000
RHO GTPases activate IQGAPs 10 4.26e-01 6.03e-01 0.23800 2.31e-01 5.71e-02 2.05e-01 0.755000
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 11 3.94e-01 5.79e-01 0.23800 -4.25e-02 2.34e-01 8.07e-01 0.179000
Glycosphingolipid metabolism 26 1.11e-01 2.53e-01 0.23800 2.38e-01 4.58e-03 3.59e-02 0.968000
Extracellular matrix organization 204 3.83e-08 6.36e-07 0.23800 -1.79e-01 -1.57e-01 1.15e-05 0.000124
Circadian Clock 53 1.18e-02 4.48e-02 0.23700 -2.06e-01 1.18e-01 9.67e-03 0.137000
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 37 4.44e-02 1.35e-01 0.23700 -1.21e-01 -2.03e-01 2.02e-01 0.032500
FRS-mediated FGFR2 signaling 12 3.66e-01 5.51e-01 0.23700 -2.36e-01 -1.08e-02 1.57e-01 0.948000
NOTCH4 Intracellular Domain Regulates Transcription 18 2.24e-01 4.06e-01 0.23600 -1.48e-01 1.84e-01 2.77e-01 0.177000
Heparan sulfate/heparin (HS-GAG) metabolism 34 5.93e-02 1.66e-01 0.23600 8.22e-02 -2.21e-01 4.07e-01 0.025600
Biosynthesis of specialized proresolving mediators (SPMs) 12 3.67e-01 5.52e-01 0.23600 2.36e-01 6.84e-03 1.57e-01 0.967000
RORA activates gene expression 16 2.65e-01 4.52e-01 0.23600 -2.00e-01 1.25e-01 1.65e-01 0.389000
TNF signaling 31 7.56e-02 1.93e-01 0.23600 -2.35e-01 -2.32e-02 2.38e-02 0.823000
Transcriptional regulation by RUNX2 81 1.22e-03 6.27e-03 0.23600 2.35e-01 2.19e-02 2.66e-04 0.733000
Respiratory electron transport 59 7.57e-03 3.10e-02 0.23600 2.32e-01 -4.19e-02 2.08e-03 0.578000
RNA Polymerase I Transcription Initiation 29 9.10e-02 2.18e-01 0.23600 1.49e-01 -1.82e-01 1.64e-01 0.089700
Sialic acid metabolism 23 1.51e-01 3.18e-01 0.23500 1.92e-01 -1.35e-01 1.11e-01 0.262000
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) 10 4.37e-01 6.09e-01 0.23500 4.32e-02 2.31e-01 8.13e-01 0.206000
Disorders of transmembrane transporters 110 1.23e-04 8.59e-04 0.23500 2.34e-01 1.63e-02 2.31e-05 0.769000
Abortive elongation of HIV-1 transcript in the absence of Tat 12 3.72e-01 5.56e-01 0.23500 2.33e-01 -2.25e-02 1.62e-01 0.893000
Regulation of insulin secretion 55 1.09e-02 4.20e-02 0.23400 -2.23e-01 -7.25e-02 4.31e-03 0.353000
GPVI-mediated activation cascade 25 1.29e-01 2.86e-01 0.23400 -2.34e-01 1.47e-02 4.33e-02 0.899000
RNA Polymerase I Promoter Escape 16 2.71e-01 4.60e-01 0.23400 2.01e-01 -1.19e-01 1.63e-01 0.410000
Downstream signaling of activated FGFR2 17 2.50e-01 4.35e-01 0.23300 -2.32e-01 -2.55e-02 9.79e-02 0.856000
Regulation of TP53 Activity through Phosphorylation 63 6.13e-03 2.60e-02 0.23300 1.93e-01 -1.32e-01 8.27e-03 0.071200
Triglyceride catabolism 13 3.45e-01 5.32e-01 0.23300 -1.51e-01 -1.77e-01 3.45e-01 0.268000
NoRC negatively regulates rRNA expression 25 1.32e-01 2.89e-01 0.23300 1.83e-01 -1.45e-01 1.14e-01 0.210000
Cell junction organization 51 1.59e-02 5.80e-02 0.23300 -2.08e-01 -1.05e-01 1.04e-02 0.193000
DNA Double Strand Break Response 32 7.53e-02 1.93e-01 0.23200 2.27e-01 5.10e-02 2.66e-02 0.618000
RNA Polymerase I Promoter Clearance 32 7.70e-02 1.94e-01 0.23200 1.99e-01 -1.20e-01 5.18e-02 0.242000
Signaling by Activin 10 4.47e-01 6.17e-01 0.23200 -2.27e-01 4.50e-02 2.13e-01 0.805000
CTLA4 inhibitory signaling 19 2.18e-01 4.05e-01 0.23200 2.08e-01 -1.02e-01 1.16e-01 0.444000
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 11 4.16e-01 5.98e-01 0.23100 -1.76e-01 1.49e-01 3.11e-01 0.391000
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 32 7.69e-02 1.94e-01 0.23100 -2.10e-01 -9.73e-02 4.02e-02 0.341000
ATF4 activates genes in response to endoplasmic reticulum stress 16 2.77e-01 4.66e-01 0.23100 1.42e-01 1.82e-01 3.27e-01 0.207000
CS/DS degradation 11 4.18e-01 5.98e-01 0.23000 2.06e-01 -1.03e-01 2.37e-01 0.554000
Prefoldin mediated transfer of substrate to CCT/TriC 19 2.20e-01 4.05e-01 0.23000 1.19e-01 1.97e-01 3.70e-01 0.137000
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 20 2.06e-01 3.95e-01 0.22900 6.33e-02 2.20e-01 6.24e-01 0.088100
Signaling by EGFR 35 6.42e-02 1.75e-01 0.22900 -2.26e-01 -3.88e-02 2.10e-02 0.692000
Transport of Mature mRNA derived from an Intron-Containing Transcript 53 1.60e-02 5.84e-02 0.22800 1.94e-01 1.21e-01 1.49e-02 0.129000
Signaling by BMP 21 1.95e-01 3.80e-01 0.22800 -1.76e-01 -1.45e-01 1.63e-01 0.251000
Prolonged ERK activation events 12 3.98e-01 5.84e-01 0.22700 -1.09e-01 1.99e-01 5.14e-01 0.233000
Gap junction trafficking and regulation 15 3.18e-01 5.03e-01 0.22500 1.96e-01 1.12e-01 1.90e-01 0.455000
SUMOylation of RNA binding proteins 35 7.03e-02 1.84e-01 0.22500 2.07e-01 8.84e-02 3.44e-02 0.366000
Unfolded Protein Response (UPR) 64 8.35e-03 3.35e-02 0.22400 2.21e-01 -3.75e-02 2.27e-03 0.604000
Lewis blood group biosynthesis 10 4.74e-01 6.42e-01 0.22400 1.73e-01 -1.42e-01 3.44e-01 0.437000
Kinesins 29 1.15e-01 2.61e-01 0.22400 6.19e-02 -2.15e-01 5.64e-01 0.045400
Meiosis 41 4.65e-02 1.39e-01 0.22300 1.80e-01 1.33e-01 4.67e-02 0.142000
TGF-beta receptor signaling activates SMADs 18 2.61e-01 4.48e-01 0.22300 -1.94e-01 -1.09e-01 1.54e-01 0.423000
Formation of TC-NER Pre-Incision Complex 32 9.28e-02 2.21e-01 0.22300 2.20e-01 3.62e-02 3.16e-02 0.723000
Gamma carboxylation, hypusine formation and arylsulfatase activation 21 2.13e-01 3.99e-01 0.22200 1.62e-01 -1.52e-01 1.98e-01 0.228000
IGF1R signaling cascade 36 6.93e-02 1.83e-01 0.22200 -9.78e-02 -2.00e-01 3.10e-01 0.038300
Other semaphorin interactions 18 2.67e-01 4.55e-01 0.22200 -2.01e-01 9.32e-02 1.39e-01 0.494000
Formation of HIV elongation complex in the absence of HIV Tat 23 1.85e-01 3.67e-01 0.22200 2.04e-01 -8.57e-02 8.99e-02 0.477000
Formation of HIV-1 elongation complex containing HIV-1 Tat 23 1.85e-01 3.67e-01 0.22200 2.04e-01 -8.57e-02 8.99e-02 0.477000
HIV Transcription Elongation 23 1.85e-01 3.67e-01 0.22200 2.04e-01 -8.57e-02 8.99e-02 0.477000
Tat-mediated elongation of the HIV-1 transcript 23 1.85e-01 3.67e-01 0.22200 2.04e-01 -8.57e-02 8.99e-02 0.477000
PI-3K cascade:FGFR3 10 4.79e-01 6.47e-01 0.22100 -1.85e-01 -1.21e-01 3.11e-01 0.506000
Protein localization 108 4.03e-04 2.41e-03 0.22100 2.08e-01 -7.40e-02 1.91e-04 0.185000
Signaling by Hedgehog 93 1.20e-03 6.20e-03 0.22100 2.18e-01 -3.11e-02 2.80e-04 0.605000
Plasma lipoprotein assembly, remodeling, and clearance 45 3.84e-02 1.21e-01 0.22000 2.16e-01 -4.46e-02 1.23e-02 0.605000
Glucuronidation 10 4.85e-01 6.52e-01 0.22000 -1.76e-01 1.32e-01 3.34e-01 0.471000
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 31 1.05e-01 2.44e-01 0.22000 2.03e-01 8.50e-02 5.06e-02 0.413000
Signaling by ROBO receptors 114 2.75e-04 1.75e-03 0.22000 2.02e-01 8.59e-02 1.99e-04 0.114000
Protein ubiquitination 37 6.86e-02 1.82e-01 0.22000 1.45e-01 1.65e-01 1.28e-01 0.082400
IRS-related events triggered by IGF1R 35 7.93e-02 1.99e-01 0.22000 -1.16e-01 -1.86e-01 2.35e-01 0.056500
Degradation of the extracellular matrix 70 6.38e-03 2.68e-02 0.22000 -1.42e-01 -1.68e-01 4.09e-02 0.015300
WNT5A-dependent internalization of FZD4 12 4.19e-01 5.98e-01 0.21900 1.97e-01 9.64e-02 2.37e-01 0.563000
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 21 2.22e-01 4.05e-01 0.21900 2.19e-01 5.67e-03 8.27e-02 0.964000
NOTCH2 intracellular domain regulates transcription 10 4.91e-01 6.58e-01 0.21800 -1.63e-01 1.45e-01 3.72e-01 0.427000
TNFR2 non-canonical NF-kB pathway 67 8.76e-03 3.51e-02 0.21800 2.16e-01 2.26e-02 2.21e-03 0.749000
Negative regulation of NMDA receptor-mediated neuronal transmission 15 3.44e-01 5.32e-01 0.21800 -2.04e-01 -7.58e-02 1.72e-01 0.611000
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest 11 4.59e-01 6.27e-01 0.21700 2.10e-01 5.60e-02 2.29e-01 0.748000
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 64 1.14e-02 4.34e-02 0.21700 2.13e-01 -3.90e-02 3.24e-03 0.590000
Adrenaline,noradrenaline inhibits insulin secretion 19 2.65e-01 4.52e-01 0.21600 -2.15e-01 -2.31e-02 1.05e-01 0.862000
TP53 Regulates Transcription of Cell Cycle Genes 39 6.58e-02 1.77e-01 0.21600 2.10e-01 4.85e-02 2.31e-02 0.601000
Interleukin-1 signaling 71 7.25e-03 2.99e-02 0.21600 2.10e-01 5.04e-02 2.30e-03 0.463000
tRNA processing 75 5.72e-03 2.48e-02 0.21500 2.12e-01 3.27e-02 1.50e-03 0.625000
G-protein activation 14 3.79e-01 5.63e-01 0.21500 -1.76e-01 -1.24e-01 2.55e-01 0.424000
Transmission across Chemical Synapses 151 3.35e-05 2.80e-04 0.21400 -2.00e-01 -7.70e-02 2.33e-05 0.104000
Nephrin family interactions 17 3.11e-01 4.97e-01 0.21400 -2.08e-01 5.05e-02 1.37e-01 0.719000
Processing of Capped Intronless Pre-mRNA 17 3.11e-01 4.97e-01 0.21400 1.26e-01 1.73e-01 3.70e-01 0.217000
Neuronal System 225 2.66e-07 3.80e-06 0.21400 -2.02e-01 -7.08e-02 2.17e-07 0.068500
Retrograde transport at the Trans-Golgi-Network 36 8.60e-02 2.12e-01 0.21300 -2.11e-01 -3.32e-02 2.88e-02 0.730000
Paradoxical activation of RAF signaling by kinase inactive BRAF 30 1.32e-01 2.89e-01 0.21300 -2.02e-01 6.80e-02 5.60e-02 0.519000
Signaling by RAS mutants 30 1.32e-01 2.89e-01 0.21300 -2.02e-01 6.80e-02 5.60e-02 0.519000
Signaling by moderate kinase activity BRAF mutants 30 1.32e-01 2.89e-01 0.21300 -2.02e-01 6.80e-02 5.60e-02 0.519000
Signaling downstream of RAS mutants 30 1.32e-01 2.89e-01 0.21300 -2.02e-01 6.80e-02 5.60e-02 0.519000
Pyruvate metabolism 21 2.40e-01 4.25e-01 0.21300 -1.16e-01 -1.78e-01 3.57e-01 0.158000
Signaling by PDGF 45 4.78e-02 1.42e-01 0.21200 -2.07e-01 -4.75e-02 1.63e-02 0.582000
Ion transport by P-type ATPases 34 1.02e-01 2.39e-01 0.21200 -2.12e-01 9.72e-03 3.28e-02 0.922000
Formation of Incision Complex in GG-NER 28 1.52e-01 3.20e-01 0.21200 1.95e-01 8.16e-02 7.38e-02 0.455000
Interleukin-35 Signalling 11 4.81e-01 6.48e-01 0.21100 -4.13e-02 2.07e-01 8.13e-01 0.235000
Nucleotide salvage 16 3.45e-01 5.32e-01 0.21000 2.05e-01 4.89e-02 1.56e-01 0.735000
TRP channels 16 3.45e-01 5.32e-01 0.21000 -1.57e-01 -1.40e-01 2.77e-01 0.333000
G-protein beta:gamma signalling 21 2.49e-01 4.35e-01 0.21000 -2.03e-01 -5.32e-02 1.07e-01 0.673000
Trafficking of GluR2-containing AMPA receptors 10 5.16e-01 6.84e-01 0.21000 8.19e-02 1.93e-01 6.54e-01 0.290000
Metabolic disorders of biological oxidation enzymes 19 2.86e-01 4.75e-01 0.21000 -2.01e-01 -5.87e-02 1.29e-01 0.658000
RUNX3 regulates NOTCH signaling 13 4.26e-01 6.03e-01 0.20900 -2.09e-01 1.53e-02 1.92e-01 0.924000
Downregulation of TGF-beta receptor signaling 16 3.51e-01 5.36e-01 0.20900 -2.03e-01 -5.01e-02 1.61e-01 0.729000
TNFs bind their physiological receptors 19 2.91e-01 4.79e-01 0.20800 -4.25e-02 2.04e-01 7.49e-01 0.124000
CD28 dependent PI3K/Akt signaling 20 2.72e-01 4.61e-01 0.20800 -5.41e-02 -2.01e-01 6.75e-01 0.120000
Interleukin-12 family signaling 40 7.51e-02 1.93e-01 0.20800 7.07e-02 1.95e-01 4.39e-01 0.032600
Purine salvage 11 4.91e-01 6.58e-01 0.20700 1.70e-01 1.18e-01 3.28e-01 0.499000
Transcriptional activation of mitochondrial biogenesis 45 5.70e-02 1.61e-01 0.20700 -1.85e-01 9.28e-02 3.21e-02 0.282000
EGFR downregulation 19 3.00e-01 4.88e-01 0.20600 -2.06e-01 4.10e-03 1.21e-01 0.975000
Cell recruitment (pro-inflammatory response) 19 3.04e-01 4.91e-01 0.20500 1.18e-01 -1.68e-01 3.73e-01 0.206000
Purinergic signaling in leishmaniasis infection 19 3.04e-01 4.91e-01 0.20500 1.18e-01 -1.68e-01 3.73e-01 0.206000
Cilium Assembly 141 1.58e-04 1.09e-03 0.20500 2.05e-01 1.08e-03 2.87e-05 0.982000
Activation of BAD and translocation to mitochondria 14 4.18e-01 5.98e-01 0.20400 5.49e-02 1.96e-01 7.22e-01 0.204000
PLC beta mediated events 42 7.53e-02 1.93e-01 0.20300 -2.02e-01 -2.37e-02 2.40e-02 0.791000
TP53 Regulates Transcription of Cell Death Genes 30 1.60e-01 3.33e-01 0.20200 -2.02e-01 5.65e-03 5.55e-02 0.957000
Signaling by MET 53 3.94e-02 1.24e-01 0.20200 -1.97e-01 -4.65e-02 1.34e-02 0.558000
Biosynthesis of DHA-derived SPMs 10 5.43e-01 7.08e-01 0.20200 1.99e-01 3.42e-02 2.77e-01 0.851000
RNA Polymerase I Transcription 33 1.38e-01 3.00e-01 0.20100 1.73e-01 -1.01e-01 8.54e-02 0.314000
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 40 9.07e-02 2.18e-01 0.20100 -1.96e-01 4.14e-02 3.19e-02 0.651000
CaM pathway 27 2.00e-01 3.85e-01 0.20000 -1.99e-01 -1.44e-02 7.35e-02 0.897000
Calmodulin induced events 27 2.00e-01 3.85e-01 0.20000 -1.99e-01 -1.44e-02 7.35e-02 0.897000
VxPx cargo-targeting to cilium 13 4.61e-01 6.28e-01 0.19900 1.78e-01 8.88e-02 2.66e-01 0.580000
MET promotes cell motility 26 2.15e-01 4.02e-01 0.19900 -1.97e-01 2.71e-02 8.22e-02 0.811000
G alpha (12/13) signalling events 61 2.71e-02 9.11e-02 0.19900 -1.16e-01 -1.61e-01 1.17e-01 0.029600
Calnexin/calreticulin cycle 14 4.43e-01 6.13e-01 0.19700 1.86e-01 -6.64e-02 2.29e-01 0.667000
Synthesis of PIPs at the plasma membrane 47 6.61e-02 1.77e-01 0.19700 -1.55e-01 1.21e-01 6.57e-02 0.150000
Ovarian tumor domain proteases 26 2.22e-01 4.05e-01 0.19700 -1.56e-01 1.21e-01 1.70e-01 0.287000
RHO GTPases Activate WASPs and WAVEs 30 1.77e-01 3.58e-01 0.19700 -7.59e-02 1.82e-01 4.72e-01 0.085500
Senescence-Associated Secretory Phenotype (SASP) 37 1.18e-01 2.66e-01 0.19700 1.91e-01 -4.59e-02 4.42e-02 0.629000
Keratinization 27 2.11e-01 3.99e-01 0.19600 -1.68e-01 -1.00e-01 1.30e-01 0.369000
Bile acid and bile salt metabolism 20 3.17e-01 5.03e-01 0.19600 1.87e-01 5.71e-02 1.48e-01 0.659000
Intrinsic Pathway for Apoptosis 42 9.03e-02 2.18e-01 0.19500 1.77e-01 8.23e-02 4.71e-02 0.357000
COPI-dependent Golgi-to-ER retrograde traffic 57 4.00e-02 1.25e-01 0.19500 1.21e-01 -1.53e-01 1.15e-01 0.046100
MAP2K and MAPK activation 25 2.43e-01 4.29e-01 0.19500 -1.46e-01 1.30e-01 2.08e-01 0.262000
SHC-mediated cascade:FGFR4 10 5.66e-01 7.25e-01 0.19500 -1.25e-01 -1.49e-01 4.93e-01 0.415000
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 60 3.42e-02 1.12e-01 0.19400 1.92e-01 -3.06e-02 1.02e-02 0.682000
Negative regulation of MET activity 13 4.80e-01 6.48e-01 0.19400 -1.89e-01 4.63e-02 2.39e-01 0.773000
NGF-stimulated transcription 27 2.20e-01 4.05e-01 0.19400 -1.67e-01 9.85e-02 1.33e-01 0.376000
Binding and Uptake of Ligands by Scavenger Receptors 27 2.21e-01 4.05e-01 0.19400 9.59e-02 -1.68e-01 3.89e-01 0.131000
Interconversion of nucleotide di- and triphosphates 22 2.92e-01 4.79e-01 0.19300 1.80e-01 7.04e-02 1.45e-01 0.568000
Downstream signaling of activated FGFR3 15 4.33e-01 6.09e-01 0.19300 -1.88e-01 -4.10e-02 2.07e-01 0.783000
Formation of the beta-catenin:TCF transactivating complex 29 1.99e-01 3.85e-01 0.19200 -1.78e-01 -7.21e-02 9.64e-02 0.502000
BMAL1:CLOCK,NPAS2 activates circadian gene expression 19 3.49e-01 5.36e-01 0.19200 -1.79e-01 -7.05e-02 1.78e-01 0.595000
Post NMDA receptor activation events 49 6.94e-02 1.83e-01 0.19100 -1.90e-01 -1.88e-02 2.16e-02 0.820000
Transport of inorganic cations/anions and amino acids/oligopeptides 68 2.47e-02 8.37e-02 0.19100 -1.80e-01 -6.22e-02 1.02e-02 0.376000
Synthesis of very long-chain fatty acyl-CoAs 15 4.42e-01 6.13e-01 0.19100 -5.46e-02 1.83e-01 7.14e-01 0.220000
Interleukin-37 signaling 15 4.42e-01 6.13e-01 0.19100 -1.89e-01 2.74e-02 2.06e-01 0.854000
Lysosome Vesicle Biogenesis 25 2.58e-01 4.45e-01 0.19000 1.87e-01 3.42e-02 1.06e-01 0.767000
Class B/2 (Secretin family receptors) 49 7.04e-02 1.84e-01 0.19000 1.33e-01 1.36e-01 1.09e-01 0.099700
DARPP-32 events 19 3.60e-01 5.44e-01 0.18900 7.02e-02 1.76e-01 5.96e-01 0.185000
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) 10 5.87e-01 7.41e-01 0.18900 -6.05e-02 1.79e-01 7.41e-01 0.328000
G alpha (z) signalling events 31 1.94e-01 3.80e-01 0.18800 -1.82e-01 4.64e-02 7.89e-02 0.655000
RET signaling 32 1.82e-01 3.65e-01 0.18800 -1.29e-01 -1.37e-01 2.06e-01 0.181000
Transport of vitamins, nucleosides, and related molecules 28 2.30e-01 4.13e-01 0.18700 -2.68e-02 1.86e-01 8.07e-01 0.089500
Synthesis of IP2, IP, and Ins in the cytosol 12 5.33e-01 6.98e-01 0.18700 -1.61e-01 9.62e-02 3.35e-01 0.564000
CD209 (DC-SIGN) signaling 18 3.92e-01 5.77e-01 0.18700 -1.34e-01 1.31e-01 3.26e-01 0.338000
Metabolism of nitric oxide: NOS3 activation and regulation 14 4.81e-01 6.48e-01 0.18700 9.88e-03 -1.87e-01 9.49e-01 0.227000
IL-6-type cytokine receptor ligand interactions 12 5.33e-01 6.98e-01 0.18700 -7.04e-02 -1.73e-01 6.73e-01 0.300000
G beta:gamma signalling through CDC42 11 5.63e-01 7.24e-01 0.18600 -1.70e-01 -7.69e-02 3.30e-01 0.659000
Activation of NMDA receptors and postsynaptic events 54 6.09e-02 1.69e-01 0.18600 -1.80e-01 -4.71e-02 2.22e-02 0.550000
RMTs methylate histone arginines 25 2.74e-01 4.63e-01 0.18600 1.85e-01 1.89e-02 1.10e-01 0.870000
Signaling by NOTCH2 23 3.04e-01 4.91e-01 0.18600 -1.79e-01 -4.95e-02 1.37e-01 0.681000
Base-Excision Repair, AP Site Formation 17 4.15e-01 5.98e-01 0.18600 1.70e-01 7.36e-02 2.24e-01 0.599000
G-protein mediated events 43 1.10e-01 2.53e-01 0.18500 -1.81e-01 -3.97e-02 4.05e-02 0.653000
TP53 Regulates Transcription of DNA Repair Genes 38 1.43e-01 3.07e-01 0.18500 1.85e-01 3.51e-03 4.88e-02 0.970000
mRNA Splicing - Minor Pathway 30 2.19e-01 4.05e-01 0.18400 1.65e-01 -8.12e-02 1.17e-01 0.442000
Peptide hormone metabolism 44 1.08e-01 2.48e-01 0.18400 -1.77e-01 5.16e-02 4.24e-02 0.554000
Neurotransmitter receptors and postsynaptic signal transmission 114 3.32e-03 1.56e-02 0.18300 -1.63e-01 -8.41e-02 2.73e-03 0.122000
HSF1-dependent transactivation 24 3.01e-01 4.88e-01 0.18300 -1.82e-01 1.71e-02 1.23e-01 0.885000
Golgi-to-ER retrograde transport 83 1.63e-02 5.89e-02 0.18300 1.29e-01 -1.30e-01 4.31e-02 0.041100
Endogenous sterols 17 4.27e-01 6.04e-01 0.18200 -1.52e-01 -1.00e-01 2.77e-01 0.475000
PTEN Regulation 101 6.78e-03 2.81e-02 0.18200 1.74e-01 5.43e-02 2.59e-03 0.347000
O-linked glycosylation 68 3.50e-02 1.13e-01 0.18200 -5.85e-02 -1.72e-01 4.05e-01 0.014400
Arachidonic acid metabolism 36 1.70e-01 3.48e-01 0.18100 9.47e-02 1.54e-01 3.26e-01 0.109000
G alpha (q) signalling events 118 3.35e-03 1.57e-02 0.18000 -1.75e-01 -4.09e-02 1.02e-03 0.444000
Insulin receptor signalling cascade 38 1.62e-01 3.35e-01 0.17900 -1.35e-01 -1.17e-01 1.49e-01 0.213000
Notch-HLH transcription pathway 22 3.49e-01 5.36e-01 0.17900 -1.64e-01 -6.98e-02 1.82e-01 0.571000
Stimuli-sensing channels 55 7.29e-02 1.89e-01 0.17800 -1.62e-01 -7.42e-02 3.77e-02 0.342000
Ca-dependent events 29 2.54e-01 4.40e-01 0.17800 -1.73e-01 4.36e-02 1.08e-01 0.685000
TNFR1-induced proapoptotic signaling 12 5.67e-01 7.25e-01 0.17800 -1.74e-01 3.73e-02 2.97e-01 0.823000
Signaling by Erythropoietin 20 3.93e-01 5.78e-01 0.17700 -1.43e-01 1.05e-01 2.70e-01 0.417000
RNA Polymerase II Transcription Termination 46 1.16e-01 2.62e-01 0.17700 7.82e-02 1.59e-01 3.60e-01 0.063100
Oncogene Induced Senescence 24 3.28e-01 5.11e-01 0.17600 1.69e-03 1.76e-01 9.89e-01 0.135000
Regulation of TP53 Activity 116 4.87e-03 2.20e-02 0.17600 1.50e-01 -9.18e-02 5.26e-03 0.088400
Constitutive Signaling by EGFRvIII 13 5.48e-01 7.09e-01 0.17600 -7.47e-02 1.60e-01 6.41e-01 0.319000
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 13 5.48e-01 7.09e-01 0.17600 -7.47e-02 1.60e-01 6.41e-01 0.319000
Signaling by EGFRvIII in Cancer 13 5.48e-01 7.09e-01 0.17600 -7.47e-02 1.60e-01 6.41e-01 0.319000
Signaling by Ligand-Responsive EGFR Variants in Cancer 13 5.48e-01 7.09e-01 0.17600 -7.47e-02 1.60e-01 6.41e-01 0.319000
Complement cascade 37 1.82e-01 3.65e-01 0.17600 9.67e-02 -1.47e-01 3.09e-01 0.122000
Gastrin-CREB signalling pathway via PKC and MAPK 14 5.24e-01 6.91e-01 0.17600 -6.34e-02 1.64e-01 6.82e-01 0.288000
Metal ion SLC transporters 18 4.36e-01 6.09e-01 0.17600 1.74e-01 -2.59e-02 2.02e-01 0.849000
Interleukin-12 signaling 32 2.28e-01 4.12e-01 0.17500 5.82e-02 1.66e-01 5.69e-01 0.105000
VEGFR2 mediated vascular permeability 25 3.16e-01 5.03e-01 0.17500 1.54e-02 -1.75e-01 8.94e-01 0.131000
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 12 5.74e-01 7.30e-01 0.17500 1.64e-01 6.20e-02 3.25e-01 0.710000
Signaling by KIT in disease 17 4.60e-01 6.27e-01 0.17500 -1.59e-01 7.43e-02 2.58e-01 0.596000
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants 17 4.60e-01 6.27e-01 0.17500 -1.59e-01 7.43e-02 2.58e-01 0.596000
Regulation of MECP2 expression and activity 23 3.50e-01 5.36e-01 0.17500 -1.46e-01 9.59e-02 2.25e-01 0.426000
FRS-mediated FGFR3 signaling 10 6.33e-01 7.79e-01 0.17500 -1.72e-01 -3.12e-02 3.47e-01 0.864000
SUMOylation of chromatin organization proteins 40 1.61e-01 3.35e-01 0.17400 1.55e-01 8.08e-02 9.08e-02 0.377000
Response of Mtb to phagocytosis 17 4.62e-01 6.29e-01 0.17400 3.63e-02 1.70e-01 7.96e-01 0.225000
HIV Transcription Initiation 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
RNA Polymerase II HIV Promoter Escape 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
RNA Polymerase II Promoter Escape 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
RNA Polymerase II Transcription Initiation 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
RNA Polymerase II Transcription Initiation And Promoter Clearance 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 31 2.47e-01 4.32e-01 0.17400 1.58e-01 -7.34e-02 1.29e-01 0.480000
Synthesis of IP3 and IP4 in the cytosol 20 4.05e-01 5.87e-01 0.17400 -3.58e-02 1.70e-01 7.82e-01 0.188000
Platelet homeostasis 63 5.79e-02 1.63e-01 0.17400 -1.53e-01 -8.29e-02 3.63e-02 0.256000
G beta:gamma signalling through PI3Kgamma 16 4.87e-01 6.55e-01 0.17300 -1.72e-01 2.37e-02 2.35e-01 0.870000
Downstream TCR signaling 64 5.75e-02 1.62e-01 0.17300 1.72e-01 1.54e-02 1.73e-02 0.831000
CD28 dependent Vav1 pathway 11 6.15e-01 7.66e-01 0.17200 -9.94e-02 1.40e-01 5.68e-01 0.420000
Signaling by FGFR1 in disease 27 3.04e-01 4.91e-01 0.17200 -1.43e-01 9.51e-02 1.98e-01 0.393000
WNT ligand biogenesis and trafficking 16 4.93e-01 6.58e-01 0.17200 1.69e-01 3.23e-02 2.43e-01 0.823000
Cargo concentration in the ER 19 4.35e-01 6.09e-01 0.17100 1.34e-01 -1.07e-01 3.12e-01 0.421000
Signaling by SCF-KIT 36 2.07e-01 3.95e-01 0.17100 -1.61e-01 5.90e-02 9.50e-02 0.540000
Cleavage of the damaged pyrimidine 15 5.19e-01 6.85e-01 0.17100 1.68e-01 2.87e-02 2.59e-01 0.847000
Depyrimidination 15 5.19e-01 6.85e-01 0.17100 1.68e-01 2.87e-02 2.59e-01 0.847000
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 15 5.19e-01 6.85e-01 0.17100 1.68e-01 2.87e-02 2.59e-01 0.847000
Downstream signal transduction 26 3.24e-01 5.07e-01 0.17100 -1.40e-01 9.81e-02 2.18e-01 0.387000
Signalling to ERKs 28 2.98e-01 4.88e-01 0.17000 -9.25e-02 1.43e-01 3.97e-01 0.190000
STING mediated induction of host immune responses 10 6.47e-01 7.88e-01 0.17000 -5.76e-04 1.70e-01 9.97e-01 0.351000
Chaperone Mediated Autophagy 13 5.70e-01 7.27e-01 0.17000 9.97e-02 -1.38e-01 5.34e-01 0.389000
Phase I - Functionalization of compounds 57 8.66e-02 2.13e-01 0.16900 3.00e-02 1.67e-01 6.96e-01 0.029600
Signal transduction by L1 15 5.26e-01 6.92e-01 0.16900 2.22e-02 1.68e-01 8.82e-01 0.261000
Transcriptional regulation of granulopoiesis 29 2.88e-01 4.76e-01 0.16900 1.33e-01 1.04e-01 2.15e-01 0.332000
Interferon gamma signaling 55 9.71e-02 2.29e-01 0.16900 1.68e-01 -6.68e-03 3.09e-02 0.932000
Glutathione conjugation 27 3.19e-01 5.03e-01 0.16900 1.42e-01 -9.04e-02 2.01e-01 0.416000
O-linked glycosylation of mucins 33 2.47e-01 4.32e-01 0.16800 3.69e-02 -1.64e-01 7.14e-01 0.102000
Potassium Channels 51 1.16e-01 2.62e-01 0.16800 -1.65e-01 3.07e-02 4.11e-02 0.705000
Apoptosis 130 4.32e-03 1.99e-02 0.16800 1.56e-01 6.16e-02 2.18e-03 0.227000
NOTCH1 Intracellular Domain Regulates Transcription 37 2.16e-01 4.03e-01 0.16700 -1.41e-01 8.85e-02 1.37e-01 0.352000
RHO GTPases activate PAKs 18 4.75e-01 6.42e-01 0.16700 -1.47e-01 7.85e-02 2.81e-01 0.564000
Retinoid metabolism and transport 25 3.54e-01 5.37e-01 0.16700 7.05e-03 -1.66e-01 9.51e-01 0.150000
Synaptic adhesion-like molecules 14 5.64e-01 7.24e-01 0.16500 2.74e-02 -1.63e-01 8.59e-01 0.291000
Programmed Cell Death 133 4.50e-03 2.05e-02 0.16500 1.54e-01 6.14e-02 2.30e-03 0.223000
Interleukin-17 signaling 52 1.22e-01 2.74e-01 0.16500 -1.56e-01 5.32e-02 5.19e-02 0.507000
Caspase activation via Death Receptors in the presence of ligand 14 5.66e-01 7.25e-01 0.16500 -1.63e-01 -2.45e-02 2.91e-01 0.874000
Cargo trafficking to the periciliary membrane 33 2.63e-01 4.50e-01 0.16500 1.62e-01 -3.07e-02 1.08e-01 0.761000
COPI-independent Golgi-to-ER retrograde traffic 26 3.51e-01 5.36e-01 0.16400 1.44e-01 -7.83e-02 2.03e-01 0.490000
Regulation of TP53 Activity through Acetylation 23 3.97e-01 5.83e-01 0.16400 9.22e-02 -1.36e-01 4.44e-01 0.260000
Toll Like Receptor 3 (TLR3) Cascade 71 5.88e-02 1.65e-01 0.16400 -1.16e-01 1.16e-01 9.29e-02 0.090400
Cellular responses to external stimuli 323 3.14e-06 3.43e-05 0.16400 1.59e-01 3.89e-02 1.03e-06 0.232000
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 18 4.88e-01 6.55e-01 0.16300 -6.75e-02 1.49e-01 6.20e-01 0.275000
CLEC7A (Dectin-1) signaling 69 6.47e-02 1.75e-01 0.16300 1.61e-01 -2.93e-02 2.12e-02 0.675000
Signaling by WNT in cancer 26 3.53e-01 5.37e-01 0.16300 -1.20e-01 -1.10e-01 2.89e-01 0.330000
Signaling by high-kinase activity BRAF mutants 23 4.03e-01 5.86e-01 0.16300 -1.31e-01 9.69e-02 2.77e-01 0.421000
Interleukin-2 family signaling 29 3.19e-01 5.03e-01 0.16200 -1.62e-01 9.69e-03 1.31e-01 0.928000
ROS and RNS production in phagocytes 22 4.20e-01 5.98e-01 0.16200 1.58e-01 3.72e-02 2.00e-01 0.763000
VEGFA-VEGFR2 Pathway 85 3.63e-02 1.17e-01 0.16200 -1.52e-01 -5.38e-02 1.53e-02 0.392000
Transcription of the HIV genome 44 1.82e-01 3.65e-01 0.16100 1.31e-01 -9.41e-02 1.33e-01 0.281000
Signalling to RAS 16 5.37e-01 7.01e-01 0.16100 -9.56e-02 1.30e-01 5.08e-01 0.368000
Signaling by FGFR2 in disease 21 4.47e-01 6.17e-01 0.16000 -1.60e-01 -3.74e-03 2.05e-01 0.976000
Attenuation phase 15 5.68e-01 7.25e-01 0.15900 -1.40e-01 7.55e-02 3.48e-01 0.613000
Positive epigenetic regulation of rRNA expression 32 3.00e-01 4.88e-01 0.15900 6.17e-02 -1.46e-01 5.46e-01 0.152000
Cellular responses to stress 319 7.95e-06 8.18e-05 0.15900 1.54e-01 3.92e-02 2.72e-06 0.232000
Selective autophagy 43 2.00e-01 3.85e-01 0.15900 4.03e-02 -1.53e-01 6.48e-01 0.082300
Metabolism of steroid hormones 21 4.54e-01 6.21e-01 0.15800 -5.31e-02 -1.49e-01 6.74e-01 0.237000
SHC-mediated cascade:FGFR2 11 6.63e-01 8.03e-01 0.15800 -1.58e-01 1.02e-03 3.65e-01 0.995000
COPI-mediated anterograde transport 65 9.05e-02 2.18e-01 0.15800 1.09e-01 -1.14e-01 1.30e-01 0.112000
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 68 8.01e-02 2.00e-01 0.15800 -6.87e-02 -1.42e-01 3.28e-01 0.043500
MAPK targets/ Nuclear events mediated by MAP kinases 26 3.83e-01 5.66e-01 0.15700 -7.88e-02 1.36e-01 4.87e-01 0.229000
COPII-mediated vesicle transport 48 1.69e-01 3.47e-01 0.15700 1.52e-01 3.97e-02 6.82e-02 0.634000
Signaling by Retinoic Acid 31 3.18e-01 5.03e-01 0.15700 -1.34e-01 -8.21e-02 1.98e-01 0.429000
Synthesis of bile acids and bile salts 18 5.15e-01 6.83e-01 0.15700 1.53e-01 3.40e-02 2.61e-01 0.803000
mRNA decay by 5' to 3' exoribonuclease 12 6.44e-01 7.84e-01 0.15600 -5.45e-02 -1.47e-01 7.44e-01 0.380000
Branched-chain amino acid catabolism 19 5.01e-01 6.67e-01 0.15600 -1.53e-01 3.17e-02 2.49e-01 0.811000
PI-3K cascade:FGFR1 11 6.69e-01 8.07e-01 0.15600 -1.31e-01 -8.43e-02 4.51e-01 0.628000
Interaction between L1 and Ankyrins 22 4.53e-01 6.21e-01 0.15500 -9.29e-02 1.25e-01 4.51e-01 0.312000
FCGR3A-mediated IL10 synthesis 36 2.71e-01 4.60e-01 0.15500 1.48e-01 4.90e-02 1.26e-01 0.611000
Asparagine N-linked glycosylation 205 6.93e-04 3.75e-03 0.15500 1.52e-01 -3.37e-02 1.94e-04 0.408000
Cell-Cell communication 78 6.00e-02 1.68e-01 0.15500 -1.41e-01 -6.54e-02 3.17e-02 0.319000
Triglyceride metabolism 19 5.03e-01 6.69e-01 0.15500 -1.47e-01 -4.85e-02 2.66e-01 0.715000
Nuclear signaling by ERBB4 23 4.37e-01 6.09e-01 0.15500 5.06e-02 -1.47e-01 6.74e-01 0.224000
MAP kinase activation 48 1.79e-01 3.61e-01 0.15500 -1.41e-01 6.47e-02 9.13e-02 0.438000
Acyl chain remodelling of PG 13 6.29e-01 7.78e-01 0.15400 -8.44e-02 -1.29e-01 5.99e-01 0.421000
Major pathway of rRNA processing in the nucleolus and cytosol 91 4.00e-02 1.25e-01 0.15400 1.42e-01 5.97e-02 1.96e-02 0.326000
Sema4D in semaphorin signaling 19 5.12e-01 6.80e-01 0.15400 4.08e-02 -1.48e-01 7.58e-01 0.264000
Signaling by NOTCH1 56 1.39e-01 3.01e-01 0.15400 -1.53e-01 -1.20e-02 4.77e-02 0.877000
SUMOylation of transcription factors 13 6.33e-01 7.79e-01 0.15300 -1.51e-01 2.50e-02 3.45e-01 0.876000
Basigin interactions 21 4.80e-01 6.48e-01 0.15300 3.01e-02 -1.50e-01 8.11e-01 0.235000
Diseases associated with glycosaminoglycan metabolism 30 3.50e-01 5.36e-01 0.15300 -6.48e-02 -1.38e-01 5.40e-01 0.190000
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 14 6.14e-01 7.66e-01 0.15300 -1.44e-01 5.06e-02 3.51e-01 0.743000
Repression of WNT target genes 11 6.82e-01 8.15e-01 0.15200 -1.49e-01 3.28e-02 3.93e-01 0.851000
Carboxyterminal post-translational modifications of tubulin 24 4.35e-01 6.09e-01 0.15200 -9.55e-03 1.52e-01 9.35e-01 0.198000
Synthesis of PA 25 4.19e-01 5.98e-01 0.15200 -4.54e-02 -1.45e-01 6.94e-01 0.209000
mRNA 3'-end processing 40 2.50e-01 4.35e-01 0.15200 3.99e-02 1.47e-01 6.63e-01 0.109000
Inactivation, recovery and regulation of the phototransduction cascade 18 5.36e-01 7.01e-01 0.15200 -1.51e-01 2.16e-02 2.69e-01 0.874000
The phototransduction cascade 18 5.36e-01 7.01e-01 0.15200 -1.51e-01 2.16e-02 2.69e-01 0.874000
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 45 2.12e-01 3.99e-01 0.15200 -1.43e-01 5.24e-02 9.78e-02 0.544000
Constitutive Signaling by NOTCH1 PEST Domain Mutants 45 2.12e-01 3.99e-01 0.15200 -1.43e-01 5.24e-02 9.78e-02 0.544000
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 45 2.12e-01 3.99e-01 0.15200 -1.43e-01 5.24e-02 9.78e-02 0.544000
Signaling by NOTCH1 PEST Domain Mutants in Cancer 45 2.12e-01 3.99e-01 0.15200 -1.43e-01 5.24e-02 9.78e-02 0.544000
Signaling by NOTCH1 in Cancer 45 2.12e-01 3.99e-01 0.15200 -1.43e-01 5.24e-02 9.78e-02 0.544000
Caspase-mediated cleavage of cytoskeletal proteins 10 7.09e-01 8.39e-01 0.15200 -9.31e-02 1.20e-01 6.10e-01 0.511000
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 26 4.06e-01 5.88e-01 0.15200 -1.17e-01 -9.69e-02 3.02e-01 0.393000
Signaling by VEGF 91 4.46e-02 1.35e-01 0.15100 -1.41e-01 -5.51e-02 2.04e-02 0.364000
Signaling by FGFR1 30 3.58e-01 5.42e-01 0.15100 -1.69e-02 1.50e-01 8.72e-01 0.154000
Role of LAT2/NTAL/LAB on calcium mobilization 13 6.41e-01 7.82e-01 0.15100 6.79e-02 1.35e-01 6.72e-01 0.401000
Potential therapeutics for SARS 26 4.13e-01 5.97e-01 0.15000 1.31e-01 7.34e-02 2.47e-01 0.517000
Mitophagy 17 5.63e-01 7.24e-01 0.15000 1.20e-01 9.04e-02 3.94e-01 0.519000
FOXO-mediated transcription 49 1.96e-01 3.81e-01 0.15000 -1.36e-01 6.22e-02 9.99e-02 0.452000
Post-translational modification: synthesis of GPI-anchored proteins 51 1.84e-01 3.67e-01 0.14900 -4.48e-02 1.42e-01 5.80e-01 0.078800
RNA Polymerase III Transcription Termination 15 6.08e-01 7.61e-01 0.14900 1.01e-01 -1.09e-01 4.97e-01 0.463000
ERBB2 Activates PTK6 Signaling 10 7.18e-01 8.45e-01 0.14800 -1.27e-01 -7.59e-02 4.86e-01 0.678000
Synthesis of substrates in N-glycan biosythesis 48 2.08e-01 3.97e-01 0.14800 1.48e-01 -5.41e-03 7.64e-02 0.948000
Ub-specific processing proteases 123 1.82e-02 6.49e-02 0.14800 1.05e-01 1.04e-01 4.42e-02 0.047400
Prolactin receptor signaling 12 6.74e-01 8.12e-01 0.14800 4.65e-02 1.40e-01 7.81e-01 0.400000
Transcriptional regulation by RUNX1 132 1.44e-02 5.35e-02 0.14700 1.40e-01 -4.53e-02 5.52e-03 0.371000
Signaling by ERBB2 ECD mutants 14 6.37e-01 7.79e-01 0.14700 -6.27e-02 1.33e-01 6.85e-01 0.390000
Ion channel transport 97 4.47e-02 1.35e-01 0.14700 -1.46e-01 -1.16e-02 1.30e-02 0.843000
RNA Polymerase III Transcription Initiation From Type 1 Promoter 17 5.79e-01 7.34e-01 0.14600 1.19e-01 8.52e-02 3.96e-01 0.543000
Collagen degradation 28 4.08e-01 5.90e-01 0.14600 -9.83e-02 -1.08e-01 3.68e-01 0.323000
Frs2-mediated activation 10 7.30e-01 8.49e-01 0.14500 7.75e-03 1.45e-01 9.66e-01 0.429000
N-glycan antennae elongation in the medial/trans-Golgi 16 6.04e-01 7.59e-01 0.14500 -1.06e-01 -9.81e-02 4.62e-01 0.497000
Cell-cell junction organization 29 4.04e-01 5.87e-01 0.14400 -1.04e-01 -1.00e-01 3.35e-01 0.350000
Transcriptional Regulation by MECP2 41 2.82e-01 4.73e-01 0.14400 -1.44e-01 -8.50e-04 1.12e-01 0.992000
Regulation of RUNX1 Expression and Activity 14 6.50e-01 7.90e-01 0.14400 -8.84e-02 1.13e-01 5.67e-01 0.463000
Sema3A PAK dependent Axon repulsion 12 6.93e-01 8.25e-01 0.14300 -5.95e-02 1.30e-01 7.21e-01 0.435000
Metabolism of RNA 429 3.08e-06 3.42e-05 0.14300 1.34e-01 5.11e-02 2.63e-06 0.072300
GPCR downstream signalling 389 9.72e-06 9.76e-05 0.14300 -1.25e-01 -6.91e-02 2.71e-05 0.020400
RNA Pol II CTD phosphorylation and interaction with CE 15 6.34e-01 7.79e-01 0.14300 1.12e-01 -8.77e-02 4.51e-01 0.557000
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 15 6.34e-01 7.79e-01 0.14300 1.12e-01 -8.77e-02 4.51e-01 0.557000
Glycosaminoglycan metabolism 81 8.70e-02 2.13e-01 0.14300 1.34e-01 -4.78e-02 3.71e-02 0.458000
Processing of Capped Intron-Containing Pre-mRNA 162 7.68e-03 3.13e-02 0.14200 1.37e-01 3.79e-02 2.66e-03 0.407000
trans-Golgi Network Vesicle Budding 50 2.20e-01 4.05e-01 0.14200 1.37e-01 3.84e-02 9.40e-02 0.639000
Inositol phosphate metabolism 36 3.38e-01 5.25e-01 0.14200 -1.01e-01 9.99e-02 2.93e-01 0.300000
KSRP (KHSRP) binds and destabilizes mRNA 13 6.75e-01 8.12e-01 0.14200 -4.63e-02 1.35e-01 7.73e-01 0.401000
Regulation of signaling by CBL 15 6.36e-01 7.79e-01 0.14200 -6.32e-02 1.27e-01 6.72e-01 0.393000
Listeria monocytogenes entry into host cells 13 6.76e-01 8.12e-01 0.14200 -1.21e-01 7.40e-02 4.49e-01 0.644000
Integration of energy metabolism 84 8.05e-02 2.01e-01 0.14200 -1.42e-01 9.48e-03 2.51e-02 0.881000
Aggrephagy 15 6.37e-01 7.79e-01 0.14200 7.45e-02 -1.21e-01 6.18e-01 0.418000
Formation of RNA Pol II elongation complex 33 3.71e-01 5.56e-01 0.14200 1.39e-01 2.48e-02 1.66e-01 0.805000
RNA Polymerase II Transcription Elongation 33 3.71e-01 5.56e-01 0.14200 1.39e-01 2.48e-02 1.66e-01 0.805000
PI Metabolism 68 1.33e-01 2.90e-01 0.14100 -1.33e-01 4.76e-02 5.81e-02 0.498000
ER to Golgi Anterograde Transport 102 4.99e-02 1.45e-01 0.14100 1.17e-01 -7.88e-02 4.20e-02 0.170000
TBC/RABGAPs 33 3.76e-01 5.60e-01 0.14100 1.37e-01 3.11e-02 1.73e-01 0.757000
The NLRP3 inflammasome 11 7.24e-01 8.45e-01 0.14000 6.48e-02 -1.24e-01 7.10e-01 0.475000
Diseases of glycosylation 104 4.76e-02 1.42e-01 0.14000 -2.21e-02 -1.39e-01 6.97e-01 0.014900
Growth hormone receptor signaling 19 5.72e-01 7.29e-01 0.14000 8.23e-02 1.13e-01 5.35e-01 0.394000
SHC1 events in ERBB4 signaling 10 7.46e-01 8.56e-01 0.14000 -1.10e-01 -8.57e-02 5.47e-01 0.639000
Processing of Intronless Pre-mRNAs 11 7.26e-01 8.46e-01 0.13900 1.31e-02 1.39e-01 9.40e-01 0.425000
Synthesis of glycosylphosphatidylinositol (GPI) 12 7.05e-01 8.37e-01 0.13900 8.21e-02 1.12e-01 6.23e-01 0.500000
Inwardly rectifying K+ channels 19 5.76e-01 7.32e-01 0.13900 -4.90e-02 -1.30e-01 7.11e-01 0.326000
Reproduction 50 2.36e-01 4.19e-01 0.13900 1.09e-01 8.58e-02 1.82e-01 0.294000
Free fatty acids regulate insulin secretion 11 7.28e-01 8.47e-01 0.13900 -6.21e-02 -1.24e-01 7.21e-01 0.477000
Amyloid fiber formation 30 4.22e-01 6.00e-01 0.13900 1.11e-02 1.38e-01 9.16e-01 0.191000
Beta-catenin independent WNT signaling 107 4.72e-02 1.40e-01 0.13800 1.01e-01 9.42e-02 7.09e-02 0.093100
MyD88-independent TLR4 cascade 74 1.26e-01 2.80e-01 0.13700 -1.14e-01 7.61e-02 8.92e-02 0.258000
TRIF(TICAM1)-mediated TLR4 signaling 74 1.26e-01 2.80e-01 0.13700 -1.14e-01 7.61e-02 8.92e-02 0.258000
CD28 co-stimulation 29 4.39e-01 6.11e-01 0.13700 -1.16e-01 -7.41e-02 2.81e-01 0.490000
Sema4D induced cell migration and growth-cone collapse 16 6.36e-01 7.79e-01 0.13700 -6.99e-02 -1.18e-01 6.29e-01 0.414000
Sphingolipid de novo biosynthesis 27 4.70e-01 6.38e-01 0.13700 -5.20e-02 1.27e-01 6.40e-01 0.255000
Regulation of HSF1-mediated heat shock response 51 2.44e-01 4.30e-01 0.13600 1.27e-01 4.86e-02 1.17e-01 0.549000
FGFR1 mutant receptor activation 21 5.65e-01 7.25e-01 0.13500 -1.24e-01 5.32e-02 3.25e-01 0.673000
Transport of bile salts and organic acids, metal ions and amine compounds 51 2.51e-01 4.36e-01 0.13500 5.47e-03 1.35e-01 9.46e-01 0.096900
Extra-nuclear estrogen signaling 57 2.14e-01 4.01e-01 0.13400 -1.22e-01 -5.74e-02 1.13e-01 0.454000
Recycling pathway of L1 24 5.22e-01 6.88e-01 0.13400 5.90e-02 1.21e-01 6.17e-01 0.306000
NRAGE signals death through JNK 51 2.52e-01 4.37e-01 0.13400 -1.29e-01 -3.71e-02 1.11e-01 0.647000
Translocation of SLC2A4 (GLUT4) to the plasma membrane 44 3.11e-01 4.97e-01 0.13400 -1.19e-01 6.12e-02 1.73e-01 0.483000
Phase II - Conjugation of compounds 63 1.87e-01 3.69e-01 0.13400 1.33e-01 1.64e-02 6.93e-02 0.823000
PKA-mediated phosphorylation of CREB 15 6.70e-01 8.09e-01 0.13300 1.35e-02 1.33e-01 9.28e-01 0.374000
Interleukin-3, Interleukin-5 and GM-CSF signaling 32 4.31e-01 6.09e-01 0.13300 -1.20e-01 5.65e-02 2.40e-01 0.580000
Signaling by NTRK2 (TRKB) 19 6.07e-01 7.61e-01 0.13300 -8.93e-02 9.82e-02 5.01e-01 0.459000
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 23 5.48e-01 7.09e-01 0.13200 -1.32e-01 5.45e-03 2.73e-01 0.964000
FGFR2 mutant receptor activation 12 7.31e-01 8.49e-01 0.13200 -6.76e-02 -1.13e-01 6.85e-01 0.498000
Diseases associated with glycosylation precursor biosynthesis 15 6.78e-01 8.13e-01 0.13100 1.05e-01 7.88e-02 4.81e-01 0.598000
Synthesis, secretion, and deacylation of Ghrelin 10 7.73e-01 8.70e-01 0.13100 5.54e-02 -1.19e-01 7.62e-01 0.515000
Signaling by PDGFRA extracellular domain mutants 11 7.53e-01 8.57e-01 0.13100 7.22e-02 1.09e-01 6.79e-01 0.530000
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants 11 7.53e-01 8.57e-01 0.13100 7.22e-02 1.09e-01 6.79e-01 0.530000
Death Receptor Signalling 108 6.43e-02 1.75e-01 0.13100 -1.27e-01 -3.07e-02 2.29e-02 0.582000
Metabolism of fat-soluble vitamins 26 5.15e-01 6.83e-01 0.13100 2.33e-02 -1.29e-01 8.37e-01 0.257000
Nuclear Events (kinase and transcription factor activation) 46 3.14e-01 5.01e-01 0.13000 -8.59e-02 9.77e-02 3.14e-01 0.252000
SHC1 events in ERBB2 signaling 18 6.34e-01 7.79e-01 0.13000 -1.29e-01 1.37e-02 3.42e-01 0.920000
Golgi Associated Vesicle Biogenesis 39 3.72e-01 5.56e-01 0.13000 8.53e-02 9.80e-02 3.57e-01 0.290000
Signaling by ERBB2 in Cancer 21 5.90e-01 7.43e-01 0.13000 -1.08e-01 7.15e-02 3.90e-01 0.571000
Acyl chain remodelling of PC 19 6.21e-01 7.69e-01 0.13000 1.12e-01 -6.52e-02 3.98e-01 0.623000
Class A/1 (Rhodopsin-like receptors) 135 3.43e-02 1.12e-01 0.13000 -9.35e-02 -8.97e-02 6.15e-02 0.072700
Metabolism of steroids 96 9.14e-02 2.18e-01 0.12900 -1.29e-01 -3.54e-03 2.88e-02 0.952000
Signaling by FGFR in disease 38 3.87e-01 5.73e-01 0.12900 -1.28e-01 2.01e-02 1.73e-01 0.830000
Dectin-2 family 10 7.79e-01 8.73e-01 0.12900 1.71e-02 1.28e-01 9.26e-01 0.484000
MyD88 cascade initiated on plasma membrane 61 2.22e-01 4.05e-01 0.12900 -8.59e-02 9.62e-02 2.47e-01 0.194000
Toll Like Receptor 10 (TLR10) Cascade 61 2.22e-01 4.05e-01 0.12900 -8.59e-02 9.62e-02 2.47e-01 0.194000
Toll Like Receptor 5 (TLR5) Cascade 61 2.22e-01 4.05e-01 0.12900 -8.59e-02 9.62e-02 2.47e-01 0.194000
SUMOylation of transcription cofactors 33 4.41e-01 6.12e-01 0.12900 -1.23e-01 -3.83e-02 2.22e-01 0.704000
Platelet activation, signaling and aggregation 186 1.08e-02 4.17e-02 0.12800 -1.28e-01 5.64e-03 2.65e-03 0.895000
GRB2 events in ERBB2 signaling 12 7.45e-01 8.56e-01 0.12800 -1.20e-01 4.53e-02 4.72e-01 0.786000
Biological oxidations 124 4.84e-02 1.43e-01 0.12800 8.99e-02 9.11e-02 8.46e-02 0.080600
Deubiquitination 182 1.24e-02 4.66e-02 0.12800 6.80e-02 1.08e-01 1.15e-01 0.012300
EPH-ephrin mediated repulsion of cells 36 4.17e-01 5.98e-01 0.12800 1.21e-01 -4.00e-02 2.08e-01 0.678000
rRNA processing in the nucleus and cytosol 97 9.63e-02 2.27e-01 0.12700 1.20e-01 4.33e-02 4.22e-02 0.462000
RNA Polymerase II Pre-transcription Events 52 2.86e-01 4.75e-01 0.12700 1.26e-01 -1.56e-02 1.16e-01 0.846000
Oncogenic MAPK signaling 56 2.61e-01 4.48e-01 0.12700 -1.19e-01 4.45e-02 1.24e-01 0.565000
Intraflagellar transport 34 4.44e-01 6.14e-01 0.12700 9.46e-02 -8.42e-02 3.40e-01 0.396000
Opioid Signalling 65 2.12e-01 3.99e-01 0.12700 -1.25e-01 1.74e-02 8.09e-02 0.809000
G alpha (s) signalling events 77 1.59e-01 3.33e-01 0.12600 -1.18e-01 -4.58e-02 7.45e-02 0.488000
PKA activation in glucagon signalling 14 7.15e-01 8.43e-01 0.12600 7.40e-02 1.02e-01 6.32e-01 0.508000
Association of TriC/CCT with target proteins during biosynthesis 29 5.00e-01 6.67e-01 0.12600 8.73e-02 9.11e-02 4.16e-01 0.396000
Acyl chain remodelling of PE 17 6.68e-01 8.07e-01 0.12600 9.93e-02 -7.77e-02 4.79e-01 0.579000
Infectious disease 459 2.81e-05 2.48e-04 0.12600 1.25e-01 1.52e-02 5.57e-06 0.582000
Costimulation by the CD28 family 50 3.05e-01 4.92e-01 0.12600 -7.38e-02 -1.02e-01 3.67e-01 0.213000
PI3K events in ERBB2 signaling 13 7.38e-01 8.53e-01 0.12500 -1.25e-01 -7.74e-03 4.36e-01 0.961000
Cell-extracellular matrix interactions 14 7.21e-01 8.45e-01 0.12500 -1.24e-01 -1.18e-02 4.21e-01 0.939000
Caspase activation via extrinsic apoptotic signalling pathway 21 6.12e-01 7.65e-01 0.12500 -1.01e-01 -7.36e-02 4.25e-01 0.559000
rRNA processing 104 9.12e-02 2.18e-01 0.12400 1.13e-01 5.22e-02 4.75e-02 0.358000
Presynaptic function of Kainate receptors 13 7.41e-01 8.55e-01 0.12400 -1.21e-01 -2.75e-02 4.51e-01 0.864000
Ephrin signaling 17 6.79e-01 8.13e-01 0.12300 -1.22e-01 1.82e-02 3.84e-01 0.897000
PINK1-PRKN Mediated Mitophagy 13 7.47e-01 8.56e-01 0.12200 1.21e-01 1.86e-02 4.51e-01 0.908000
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 10 7.99e-01 8.86e-01 0.12200 -1.19e-01 -2.63e-02 5.13e-01 0.885000
Vitamin B5 (pantothenate) metabolism 12 7.64e-01 8.64e-01 0.12200 -1.20e-01 -2.31e-02 4.72e-01 0.890000
Glycolysis 51 3.20e-01 5.04e-01 0.12200 1.12e-01 4.84e-02 1.66e-01 0.550000
Pre-NOTCH Processing in Golgi 14 7.34e-01 8.51e-01 0.12200 9.97e-02 -6.96e-02 5.18e-01 0.652000
Signaling by ERBB2 36 4.51e-01 6.20e-01 0.12100 -1.12e-01 -4.68e-02 2.45e-01 0.627000
Scavenging by Class A Receptors 11 7.85e-01 8.76e-01 0.12100 -2.30e-03 1.21e-01 9.89e-01 0.487000
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 15 7.20e-01 8.45e-01 0.12100 -1.16e-01 3.40e-02 4.37e-01 0.819000
ERBB2 Regulates Cell Motility 11 7.85e-01 8.76e-01 0.12100 -8.16e-02 -8.93e-02 6.40e-01 0.608000
Signaling by NOTCH 135 5.67e-02 1.61e-01 0.12000 1.19e-01 1.11e-02 1.71e-02 0.825000
Semaphorin interactions 53 3.22e-01 5.06e-01 0.12000 -1.12e-01 -4.12e-02 1.58e-01 0.604000
Activation of kainate receptors upon glutamate binding 21 6.38e-01 7.79e-01 0.11900 -1.02e-01 -6.26e-02 4.20e-01 0.620000
FRS-mediated FGFR1 signaling 11 7.91e-01 8.81e-01 0.11900 -1.19e-01 -2.39e-03 4.94e-01 0.989000
Protein folding 68 2.36e-01 4.19e-01 0.11900 5.16e-02 1.07e-01 4.62e-01 0.126000
Metabolism of carbohydrates 198 1.64e-02 5.90e-02 0.11900 1.11e-01 -4.36e-02 7.55e-03 0.292000
FGFR2 alternative splicing 13 7.62e-01 8.62e-01 0.11800 -6.56e-03 1.18e-01 9.67e-01 0.461000
Signaling by Non-Receptor Tyrosine Kinases 40 4.36e-01 6.09e-01 0.11800 -8.00e-03 1.18e-01 9.30e-01 0.198000
Signaling by PTK6 40 4.36e-01 6.09e-01 0.11800 -8.00e-03 1.18e-01 9.30e-01 0.198000
Thromboxane signalling through TP receptor 14 7.50e-01 8.56e-01 0.11700 9.24e-02 -7.25e-02 5.50e-01 0.639000
Rho GTPase cycle 112 1.01e-01 2.36e-01 0.11700 -1.17e-01 -1.38e-03 3.22e-02 0.980000
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 7.97e-01 8.86e-01 0.11700 -4.70e-02 1.08e-01 7.87e-01 0.537000
Inflammasomes 16 7.21e-01 8.45e-01 0.11700 -7.59e-02 8.90e-02 5.99e-01 0.538000
RAB geranylgeranylation 37 4.71e-01 6.39e-01 0.11700 -1.17e-01 -5.75e-03 2.20e-01 0.952000
mRNA Splicing - Major Pathway 117 9.43e-02 2.24e-01 0.11700 1.14e-01 2.57e-02 3.42e-02 0.632000
Mitochondrial biogenesis 60 2.99e-01 4.88e-01 0.11600 -1.11e-01 3.54e-02 1.38e-01 0.636000
Chaperonin-mediated protein folding 62 2.87e-01 4.76e-01 0.11600 3.13e-03 1.16e-01 9.66e-01 0.114000
Neddylation 164 3.84e-02 1.21e-01 0.11600 1.13e-01 -2.49e-02 1.26e-02 0.584000
NCAM signaling for neurite out-growth 44 4.14e-01 5.97e-01 0.11600 -9.01e-02 -7.25e-02 3.02e-01 0.406000
Post-translational protein phosphorylation 59 3.08e-01 4.94e-01 0.11600 -3.98e-02 -1.09e-01 5.98e-01 0.150000
Amino acid transport across the plasma membrane 26 5.95e-01 7.48e-01 0.11500 -1.07e-01 -4.40e-02 3.47e-01 0.698000
GAB1 signalosome 12 7.88e-01 8.78e-01 0.11500 -4.33e-02 -1.07e-01 7.95e-01 0.523000
Lysine catabolism 10 8.19e-01 9.03e-01 0.11500 7.66e-02 8.58e-02 6.75e-01 0.638000
Toll Like Receptor 4 (TLR4) Cascade 95 1.56e-01 3.27e-01 0.11500 -1.09e-01 3.72e-02 6.78e-02 0.531000
Interleukin receptor SHC signaling 18 7.01e-01 8.33e-01 0.11500 -8.90e-02 -7.24e-02 5.14e-01 0.595000
RHO GTPases activate CIT 16 7.31e-01 8.49e-01 0.11500 -5.35e-02 1.01e-01 7.11e-01 0.483000
Interleukin-1 family signaling 95 1.57e-01 3.29e-01 0.11400 1.01e-01 5.25e-02 8.83e-02 0.378000
ADP signalling through P2Y purinoceptor 12 13 7.75e-01 8.71e-01 0.11400 -5.29e-02 -1.01e-01 7.41e-01 0.528000
Interleukin-10 signaling 28 5.80e-01 7.35e-01 0.11400 1.06e-01 -4.17e-02 3.31e-01 0.703000
Regulation of localization of FOXO transcription factors 10 8.22e-01 9.04e-01 0.11400 9.03e-02 6.96e-02 6.21e-01 0.703000
RAF-independent MAPK1/3 activation 18 7.06e-01 8.37e-01 0.11400 -5.06e-02 1.02e-01 7.10e-01 0.454000
Cargo recognition for clathrin-mediated endocytosis 65 2.85e-01 4.75e-01 0.11400 1.10e-01 2.85e-02 1.25e-01 0.691000
The canonical retinoid cycle in rods (twilight vision) 13 7.77e-01 8.73e-01 0.11400 -2.47e-02 -1.11e-01 8.78e-01 0.489000
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 63 2.99e-01 4.88e-01 0.11400 1.11e-01 -2.52e-02 1.29e-01 0.730000
Transcriptional Regulation by TP53 252 8.82e-03 3.52e-02 0.11300 1.06e-01 -3.99e-02 3.94e-03 0.278000
Mitochondrial Fatty Acid Beta-Oxidation 25 6.21e-01 7.69e-01 0.11300 7.46e-02 -8.51e-02 5.19e-01 0.462000
Negative regulation of FGFR1 signaling 16 7.36e-01 8.52e-01 0.11300 6.57e-02 9.17e-02 6.49e-01 0.526000
RHO GTPases Activate NADPH Oxidases 18 7.10e-01 8.39e-01 0.11300 -1.11e-01 -1.64e-02 4.13e-01 0.904000
Tie2 Signaling 15 7.51e-01 8.57e-01 0.11300 -7.12e-02 -8.72e-02 6.33e-01 0.559000
Sphingolipid metabolism 53 3.66e-01 5.51e-01 0.11200 9.04e-02 6.70e-02 2.56e-01 0.400000
Acyl chain remodelling of PI 12 7.99e-01 8.86e-01 0.11200 5.48e-02 -9.78e-02 7.43e-01 0.558000
Signaling by TGF-beta Receptor Complex 48 4.05e-01 5.87e-01 0.11200 -5.82e-02 -9.58e-02 4.86e-01 0.252000
Organelle biogenesis and maintenance 201 2.52e-02 8.53e-02 0.11100 1.11e-01 1.15e-02 6.99e-03 0.780000
RHO GTPase Effectors 186 3.29e-02 1.08e-01 0.11100 7.05e-02 8.62e-02 9.88e-02 0.043600
Signaling by GPCR 423 5.09e-04 2.90e-03 0.11100 -9.25e-02 -6.17e-02 1.23e-03 0.031000
mRNA Splicing 124 1.03e-01 2.40e-01 0.11100 1.10e-01 1.24e-02 3.42e-02 0.811000
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 27 6.08e-01 7.61e-01 0.11100 1.11e-01 7.09e-03 3.19e-01 0.949000
Plasma lipoprotein remodeling 16 7.49e-01 8.56e-01 0.11000 7.01e-02 -8.48e-02 6.27e-01 0.557000
Transcriptional regulation of white adipocyte differentiation 66 3.05e-01 4.92e-01 0.11000 4.23e-02 1.01e-01 5.53e-01 0.156000
Infection with Mycobacterium tuberculosis 21 6.85e-01 8.17e-01 0.11000 8.91e-02 6.36e-02 4.80e-01 0.614000
mRNA Capping 16 7.51e-01 8.57e-01 0.10900 9.16e-02 -5.98e-02 5.26e-01 0.679000
Defects in vitamin and cofactor metabolism 15 7.65e-01 8.64e-01 0.10900 -1.06e-01 2.81e-02 4.78e-01 0.850000
RHO GTPases Activate ROCKs 13 7.94e-01 8.83e-01 0.10900 -1.08e-01 1.03e-02 4.98e-01 0.949000
Signaling by BRAF and RAF fusions 44 4.59e-01 6.27e-01 0.10900 -1.04e-01 3.26e-02 2.33e-01 0.708000
PPARA activates gene expression 91 2.00e-01 3.85e-01 0.10900 4.47e-02 9.94e-02 4.62e-01 0.102000
Inhibition of DNA recombination at telomere 12 8.10e-01 8.95e-01 0.10800 1.04e-01 2.88e-02 5.32e-01 0.863000
Signaling by ERBB2 KD Mutants 20 7.06e-01 8.37e-01 0.10800 -1.03e-01 3.18e-02 4.25e-01 0.806000
Nuclear Receptor transcription pathway 41 4.98e-01 6.65e-01 0.10700 -1.07e-01 2.09e-03 2.38e-01 0.982000
Neutrophil degranulation 316 5.39e-03 2.38e-02 0.10700 1.02e-01 -2.95e-02 1.87e-03 0.370000
Activation of G protein gated Potassium channels 16 7.61e-01 8.62e-01 0.10600 -7.78e-02 -7.27e-02 5.90e-01 0.615000
G protein gated Potassium channels 16 7.61e-01 8.62e-01 0.10600 -7.78e-02 -7.27e-02 5.90e-01 0.615000
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 16 7.61e-01 8.62e-01 0.10600 -7.78e-02 -7.27e-02 5.90e-01 0.615000
Cell surface interactions at the vascular wall 93 2.09e-01 3.98e-01 0.10600 -8.19e-02 -6.77e-02 1.73e-01 0.260000
TCF dependent signaling in response to WNT 121 1.33e-01 2.91e-01 0.10600 1.03e-01 -2.43e-02 5.05e-02 0.645000
Metabolism of proteins 1234 1.11e-08 2.30e-07 0.10600 1.05e-01 7.27e-03 1.57e-09 0.677000
SUMOylation of DNA methylation proteins 15 7.80e-01 8.73e-01 0.10500 -7.10e-02 7.79e-02 6.34e-01 0.602000
G alpha (i) signalling events 200 3.81e-02 1.21e-01 0.10500 -8.88e-02 -5.62e-02 3.12e-02 0.172000
Toll Like Receptor 9 (TLR9) Cascade 69 3.27e-01 5.11e-01 0.10400 -4.16e-02 9.58e-02 5.50e-01 0.170000
Constitutive Signaling by Aberrant PI3K in Cancer 53 4.21e-01 5.99e-01 0.10400 -1.01e-01 -2.52e-02 2.02e-01 0.752000
Regulation of gene expression by Hypoxia-inducible Factor 10 8.50e-01 9.19e-01 0.10400 1.30e-02 1.03e-01 9.43e-01 0.572000
Signaling by FGFR2 39 5.33e-01 6.98e-01 0.10400 -5.31e-02 8.95e-02 5.67e-01 0.334000
Signaling by the B Cell Receptor (BCR) 80 2.77e-01 4.66e-01 0.10400 1.02e-01 1.83e-02 1.15e-01 0.778000
Transport to the Golgi and subsequent modification 122 1.45e-01 3.08e-01 0.10400 8.61e-02 -5.77e-02 1.02e-01 0.273000
Disassembly of the destruction complex and recruitment of AXIN to the membrane 24 6.81e-01 8.15e-01 0.10400 8.33e-02 -6.15e-02 4.80e-01 0.602000
Cell death signalling via NRAGE, NRIF and NADE 59 3.89e-01 5.74e-01 0.10300 -1.00e-01 -2.50e-02 1.83e-01 0.740000
Activation of BH3-only proteins 27 6.52e-01 7.91e-01 0.10300 6.51e-02 7.93e-02 5.58e-01 0.476000
HATs acetylate histones 58 4.03e-01 5.86e-01 0.10200 7.62e-02 6.82e-02 3.16e-01 0.370000
The citric acid (TCA) cycle and respiratory electron transport 99 2.17e-01 4.03e-01 0.10200 9.84e-02 -2.72e-02 9.15e-02 0.641000
PRC2 methylates histones and DNA 11 8.43e-01 9.16e-01 0.10200 2.85e-03 1.02e-01 9.87e-01 0.560000
Deadenylation-dependent mRNA decay 39 5.48e-01 7.09e-01 0.10200 -1.27e-02 1.01e-01 8.91e-01 0.276000
Chemokine receptors bind chemokines 31 6.20e-01 7.69e-01 0.10100 -8.93e-02 -4.81e-02 3.90e-01 0.643000
PKA activation 14 8.05e-01 8.91e-01 0.10100 4.12e-02 9.26e-02 7.89e-01 0.549000
Other interleukin signaling 16 7.81e-01 8.74e-01 0.10100 -6.14e-02 -8.06e-02 6.71e-01 0.577000
Downstream signaling of activated FGFR1 19 7.49e-01 8.56e-01 0.10100 -1.01e-01 2.30e-03 4.47e-01 0.986000
ERK/MAPK targets 19 7.49e-01 8.56e-01 0.10100 3.00e-02 9.62e-02 8.21e-01 0.468000
Autophagy 91 2.58e-01 4.45e-01 0.10000 9.95e-02 9.67e-03 1.01e-01 0.874000
Hemostasis 400 3.20e-03 1.51e-02 0.09960 -9.84e-02 -1.56e-02 8.21e-04 0.596000
Thrombin signalling through proteinase activated receptors (PARs) 22 7.22e-01 8.45e-01 0.09950 3.44e-02 -9.34e-02 7.80e-01 0.449000
Signal amplification 22 7.22e-01 8.45e-01 0.09940 1.62e-02 -9.81e-02 8.96e-01 0.426000
Amino acids regulate mTORC1 33 6.14e-01 7.66e-01 0.09940 -6.28e-03 9.92e-02 9.50e-01 0.324000
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 30 6.42e-01 7.83e-01 0.09920 -9.48e-02 -2.91e-02 3.69e-01 0.783000
Class I MHC mediated antigen processing & presentation 261 2.43e-02 8.28e-02 0.09870 9.77e-02 -1.41e-02 6.92e-03 0.697000
activated TAK1 mediates p38 MAPK activation 14 8.15e-01 8.99e-01 0.09860 -6.62e-02 -7.30e-02 6.68e-01 0.636000
Transcriptional regulation by RUNX3 75 3.38e-01 5.25e-01 0.09850 9.85e-02 4.33e-04 1.41e-01 0.995000
DDX58/IFIH1-mediated induction of interferon-alpha/beta 44 5.31e-01 6.98e-01 0.09840 -6.44e-02 7.44e-02 4.60e-01 0.394000
Pre-NOTCH Transcription and Translation 29 6.58e-01 7.98e-01 0.09830 -3.16e-02 9.31e-02 7.69e-01 0.386000
Signaling by Receptor Tyrosine Kinases 358 6.67e-03 2.79e-02 0.09820 -9.74e-02 -1.18e-02 1.68e-03 0.705000
E3 ubiquitin ligases ubiquitinate target proteins 22 7.34e-01 8.51e-01 0.09690 2.29e-02 9.41e-02 8.53e-01 0.445000
Signaling by PDGFR in disease 18 7.79e-01 8.73e-01 0.09610 3.74e-03 9.61e-02 9.78e-01 0.481000
Antigen processing: Ubiquitination & Proteasome degradation 219 5.21e-02 1.50e-01 0.09570 9.11e-02 2.92e-02 2.08e-02 0.459000
SUMO E3 ligases SUMOylate target proteins 119 1.99e-01 3.85e-01 0.09540 8.52e-02 4.29e-02 1.09e-01 0.421000
RNA Polymerase III Transcription Initiation From Type 2 Promoter 16 8.04e-01 8.90e-01 0.09530 8.18e-02 4.89e-02 5.71e-01 0.735000
Cellular hexose transport 12 8.50e-01 9.19e-01 0.09520 -9.35e-02 1.79e-02 5.75e-01 0.915000
YAP1- and WWTR1 (TAZ)-stimulated gene expression 11 8.62e-01 9.25e-01 0.09510 -9.14e-02 2.61e-02 6.00e-01 0.881000
HDACs deacetylate histones 22 7.42e-01 8.56e-01 0.09500 9.16e-02 2.51e-02 4.57e-01 0.839000
ADORA2B mediated anti-inflammatory cytokines production 62 4.35e-01 6.09e-01 0.09500 -9.45e-02 9.66e-03 1.99e-01 0.896000
SLC-mediated transmembrane transport 155 1.30e-01 2.88e-01 0.09450 -8.68e-02 3.74e-02 6.31e-02 0.423000
MyD88 dependent cascade initiated on endosome 66 4.18e-01 5.98e-01 0.09440 -4.60e-02 8.24e-02 5.19e-01 0.248000
Toll Like Receptor 7/8 (TLR7/8) Cascade 66 4.18e-01 5.98e-01 0.09440 -4.60e-02 8.24e-02 5.19e-01 0.248000
Activation of HOX genes during differentiation 40 5.86e-01 7.40e-01 0.09430 6.28e-02 7.03e-02 4.92e-01 0.442000
Activation of anterior HOX genes in hindbrain development during early embryogenesis 40 5.86e-01 7.40e-01 0.09430 6.28e-02 7.03e-02 4.92e-01 0.442000
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 69 4.03e-01 5.86e-01 0.09420 -7.91e-02 5.12e-02 2.56e-01 0.463000
Toll Like Receptor 2 (TLR2) Cascade 69 4.03e-01 5.86e-01 0.09420 -7.91e-02 5.12e-02 2.56e-01 0.463000
Toll Like Receptor TLR1:TLR2 Cascade 69 4.03e-01 5.86e-01 0.09420 -7.91e-02 5.12e-02 2.56e-01 0.463000
Toll Like Receptor TLR6:TLR2 Cascade 69 4.03e-01 5.86e-01 0.09420 -7.91e-02 5.12e-02 2.56e-01 0.463000
Glucagon signaling in metabolic regulation 21 7.56e-01 8.59e-01 0.09420 3.98e-02 8.54e-02 7.52e-01 0.498000
RAB GEFs exchange GTP for GDP on RABs 66 4.24e-01 6.03e-01 0.09350 -4.08e-02 8.41e-02 5.67e-01 0.238000
SUMOylation 124 2.00e-01 3.85e-01 0.09340 8.70e-02 3.40e-02 9.51e-02 0.515000
ABC transporters in lipid homeostasis 12 8.56e-01 9.23e-01 0.09330 -8.40e-02 4.05e-02 6.14e-01 0.808000
C-type lectin receptors (CLRs) 91 3.09e-01 4.95e-01 0.09320 9.28e-02 8.43e-03 1.27e-01 0.890000
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 65 4.34e-01 6.09e-01 0.09300 -6.18e-02 6.95e-02 3.90e-01 0.333000
Fc epsilon receptor (FCERI) signaling 97 2.91e-01 4.79e-01 0.09240 6.88e-02 6.16e-02 2.43e-01 0.296000
RA biosynthesis pathway 13 8.48e-01 9.19e-01 0.09200 1.98e-03 9.19e-02 9.90e-01 0.566000
SUMOylation of intracellular receptors 23 7.49e-01 8.56e-01 0.09180 -4.66e-02 7.91e-02 6.99e-01 0.511000
Erythropoietin activates RAS 10 8.82e-01 9.39e-01 0.09160 5.44e-02 7.36e-02 7.66e-01 0.687000
Estrogen-dependent gene expression 65 4.47e-01 6.17e-01 0.09140 -6.01e-02 6.88e-02 4.03e-01 0.338000
Pyruvate metabolism and Citric Acid (TCA) cycle 37 6.32e-01 7.79e-01 0.09120 -9.05e-02 1.12e-02 3.41e-01 0.906000
RNA polymerase II transcribes snRNA genes 46 5.67e-01 7.25e-01 0.09110 8.11e-02 -4.14e-02 3.42e-01 0.627000
Pre-NOTCH Expression and Processing 42 5.95e-01 7.48e-01 0.09100 5.62e-03 9.08e-02 9.50e-01 0.309000
Signaling by TGFB family members 68 4.32e-01 6.09e-01 0.09080 -5.25e-02 -7.40e-02 4.55e-01 0.292000
Clathrin-mediated endocytosis 96 3.15e-01 5.01e-01 0.08990 8.77e-02 1.99e-02 1.38e-01 0.736000
Negative regulation of FGFR3 signaling 15 8.34e-01 9.09e-01 0.08960 4.28e-02 7.87e-02 7.74e-01 0.598000
RUNX2 regulates osteoblast differentiation 17 8.22e-01 9.04e-01 0.08760 2.66e-02 8.34e-02 8.50e-01 0.552000
RIP-mediated NFkB activation via ZBP1 15 8.43e-01 9.16e-01 0.08720 2.72e-02 -8.28e-02 8.55e-01 0.579000
ESR-mediated signaling 118 2.67e-01 4.55e-01 0.08690 -8.54e-02 1.60e-02 1.10e-01 0.765000
Response to elevated platelet cytosolic Ca2+ 93 3.54e-01 5.37e-01 0.08680 -7.51e-02 4.36e-02 2.12e-01 0.469000
Signaling by ERBB2 TMD/JMD mutants 17 8.27e-01 9.04e-01 0.08660 -7.95e-02 3.45e-02 5.71e-01 0.806000
N-Glycan antennae elongation 10 8.94e-01 9.50e-01 0.08650 2.51e-02 -8.28e-02 8.91e-01 0.650000
Peroxisomal lipid metabolism 22 7.82e-01 8.74e-01 0.08650 6.71e-02 -5.46e-02 5.86e-01 0.658000
Regulation of lipid metabolism by PPARalpha 93 3.54e-01 5.37e-01 0.08650 3.43e-02 7.94e-02 5.69e-01 0.187000
G beta:gamma signalling through PLC beta 12 8.75e-01 9.33e-01 0.08620 -7.96e-02 -3.30e-02 6.33e-01 0.843000
p75 NTR receptor-mediated signalling 73 4.49e-01 6.18e-01 0.08570 -6.07e-02 -6.05e-02 3.71e-01 0.372000
Signaling by NTRK1 (TRKA) 92 3.72e-01 5.56e-01 0.08520 -4.63e-02 7.15e-02 4.44e-01 0.237000
Negative regulation of FGFR2 signaling 17 8.33e-01 9.08e-01 0.08490 -2.79e-02 8.02e-02 8.42e-01 0.567000
NOTCH3 Activation and Transmission of Signal to the Nucleus 18 8.24e-01 9.04e-01 0.08490 2.42e-02 -8.13e-02 8.59e-01 0.550000
Metabolism 1332 3.24e-06 3.47e-05 0.08480 8.46e-02 6.35e-03 5.38e-07 0.707000
Nicotinate metabolism 19 8.15e-01 8.99e-01 0.08470 -7.12e-02 -4.58e-02 5.91e-01 0.730000
Synthesis of Leukotrienes (LT) and Eoxins (EX) 14 8.62e-01 9.25e-01 0.08390 4.19e-02 7.27e-02 7.86e-01 0.638000
Phospholipid metabolism 151 2.16e-01 4.03e-01 0.08290 -7.60e-02 3.32e-02 1.08e-01 0.483000
Chondroitin sulfate/dermatan sulfate metabolism 37 6.83e-01 8.15e-01 0.08290 7.28e-02 3.97e-02 4.44e-01 0.677000
MTOR signalling 30 7.39e-01 8.54e-01 0.08190 7.08e-02 4.12e-02 5.02e-01 0.696000
Signaling by Insulin receptor 48 6.17e-01 7.67e-01 0.08190 -6.63e-02 -4.80e-02 4.27e-01 0.565000
Interleukin-6 family signaling 17 8.47e-01 9.18e-01 0.08080 -1.36e-02 -7.97e-02 9.23e-01 0.570000
Visual phototransduction 56 5.85e-01 7.40e-01 0.08000 -5.37e-02 -5.93e-02 4.88e-01 0.443000
Rab regulation of trafficking 93 4.16e-01 5.98e-01 0.07960 -4.75e-03 7.95e-02 9.37e-01 0.186000
Glucose metabolism 64 5.47e-01 7.09e-01 0.07950 7.71e-02 -1.94e-02 2.87e-01 0.789000
Activation of GABAB receptors 28 7.68e-01 8.66e-01 0.07920 -4.07e-02 -6.79e-02 7.09e-01 0.534000
GABA B receptor activation 28 7.68e-01 8.66e-01 0.07920 -4.07e-02 -6.79e-02 7.09e-01 0.534000
Beta-catenin phosphorylation cascade 15 8.69e-01 9.30e-01 0.07890 6.74e-02 4.10e-02 6.51e-01 0.784000
NOTCH3 Intracellular Domain Regulates Transcription 21 8.26e-01 9.04e-01 0.07810 -1.02e-02 7.74e-02 9.35e-01 0.539000
Toll-like Receptor Cascades 107 3.81e-01 5.65e-01 0.07810 -7.25e-02 2.89e-02 1.96e-01 0.606000
Diseases of metabolism 163 2.31e-01 4.14e-01 0.07800 -1.67e-03 -7.80e-02 9.71e-01 0.087000
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 11 9.05e-01 9.56e-01 0.07780 -5.75e-02 5.23e-02 7.41e-01 0.764000
Transcriptional Regulation by VENTX 32 7.49e-01 8.56e-01 0.07770 7.71e-02 -1.00e-02 4.51e-01 0.922000
Platelet degranulation 89 4.52e-01 6.20e-01 0.07760 -4.12e-02 6.58e-02 5.03e-01 0.284000
Cytosolic sensors of pathogen-associated DNA 44 6.75e-01 8.12e-01 0.07740 2.24e-03 7.73e-02 9.80e-01 0.375000
Macroautophagy 80 4.92e-01 6.58e-01 0.07720 7.72e-02 -1.67e-03 2.34e-01 0.979000
Cellular response to heat stress 67 5.54e-01 7.15e-01 0.07680 3.46e-02 6.86e-02 6.25e-01 0.333000
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon 12 9.00e-01 9.52e-01 0.07630 -6.87e-02 -3.31e-02 6.80e-01 0.843000
Downregulation of ERBB2 signaling 18 8.56e-01 9.23e-01 0.07590 -6.69e-02 -3.59e-02 6.23e-01 0.792000
Energy dependent regulation of mTOR by LKB1-AMPK 20 8.42e-01 9.16e-01 0.07580 -7.33e-02 -1.91e-02 5.70e-01 0.882000
Regulation of PTEN gene transcription 46 6.79e-01 8.13e-01 0.07510 -5.48e-04 7.51e-02 9.95e-01 0.379000
PI3K/AKT Signaling in Cancer 76 5.31e-01 6.98e-01 0.07470 -7.43e-02 -7.42e-03 2.63e-01 0.911000
PKMTs methylate histone lysines 32 7.71e-01 8.67e-01 0.07390 -7.33e-02 8.82e-03 4.73e-01 0.931000
Signaling by NTRKs 105 4.34e-01 6.09e-01 0.07330 -2.93e-02 6.72e-02 6.05e-01 0.235000
RNA Polymerase III Chain Elongation 11 9.15e-01 9.58e-01 0.07320 7.32e-02 9.14e-05 6.74e-01 1.000000
Signaling by FGFR4 24 8.26e-01 9.04e-01 0.07310 -6.99e-02 2.13e-02 5.54e-01 0.857000
L1CAM interactions 76 5.56e-01 7.16e-01 0.07220 -4.56e-02 5.60e-02 4.93e-01 0.399000
PIP3 activates AKT signaling 194 2.27e-01 4.11e-01 0.07190 6.64e-02 2.76e-02 1.12e-01 0.510000
Signaling by Nuclear Receptors 171 2.87e-01 4.76e-01 0.07020 -6.86e-02 -1.48e-02 1.23e-01 0.739000
Glucagon-type ligand receptors 15 8.95e-01 9.50e-01 0.07010 -1.89e-04 7.01e-02 9.99e-01 0.638000
Assembly of active LPL and LIPC lipase complexes 13 9.09e-01 9.56e-01 0.06970 -4.41e-02 -5.40e-02 7.83e-01 0.736000
Adherens junctions interactions 15 8.96e-01 9.51e-01 0.06960 -4.90e-02 -4.95e-02 7.43e-01 0.740000
tRNA modification in the nucleus and cytosol 28 8.21e-01 9.04e-01 0.06860 5.42e-03 6.84e-02 9.60e-01 0.531000
Misspliced GSK3beta mutants stabilize beta-catenin 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
S33 mutants of beta-catenin aren't phosphorylated 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
S37 mutants of beta-catenin aren't phosphorylated 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
S45 mutants of beta-catenin aren't phosphorylated 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
T41 mutants of beta-catenin aren't phosphorylated 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex 13 9.13e-01 9.56e-01 0.06830 9.18e-03 -6.77e-02 9.54e-01 0.673000
Metabolism of water-soluble vitamins and cofactors 86 5.55e-01 7.15e-01 0.06800 6.47e-02 -2.09e-02 3.01e-01 0.739000
Signaling by FGFR 50 7.13e-01 8.41e-01 0.06750 -3.51e-02 5.76e-02 6.68e-01 0.481000
Oxidative Stress Induced Senescence 51 7.10e-01 8.39e-01 0.06710 -6.63e-02 -1.04e-02 4.14e-01 0.898000
SLC transporter disorders 64 6.51e-01 7.91e-01 0.06690 5.55e-02 3.74e-02 4.43e-01 0.605000
TP53 Regulates Metabolic Genes 61 6.66e-01 8.06e-01 0.06690 2.11e-02 -6.35e-02 7.76e-01 0.392000
Signaling by EGFR in Cancer 15 9.06e-01 9.56e-01 0.06640 -5.69e-03 6.61e-02 9.70e-01 0.658000
DAP12 signaling 22 8.68e-01 9.30e-01 0.06550 -2.66e-04 6.55e-02 9.98e-01 0.595000
HSP90 chaperone cycle for steroid hormone receptors (SHR) 28 8.43e-01 9.16e-01 0.06400 5.24e-02 -3.68e-02 6.32e-01 0.736000
RUNX2 regulates bone development 22 8.75e-01 9.33e-01 0.06390 -4.13e-02 4.88e-02 7.37e-01 0.692000
Regulation of TP53 Activity through Association with Co-factors 11 9.35e-01 9.74e-01 0.06370 2.74e-02 5.75e-02 8.75e-01 0.742000
Intra-Golgi and retrograde Golgi-to-ER traffic 134 4.49e-01 6.18e-01 0.06360 3.25e-02 -5.47e-02 5.18e-01 0.276000
FCGR3A-mediated phagocytosis 54 7.24e-01 8.45e-01 0.06330 7.60e-03 6.28e-02 9.23e-01 0.425000
Leishmania phagocytosis 54 7.24e-01 8.45e-01 0.06330 7.60e-03 6.28e-02 9.23e-01 0.425000
Parasite infection 54 7.24e-01 8.45e-01 0.06330 7.60e-03 6.28e-02 9.23e-01 0.425000
RNA Polymerase III Transcription Initiation 23 8.71e-01 9.32e-01 0.06320 1.23e-02 6.20e-02 9.19e-01 0.607000
Regulation of IFNG signaling 10 9.42e-01 9.79e-01 0.06320 2.32e-02 -5.88e-02 8.99e-01 0.747000
Signaling by Hippo 17 9.04e-01 9.56e-01 0.06290 -6.20e-02 1.07e-02 6.58e-01 0.939000
Adenylate cyclase inhibitory pathway 12 9.33e-01 9.73e-01 0.06190 8.79e-03 -6.13e-02 9.58e-01 0.713000
Adaptive Immune System 513 6.29e-02 1.73e-01 0.06150 5.95e-02 -1.56e-02 2.28e-02 0.549000
TCR signaling 81 6.34e-01 7.79e-01 0.06140 5.13e-02 3.37e-02 4.25e-01 0.601000
RNA Polymerase III Transcription Initiation From Type 3 Promoter 19 8.98e-01 9.51e-01 0.06140 -6.10e-02 -6.25e-03 6.45e-01 0.962000
DAP12 interactions 26 8.66e-01 9.29e-01 0.06070 5.15e-02 3.22e-02 6.50e-01 0.777000
Signaling by FGFR3 24 8.79e-01 9.37e-01 0.06000 -1.84e-02 5.71e-02 8.76e-01 0.628000
Peptide ligand-binding receptors 73 6.86e-01 8.17e-01 0.05880 -2.18e-02 -5.46e-02 7.47e-01 0.421000
Signal Transduction 1528 1.23e-03 6.31e-03 0.05820 -5.77e-02 -7.71e-03 2.87e-04 0.628000
Epigenetic regulation of gene expression 59 7.47e-01 8.56e-01 0.05770 3.20e-02 -4.81e-02 6.72e-01 0.524000
GPCR ligand binding 191 3.92e-01 5.77e-01 0.05760 -5.08e-02 -2.71e-02 2.28e-01 0.520000
Interleukin-20 family signaling 12 9.42e-01 9.79e-01 0.05740 5.53e-02 1.56e-02 7.40e-01 0.925000
HSF1 activation 18 9.16e-01 9.58e-01 0.05700 1.61e-02 5.47e-02 9.06e-01 0.688000
RAF activation 28 8.75e-01 9.33e-01 0.05670 -4.28e-02 3.71e-02 6.95e-01 0.734000
BBSome-mediated cargo-targeting to cilium 16 9.27e-01 9.68e-01 0.05650 5.41e-02 -1.60e-02 7.08e-01 0.912000
Fatty acid metabolism 118 5.73e-01 7.30e-01 0.05640 -1.59e-03 5.64e-02 9.76e-01 0.292000
Signaling by Rho GTPases 290 2.60e-01 4.48e-01 0.05640 -2.71e-03 5.63e-02 9.37e-01 0.101000
GABA receptor activation 32 8.60e-01 9.25e-01 0.05600 -4.55e-02 -3.26e-02 6.56e-01 0.750000
Metabolism of vitamins and cofactors 128 5.89e-01 7.43e-01 0.05290 4.14e-02 -3.30e-02 4.20e-01 0.521000
Keratan sulfate biosynthesis 17 9.33e-01 9.73e-01 0.05240 -3.50e-02 3.91e-02 8.03e-01 0.780000
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 30 8.89e-01 9.46e-01 0.05140 -3.09e-02 4.11e-02 7.70e-01 0.697000
Post-translational protein modification 907 3.68e-02 1.18e-01 0.05140 5.12e-02 4.96e-03 1.06e-02 0.804000
Cobalamin (Cbl, vitamin B12) transport and metabolism 10 9.64e-01 9.87e-01 0.04980 -4.95e-02 5.70e-03 7.87e-01 0.975000
AMER1 mutants destabilize the destruction complex 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
APC truncation mutants have impaired AXIN binding 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
AXIN missense mutants destabilize the destruction complex 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
AXIN mutants destabilize the destruction complex, activating WNT signaling 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
Truncations of AMER1 destabilize the destruction complex 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
truncated APC mutants destabilize the destruction complex 12 9.58e-01 9.84e-01 0.04910 1.54e-02 -4.67e-02 9.26e-01 0.780000
Metabolism of cofactors 17 9.43e-01 9.79e-01 0.04780 -1.08e-05 4.78e-02 1.00e+00 0.733000
Interleukin-4 and Interleukin-13 signaling 78 7.69e-01 8.66e-01 0.04760 2.74e-03 -4.75e-02 9.67e-01 0.469000
Signaling by Interleukins 298 3.77e-01 5.61e-01 0.04730 1.56e-02 4.47e-02 6.45e-01 0.188000
Chromatin modifying enzymes 150 6.17e-01 7.67e-01 0.04670 -2.72e-05 4.67e-02 1.00e+00 0.325000
Chromatin organization 150 6.17e-01 7.67e-01 0.04670 -2.72e-05 4.67e-02 1.00e+00 0.325000
Reversible hydration of carbon dioxide 10 9.69e-01 9.89e-01 0.04630 3.12e-02 -3.41e-02 8.64e-01 0.852000
Aflatoxin activation and detoxification 10 9.69e-01 9.89e-01 0.04610 -2.19e-02 -4.06e-02 9.05e-01 0.824000
Innate Immune System 652 1.42e-01 3.06e-01 0.04600 4.60e-02 -1.47e-03 4.84e-02 0.950000
Disease 963 6.70e-02 1.79e-01 0.04530 4.50e-02 5.15e-03 2.09e-02 0.792000
ZBP1(DAI) mediated induction of type I IFNs 18 9.49e-01 9.82e-01 0.04390 -2.32e-02 -3.73e-02 8.65e-01 0.784000
Factors involved in megakaryocyte development and platelet production 80 7.97e-01 8.86e-01 0.04380 2.15e-02 -3.81e-02 7.40e-01 0.556000
Interleukin-15 signaling 11 9.69e-01 9.89e-01 0.04370 -1.70e-02 4.02e-02 9.22e-01 0.817000
rRNA modification in the nucleus and cytosol 42 8.90e-01 9.47e-01 0.04300 -1.76e-02 -3.92e-02 8.44e-01 0.660000
Gene expression (Transcription) 866 1.12e-01 2.55e-01 0.04270 3.85e-02 1.86e-02 5.99e-02 0.363000
Cytokine Signaling in Immune system 559 2.33e-01 4.16e-01 0.04270 1.91e-02 3.82e-02 4.46e-01 0.127000
TRAF6-mediated induction of TAK1 complex within TLR4 complex 10 9.74e-01 9.93e-01 0.04240 3.03e-02 -2.97e-02 8.68e-01 0.871000
AKT phosphorylates targets in the cytosol 13 9.66e-01 9.88e-01 0.04230 -1.45e-03 -4.23e-02 9.93e-01 0.792000
Transport of small molecules 447 3.19e-01 5.03e-01 0.04210 3.57e-02 2.22e-02 2.00e-01 0.426000
Negative regulation of the PI3K/AKT network 82 8.08e-01 8.94e-01 0.04170 -4.01e-02 -1.13e-02 5.31e-01 0.860000
Signaling by WNT 192 6.20e-01 7.69e-01 0.04100 3.71e-02 1.76e-02 3.78e-01 0.676000
B-WICH complex positively regulates rRNA expression 21 9.49e-01 9.82e-01 0.04080 -1.90e-02 -3.61e-02 8.80e-01 0.774000
Metabolism of lipids 488 3.22e-01 5.06e-01 0.04030 -3.39e-02 2.18e-02 2.05e-01 0.414000
Negative regulators of DDX58/IFIH1 signaling 21 9.55e-01 9.84e-01 0.03830 -3.07e-02 -2.29e-02 8.08e-01 0.856000
EPH-Ephrin signaling 69 8.62e-01 9.25e-01 0.03810 8.68e-03 -3.71e-02 9.01e-01 0.595000
RNA Polymerase III Abortive And Retractive Initiation 27 9.44e-01 9.79e-01 0.03780 3.70e-02 -8.05e-03 7.40e-01 0.942000
RNA Polymerase III Transcription 27 9.44e-01 9.79e-01 0.03780 3.70e-02 -8.05e-03 7.40e-01 0.942000
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 77 8.51e-01 9.20e-01 0.03750 -3.03e-02 -2.21e-02 6.47e-01 0.738000
Metabolism of Angiotensinogen to Angiotensins 11 9.77e-01 9.94e-01 0.03730 8.35e-03 3.64e-02 9.62e-01 0.835000
Peroxisomal protein import 45 9.12e-01 9.56e-01 0.03690 3.17e-02 1.88e-02 7.13e-01 0.827000
RNA Polymerase II Transcription 779 2.32e-01 4.15e-01 0.03660 3.18e-02 1.81e-02 1.38e-01 0.399000
Anti-inflammatory response favouring Leishmania parasite infection 94 8.29e-01 9.05e-01 0.03650 -3.37e-02 -1.42e-02 5.73e-01 0.813000
Leishmania parasite growth and survival 94 8.29e-01 9.05e-01 0.03650 -3.37e-02 -1.42e-02 5.73e-01 0.813000
Cellular Senescence 100 8.26e-01 9.04e-01 0.03590 3.53e-02 -6.61e-03 5.43e-01 0.909000
Vesicle-mediated transport 464 4.28e-01 6.04e-01 0.03580 3.28e-02 -1.42e-02 2.31e-01 0.604000
Glycerophospholipid biosynthesis 83 8.59e-01 9.25e-01 0.03510 -2.82e-02 2.09e-02 6.57e-01 0.742000
RAF/MAP kinase cascade 183 7.36e-01 8.52e-01 0.03380 3.06e-02 -1.42e-02 4.77e-01 0.741000
FLT3 Signaling 196 7.21e-01 8.45e-01 0.03370 2.77e-02 -1.92e-02 5.06e-01 0.644000
Immune System 1345 1.36e-01 2.96e-01 0.03350 3.19e-02 1.04e-02 5.79e-02 0.537000
Regulation of actin dynamics for phagocytic cup formation 55 9.12e-01 9.56e-01 0.03340 1.60e-02 2.93e-02 8.38e-01 0.707000
Signaling by NOTCH3 38 9.40e-01 9.78e-01 0.03310 -1.89e-02 2.72e-02 8.40e-01 0.772000
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 23 9.63e-01 9.87e-01 0.03300 3.05e-02 1.25e-02 8.00e-01 0.918000
Miscellaneous transport and binding events 15 9.76e-01 9.94e-01 0.03270 2.80e-02 -1.69e-02 8.51e-01 0.910000
Intracellular signaling by second messengers 226 7.02e-01 8.34e-01 0.03250 2.14e-02 2.45e-02 5.82e-01 0.527000
MAPK1/MAPK3 signaling 188 7.61e-01 8.62e-01 0.03150 2.97e-02 -1.04e-02 4.85e-01 0.807000
Membrane Trafficking 438 5.48e-01 7.09e-01 0.03090 3.08e-02 -2.74e-03 2.74e-01 0.922000
Cytochrome P450 - arranged by substrate type 29 9.60e-01 9.85e-01 0.03080 -2.05e-02 2.29e-02 8.48e-01 0.831000
Negative regulation of MAPK pathway 33 9.58e-01 9.84e-01 0.02950 -1.56e-02 2.51e-02 8.77e-01 0.803000
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 13 9.84e-01 9.98e-01 0.02890 -2.67e-02 1.13e-02 8.68e-01 0.944000
Leishmania infection 159 8.29e-01 9.05e-01 0.02820 -2.79e-02 -4.38e-03 5.46e-01 0.924000
Generic Transcription Pathway 694 4.67e-01 6.35e-01 0.02790 2.71e-02 6.69e-03 2.31e-01 0.768000
Nervous system development 380 6.81e-01 8.15e-01 0.02640 -2.63e-02 -2.28e-03 3.83e-01 0.940000
Developmental Biology 594 5.78e-01 7.34e-01 0.02550 -2.52e-02 4.34e-03 3.02e-01 0.859000
TRAF6 mediated NF-kB activation 19 9.82e-01 9.97e-01 0.02510 1.61e-02 1.93e-02 9.03e-01 0.884000
SHC-mediated cascade:FGFR1 10 9.91e-01 9.99e-01 0.02410 -2.12e-02 1.14e-02 9.08e-01 0.950000
Regulation of TP53 Degradation 28 9.78e-01 9.94e-01 0.02290 2.24e-02 4.44e-03 8.37e-01 0.968000
Aquaporin-mediated transport 31 9.76e-01 9.94e-01 0.02280 -1.28e-02 1.89e-02 9.02e-01 0.856000
Diseases of signal transduction by growth factor receptors and second messengers 276 8.61e-01 9.25e-01 0.01930 -1.02e-02 1.64e-02 7.71e-01 0.642000
Fcgamma receptor (FCGR) dependent phagocytosis 75 9.61e-01 9.86e-01 0.01890 1.63e-02 -9.51e-03 8.07e-01 0.887000
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 19 9.90e-01 9.99e-01 0.01880 2.06e-03 -1.87e-02 9.88e-01 0.888000
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 21 9.89e-01 9.99e-01 0.01870 -2.16e-03 -1.86e-02 9.86e-01 0.883000
Zinc transporters 11 9.95e-01 9.99e-01 0.01760 1.68e-02 -5.31e-03 9.23e-01 0.976000
NR1H2 and NR1H3-mediated signaling 35 9.84e-01 9.98e-01 0.01740 -1.57e-03 1.73e-02 9.87e-01 0.859000
Vasopressin regulates renal water homeostasis via Aquaporins 28 9.88e-01 9.99e-01 0.01720 -1.58e-02 7.00e-03 8.85e-01 0.949000
Prostacyclin signalling through prostacyclin receptor 11 9.96e-01 9.99e-01 0.01640 -1.61e-02 3.53e-03 9.27e-01 0.984000
Intra-Golgi traffic 33 9.90e-01 9.99e-01 0.01470 -6.96e-03 1.29e-02 9.45e-01 0.898000
Axon guidance 361 8.98e-01 9.51e-01 0.01430 -1.39e-02 -3.61e-03 6.54e-01 0.907000
Regulation of TP53 Expression and Degradation 29 9.91e-01 9.99e-01 0.01410 1.39e-02 -2.61e-03 8.97e-01 0.981000
Synthesis of PIPs at the Golgi membrane 11 9.97e-01 9.99e-01 0.01290 -1.16e-02 -5.69e-03 9.47e-01 0.974000
Keratan sulfate/keratin metabolism 21 9.95e-01 9.99e-01 0.01240 1.18e-02 -3.55e-03 9.25e-01 0.978000
MAPK family signaling cascades 216 9.55e-01 9.84e-01 0.01210 8.32e-03 8.74e-03 8.34e-01 0.826000
Constitutive Signaling by AKT1 E17K in Cancer 22 9.96e-01 9.99e-01 0.01150 5.65e-03 -1.00e-02 9.63e-01 0.935000
Signaling by ERBB4 37 9.95e-01 9.99e-01 0.00958 -8.73e-03 -3.96e-03 9.27e-01 0.967000
Negative regulation of FGFR4 signaling 16 9.98e-01 9.99e-01 0.00853 5.03e-04 -8.52e-03 9.97e-01 0.953000
Transcriptional regulation of pluripotent stem cells 17 9.99e-01 9.99e-01 0.00666 -4.54e-03 4.88e-03 9.74e-01 0.972000
Uptake and function of anthrax toxins 11 9.99e-01 9.99e-01 0.00609 5.94e-03 1.35e-03 9.73e-01 0.994000
ADP signalling through P2Y purinoceptor 1 17 9.99e-01 9.99e-01 0.00455 6.94e-04 4.49e-03 9.96e-01 0.974000
EPHB-mediated forward signaling 24 9.99e-01 9.99e-01 0.00430 4.30e-03 -3.81e-05 9.71e-01 1.000000


Detailed Gene set reports


Leading Strand Synthesis

Leading Strand Synthesis
metric value
setSize 12
pMANOVA 1.02e-05
p.adjustMANOVA 9.8e-05
s.dist 0.799
s.rna 0.795
s.meth 0.0811
p.rna 1.87e-06
p.meth 0.627




Top 20 genes
Gene rna meth
RFC3 4802 4586
RFC1 4516 4869
POLA2 4488 3152
POLA1 4369 2250
POLD3 3311 2655
PRIM2 4573 1436
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846



Polymerase switching

Polymerase switching
metric value
setSize 12
pMANOVA 1.02e-05
p.adjustMANOVA 9.8e-05
s.dist 0.799
s.rna 0.795
s.meth 0.0811
p.rna 1.87e-06
p.meth 0.627




Top 20 genes
Gene rna meth
RFC3 4802 4586
RFC1 4516 4869
POLA2 4488 3152
POLA1 4369 2250
POLD3 3311 2655
PRIM2 4573 1436
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846



DNA strand elongation

DNA strand elongation
metric value
setSize 23
pMANOVA 3.42e-10
p.adjustMANOVA 1.52e-08
s.dist 0.795
s.rna 0.792
s.meth -0.0691
p.rna 4.7e-11
p.meth 0.566




Top 20 genes
Gene rna meth
MCM3 5094 -5013
RFC4 5403 -4135
POLD2 5448 -3613
MCM2 5363 -3563
GINS3 3865 -4733
GINS2 5297 -3392
MCM6 4995 -2391
RPA2 4244 -2685
RFC5 4881 -1846
DNA2 3164 -2748
PRIM1 4113 -1972
POLD1 4996 -608

Click HERE to show all gene set members

All member genes
rna meth
DNA2 3164 -2748
GINS2 5297 -3392
GINS3 3865 -4733
GINS4 4616 584
LIG1 4370 5174
MCM2 5363 -3563
MCM3 5094 -5013
MCM5 5383 4599
MCM6 4995 -2391
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685



Lagging Strand Synthesis

Lagging Strand Synthesis
metric value
setSize 16
pMANOVA 6.65e-07
p.adjustMANOVA 8.44e-06
s.dist 0.77
s.rna 0.766
s.meth 0.0761
p.rna 1.13e-07
p.meth 0.598




Top 20 genes
Gene rna meth
LIG1 4370 5174
RFC3 4802 4586
RFC1 4516 4869
POLA2 4488 3152
RPA1 4240 2412
POLA1 4369 2250
POLD3 3311 2655
PRIM2 4573 1436
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
DNA2 3164 -2748
LIG1 4370 5174
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685



Inhibition of replication initiation of damaged DNA by RB1/E2F1

Inhibition of replication initiation of damaged DNA by RB1/E2F1
metric value
setSize 12
pMANOVA 3.25e-05
p.adjustMANOVA 0.000277
s.dist 0.757
s.rna 0.67
s.meth 0.351
p.rna 5.81e-05
p.meth 0.0354




Top 20 genes
Gene rna meth
E2F1 5236 4409
PPP2R1B 4160 4434
RB1 4357 4204
PPP2R1A 2925 5110
POLA2 4488 3152
PPP2CA 3993 3289
POLA1 4369 2250
PRIM2 4573 1436
TFDP2 2194 2836
PPP2CB 1799 626

Click HERE to show all gene set members

All member genes
rna meth
E2F1 5236.0 4409.0
POLA1 4369.0 2250.0
POLA2 4488.0 3152.0
PPP2CA 3993.0 3289.0
PPP2CB 1799.0 626.0
PPP2R1A 2925.0 5110.0
PPP2R1B 4160.0 4434.0
PRIM1 4113.0 -1972.0
PRIM2 4573.0 1436.0
RB1 4357.0 4204.0
TFDP1 5290.5 -4292.5
TFDP2 2194.0 2836.0



Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)

Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
metric value
setSize 12
pMANOVA 4.04e-05
p.adjustMANOVA 0.000329
s.dist 0.749
s.rna 0.728
s.meth 0.177
p.rna 1.26e-05
p.meth 0.288




Top 20 genes
Gene rna meth
LIG1 4370 5174
PMS2 4183 4190
MLH1 5076 2499
RPA1 4240 2412
POLD3 3311 2655
EXO1 5250 1627
PCNA 4757 1003
MSH6 1092 3344

Click HERE to show all gene set members

All member genes
rna meth
EXO1 5250 1627
LIG1 4370 5174
MLH1 5076 2499
MSH2 4310 -1924
MSH6 1092 3344
PCNA 4757 1003
PMS2 4183 4190
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
RPA1 4240 2412
RPA2 4244 -2685



Processive synthesis on the lagging strand

Processive synthesis on the lagging strand
metric value
setSize 12
pMANOVA 4.89e-05
p.adjustMANOVA 0.000376
s.dist 0.742
s.rna 0.74
s.meth 0.061
p.rna 9.04e-06
p.meth 0.715




Top 20 genes
Gene rna meth
LIG1 4370 5174
POLA2 4488 3152
RPA1 4240 2412
POLA1 4369 2250
POLD3 3311 2655
PRIM2 4573 1436
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
DNA2 3164 -2748
LIG1 4370 5174
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RPA1 4240 2412
RPA2 4244 -2685



Removal of the Flap Intermediate

Removal of the Flap Intermediate
metric value
setSize 11
pMANOVA 0.000121
p.adjustMANOVA 0.000851
s.dist 0.74
s.rna 0.739
s.meth -0.0161
p.rna 2.17e-05
p.meth 0.926




Top 20 genes
Gene rna meth
POLD2 5448 -3613
RPA2 4244 -2685
DNA2 3164 -2748
PRIM1 4113 -1972
POLD1 4996 -608

Click HERE to show all gene set members

All member genes
rna meth
DNA2 3164 -2748
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
PRIM1 4113 -1972
PRIM2 4573 1436
RPA1 4240 2412
RPA2 4244 -2685



GP1b-IX-V activation signalling

GP1b-IX-V activation signalling
metric value
setSize 10
pMANOVA 0.000499
p.adjustMANOVA 0.00286
s.dist 0.712
s.rna -0.71
s.meth 0.0638
p.rna 0.000102
p.meth 0.727




Top 20 genes
Gene rna meth
GP1BB -4930 3490
YWHAZ -3496 4765
GP1BA -5071 2176
GP9 -2916 1929
FLNA -3912 1284
GP5 -5025 909

Click HERE to show all gene set members

All member genes
rna meth
FLNA -3912 1284
GP1BA -5071 2176
GP1BB -4930 3490
GP5 -5025 909
GP9 -2916 1929
PIK3R1 -3769 -1816
RAF1 -984 -2702
SRC -972 -555
VWF -4810 -3946
YWHAZ -3496 4765



E2F mediated regulation of DNA replication

E2F mediated regulation of DNA replication
metric value
setSize 18
pMANOVA 1.5e-06
p.adjustMANOVA 1.76e-05
s.dist 0.703
s.rna 0.55
s.meth 0.438
p.rna 5.32e-05
p.meth 0.00129




Top 20 genes
Gene rna meth
E2F1 5236 4409
ORC2 4242 4997
CDK1 4481 4276
PPP2R1B 4160 4434
RB1 4357 4204
PPP2R1A 2925 5110
ORC1 3704 4008
POLA2 4488 3152
CCNB1 3469 3871
PPP2CA 3993 3289
POLA1 4369 2250
PRIM2 4573 1436
TFDP2 2194 2836
PPP2CB 1799 626

Click HERE to show all gene set members

All member genes
rna meth
CCNB1 3469.0 3871.0
CDK1 4481.0 4276.0
E2F1 5236.0 4409.0
ORC1 3704.0 4008.0
ORC2 4242.0 4997.0
ORC3 -515.0 2150.0
ORC4 -3477.0 2024.0
POLA1 4369.0 2250.0
POLA2 4488.0 3152.0
PPP2CA 3993.0 3289.0
PPP2CB 1799.0 626.0
PPP2R1A 2925.0 5110.0
PPP2R1B 4160.0 4434.0
PRIM1 4113.0 -1972.0
PRIM2 4573.0 1436.0
RB1 4357.0 4204.0
TFDP1 5290.5 -4292.5
TFDP2 2194.0 2836.0



PCNA-Dependent Long Patch Base Excision Repair

PCNA-Dependent Long Patch Base Excision Repair
metric value
setSize 15
pMANOVA 2.47e-05
p.adjustMANOVA 0.000224
s.dist 0.686
s.rna 0.66
s.meth 0.187
p.rna 9.52e-06
p.meth 0.211




Top 20 genes
Gene rna meth
LIG1 4370 5174
RFC3 4802 4586
RFC1 4516 4869
POLE2 3151 3358
RPA1 4240 2412
POLD3 3311 2655
POLE 3539 2109
PCNA 4757 1003
POLB 378 5291

Click HERE to show all gene set members

All member genes
rna meth
LIG1 4370 5174
PCNA 4757 1003
POLB 378 5291
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685



Translesion Synthesis by POLH

Translesion Synthesis by POLH
metric value
setSize 10
pMANOVA 0.000883
p.adjustMANOVA 0.00464
s.dist 0.684
s.rna 0.634
s.meth 0.255
p.rna 0.000514
p.meth 0.162




Top 20 genes
Gene rna meth
RFC3 4802 4586
RFC1 4516 4869
NPLOC4 4061 3124
UFD1L 2355 5368
RPA1 4240 2412
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
NPLOC4 4061 3124
PCNA 4757 1003
RCHY1 -1635 3316
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685
UFD1L 2355 5368



Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)

Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
metric value
setSize 12
pMANOVA 0.000291
p.adjustMANOVA 0.00184
s.dist 0.672
s.rna 0.651
s.meth 0.168
p.rna 9.53e-05
p.meth 0.313




Top 20 genes
Gene rna meth
LIG1 4370 5174
PMS2 4183 4190
MLH1 5076 2499
RPA1 4240 2412
POLD3 3311 2655
EXO1 5250 1627
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
EXO1 5250 1627
LIG1 4370 5174
MLH1 5076 2499
MSH2 4310 -1924
MSH3 -3978 2775
PCNA 4757 1003
PMS2 4183 4190
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
RPA1 4240 2412
RPA2 4244 -2685



Heme biosynthesis

Heme biosynthesis
metric value
setSize 11
pMANOVA 0.000677
p.adjustMANOVA 0.00368
s.dist 0.664
s.rna 0.615
s.meth 0.252
p.rna 0.000416
p.meth 0.148




Top 20 genes
Gene rna meth
ABCG2 5551 5331
FECH 3902 5625
UROD 3819 5409
HMBS 3557 4630
PPOX 3160 3427
CPOX 4201 2337
ALAS2 3514 1812

Click HERE to show all gene set members

All member genes
rna meth
ABCG2 5551 5331
ALAD 4609 -3766
ALAS1 -35 -1641
ALAS2 3514 1812
COX15 3921 -1098
CPOX 4201 2337
FECH 3902 5625
HMBS 3557 4630
PPOX 3160 3427
UROD 3819 5409
UROS 4000 -4674



WNT5A-dependent internalization of FZD2, FZD5 and ROR2

WNT5A-dependent internalization of FZD2, FZD5 and ROR2
metric value
setSize 12
pMANOVA 0.000369
p.adjustMANOVA 0.00224
s.dist 0.661
s.rna 0.522
s.meth 0.406
p.rna 0.00173
p.meth 0.015




Top 20 genes
Gene rna meth
ROR2 5265 4297
AP2M1 3427 4807
AP2A2 4924 3149
CLTB 5042 2143
AP2S1 4612 2148
CLTC 1153 5124
FZD2 2323 2416
FZD5 1708 2382
WNT5A 2177 206

Click HERE to show all gene set members

All member genes
rna meth
AP2A1 4742 -1346
AP2A2 4924 3149
AP2M1 3427 4807
AP2S1 4612 2148
CLTA 4776 -1903
CLTB 5042 2143
CLTC 1153 5124
FZD2 2323 2416
FZD5 1708 2382
ROR1 -2359 5661
ROR2 5265 4297
WNT5A 2177 206



Mismatch Repair

Mismatch Repair
metric value
setSize 13
pMANOVA 0.000306
p.adjustMANOVA 0.00191
s.dist 0.644
s.rna 0.612
s.meth 0.2
p.rna 0.000134
p.meth 0.213




Top 20 genes
Gene rna meth
LIG1 4370 5174
PMS2 4183 4190
MLH1 5076 2499
RPA1 4240 2412
POLD3 3311 2655
EXO1 5250 1627
PCNA 4757 1003
MSH6 1092 3344

Click HERE to show all gene set members

All member genes
rna meth
EXO1 5250 1627
LIG1 4370 5174
MLH1 5076 2499
MSH2 4310 -1924
MSH3 -3978 2775
MSH6 1092 3344
PCNA 4757 1003
PMS2 4183 4190
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
RPA1 4240 2412
RPA2 4244 -2685



Condensation of Prophase Chromosomes

Condensation of Prophase Chromosomes
metric value
setSize 10
pMANOVA 0.00207
p.adjustMANOVA 0.0101
s.dist 0.641
s.rna 0.414
s.meth 0.489
p.rna 0.0234
p.meth 0.00744




Top 20 genes
Gene rna meth
CDK1 4481 4276
RB1 4357 4204
MCPH1 3468 4767
CCNB1 3469 3871
H2AFX 4570 2556
SMC4 18 3875
NCAPG2 3877 5

Click HERE to show all gene set members

All member genes
rna meth
CCNB1 3469 3871
CDK1 4481 4276
H2AFX 4570 2556
MCPH1 3468 4767
NCAPG2 3877 5
NCAPH2 4411 -2029
PHF8 -1596 5415
RB1 4357 4204
SET -1481 1846
SMC4 18 3875



G1/S-Specific Transcription

G1/S-Specific Transcription
metric value
setSize 23
pMANOVA 7.67e-07
p.adjustMANOVA 9.65e-06
s.dist 0.639
s.rna 0.619
s.meth 0.155
p.rna 2.72e-07
p.meth 0.197




Top 20 genes
Gene rna meth
E2F1 5236 4409
RBL1 4359 5290
CDK1 4481 4276
FBXO5 4672 3485
ORC1 3704 4008
TK1 3595 3683
RRM2 3983 2580
POLA1 4369 2250
CDC25A 3079 2868
TFDP2 2194 2836
LIN37 2600 2106
PCNA 4757 1003

Click HERE to show all gene set members

All member genes
rna meth
CCNE1 4229.0 -3124.0
CDC25A 3079.0 2868.0
CDC6 3792.0 -4341.0
CDK1 4481.0 4276.0
CDT1 4701.0 -922.0
DHFR 5147.5 -535.5
E2F1 5236.0 4409.0
E2F4 5040.0 -592.0
E2F5 -2164.0 4282.0
E2F6 4046.0 -2876.0
FBXO5 4672.0 3485.0
LIN37 2600.0 2106.0
LIN54 2430.0 -198.0
LIN9 4624.0 -850.0
ORC1 3704.0 4008.0
PCNA 4757.0 1003.0
POLA1 4369.0 2250.0
RBL1 4359.0 5290.0
RBL2 389.0 -1117.0
RRM2 3983.0 2580.0
TFDP1 5290.5 -4292.5
TFDP2 2194.0 2836.0
TK1 3595.0 3683.0



Initiation of Nuclear Envelope (NE) Reformation

Initiation of Nuclear Envelope (NE) Reformation
metric value
setSize 14
pMANOVA 0.000191
p.adjustMANOVA 0.00129
s.dist 0.638
s.rna 0.579
s.meth 0.268
p.rna 0.000177
p.meth 0.0832




Top 20 genes
Gene rna meth
VRK2 4983 4151
CDK1 4481 4276
LMNB1 3879 4674
PPP2R1A 2925 5110
CCNB1 3469 3871
PPP2CA 3993 3289
LMNA 3655 3030
LEMD2 2818 1169
SIRT2 5177 67
ANKLE2 121 2769

Click HERE to show all gene set members

All member genes
rna meth
ANKLE2 121 2769
CCNB1 3469 3871
CDK1 4481 4276
KPNB1 2091 -814
LBR 2167 -1579
LEMD2 2818 1169
LMNA 3655 3030
LMNB1 3879 4674
PPP2CA 3993 3289
PPP2R1A 2925 5110
SIRT2 5177 67
TMPO 4249 -1700
VRK1 4407 -4972
VRK2 4983 4151



Gap-filling DNA repair synthesis and ligation in GG-NER

Gap-filling DNA repair synthesis and ligation in GG-NER
metric value
setSize 17
pMANOVA 4.62e-05
p.adjustMANOVA 0.000364
s.dist 0.625
s.rna 0.61
s.meth 0.139
p.rna 1.34e-05
p.meth 0.323




Top 20 genes
Gene rna meth
LIG1 4370 5174
RFC3 4802 4586
RFC1 4516 4869
POLE2 3151 3358
RPA1 4240 2412
POLD3 3311 2655
POLE 3539 2109
PCNA 4757 1003
POLK 277 2118

Click HERE to show all gene set members

All member genes
rna meth
LIG1 4370 5174
LIG3 -311 3633
PCNA 4757 1003
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
POLK 277 2118
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685
XRCC1 3519 -2478



Formation of the ternary complex, and subsequently, the 43S complex

Formation of the ternary complex, and subsequently, the 43S complex
metric value
setSize 17
pMANOVA 4.66e-05
p.adjustMANOVA 0.000365
s.dist 0.625
s.rna 0.61
s.meth 0.136
p.rna 1.33e-05
p.meth 0.332




Top 20 genes
Gene rna meth
RPS9 4671 5151
RPS6 3660 5059
EIF3G 3436 3889
EIF3B 3906 3162
RPS26 3887 2685
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
EIF3H 4788 140
EIF2S2 2196 95

Click HERE to show all gene set members

All member genes
rna meth
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
FAU 3058 -2417
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



cGMP effects

cGMP effects
metric value
setSize 13
pMANOVA 0.000526
p.adjustMANOVA 0.00298
s.dist 0.622
s.rna -0.615
s.meth -0.0958
p.rna 0.000125
p.meth 0.55




Top 20 genes
Gene rna meth
KCNMB4 -4581 -3337
PDE10A -3435 -3556
MRVI1 -4955 -1741
PDE1A -1080 -5147
PDE2A -897 -4905
PDE9A -536 -4642

Click HERE to show all gene set members

All member genes
rna meth
ITPR1 -3717 941
KCNMA1 -4453 3488
KCNMB1 1871 3207
KCNMB4 -4581 -3337
MRVI1 -4955 -1741
PDE10A -3435 -3556
PDE11A -4871 3375
PDE1A -1080 -5147
PDE1B -5074 3648
PDE2A -897 -4905
PDE5A -5038 1356
PDE9A -536 -4642
PRKG1 -3125 3159



Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S

Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
metric value
setSize 21
pMANOVA 5.22e-06
p.adjustMANOVA 5.51e-05
s.dist 0.621
s.rna 0.579
s.meth 0.225
p.rna 4.44e-06
p.meth 0.0745




Top 20 genes
Gene rna meth
RPS9 4671 5151
RPS6 3660 5059
EIF4G1 3535 5052
EIF3G 3436 3889
EIF3B 3906 3162
EIF4EBP1 4082 2624
RPS26 3887 2685
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
EIF3H 4788 140
EIF2S2 2196 95

Click HERE to show all gene set members

All member genes
rna meth
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4EBP1 4082 2624
EIF4G1 3535 5052
EIF4H 3553 1782
FAU 3058 -2417
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Ubiquitin Mediated Degradation of Phosphorylated Cdc25A

Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
metric value
setSize 33
pMANOVA 6.76e-09
p.adjustMANOVA 1.56e-07
s.dist 0.617
s.rna 0.617
s.meth 0.00582
p.rna 8.6e-10
p.meth 0.954




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
CDC25A 3079 2868
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CDC25A 3079 2868
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



p53-Independent DNA Damage Response

p53-Independent DNA Damage Response
metric value
setSize 33
pMANOVA 6.76e-09
p.adjustMANOVA 1.56e-07
s.dist 0.617
s.rna 0.617
s.meth 0.00582
p.rna 8.6e-10
p.meth 0.954




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
CDC25A 3079 2868
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CDC25A 3079 2868
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



p53-Independent G1/S DNA damage checkpoint

p53-Independent G1/S DNA damage checkpoint
metric value
setSize 33
pMANOVA 6.76e-09
p.adjustMANOVA 1.56e-07
s.dist 0.617
s.rna 0.617
s.meth 0.00582
p.rna 8.6e-10
p.meth 0.954




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
CDC25A 3079 2868
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CDC25A 3079 2868
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



Ribosomal scanning and start codon recognition

Ribosomal scanning and start codon recognition
metric value
setSize 20
pMANOVA 1.32e-05
p.adjustMANOVA 0.000123
s.dist 0.611
s.rna 0.573
s.meth 0.214
p.rna 9.23e-06
p.meth 0.0977




Top 20 genes
Gene rna meth
RPS9 4671 5151
RPS6 3660 5059
EIF4G1 3535 5052
EIF3G 3436 3889
EIF3B 3906 3162
RPS26 3887 2685
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
EIF3H 4788 140
EIF2S2 2196 95

Click HERE to show all gene set members

All member genes
rna meth
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4G1 3535 5052
EIF4H 3553 1782
FAU 3058 -2417
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Translation initiation complex formation

Translation initiation complex formation
metric value
setSize 20
pMANOVA 1.32e-05
p.adjustMANOVA 0.000123
s.dist 0.611
s.rna 0.573
s.meth 0.214
p.rna 9.23e-06
p.meth 0.0977




Top 20 genes
Gene rna meth
RPS9 4671 5151
RPS6 3660 5059
EIF4G1 3535 5052
EIF3G 3436 3889
EIF3B 3906 3162
RPS26 3887 2685
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
EIF3H 4788 140
EIF2S2 2196 95

Click HERE to show all gene set members

All member genes
rna meth
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4G1 3535 5052
EIF4H 3553 1782
FAU 3058 -2417
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Cross-presentation of soluble exogenous antigens (endosomes)

Cross-presentation of soluble exogenous antigens (endosomes)
metric value
setSize 36
pMANOVA 2.09e-09
p.adjustMANOVA 6.5e-08
s.dist 0.609
s.rna 0.602
s.meth -0.0922
p.rna 4.01e-10
p.meth 0.339




Top 20 genes
Gene rna meth
FCGR1A 5545.5 -4810.5
FCGR1B 5545.5 -4810.5
MRC1 3932.5 -5158.5
PSMB7 4175.0 -4520.0
PSMA7 5337.0 -3323.0
PSMB9 4631.0 -3753.0
PSMD2 3397.0 -4943.0
PSMB6 4575.0 -3607.0
PSMD6 3031.0 -4213.0
PSMD5 4489.0 -2216.0
PSME2 3072.0 -3228.0
PSMD8 4998.0 -1500.0
PSMC4 4381.0 -1547.0
PSMD4 3582.0 -1267.0
PSMC3 4518.0 -761.0
PSMB10 3033.0 -979.0
PSMB2 3836.0 -514.0
PSMC2 5346.0 -32.0

Click HERE to show all gene set members

All member genes
rna meth
FCGR1A 5545.5 -4810.5
FCGR1B 5545.5 -4810.5
MRC1 3932.5 -5158.5
MRC2 -3869.0 -891.0
PSMA1 4448.0 4295.0
PSMA3 -537.0 -2323.0
PSMA6 5492.0 2708.0
PSMA7 5337.0 -3323.0
PSMA8 5181.0 1056.0
PSMB10 3033.0 -979.0
PSMB11 -67.0 -1629.0
PSMB2 3836.0 -514.0
PSMB4 4220.0 4097.0
PSMB6 4575.0 -3607.0
PSMB7 4175.0 -4520.0
PSMB8 3444.0 3538.0
PSMB9 4631.0 -3753.0
PSMC1 4461.0 112.0
PSMC2 5346.0 -32.0
PSMC3 4518.0 -761.0
PSMC4 4381.0 -1547.0
PSMD1 5507.0 5589.0
PSMD11 3386.0 1762.0
PSMD13 3352.0 1458.0
PSMD14 3173.0 4254.0
PSMD2 3397.0 -4943.0
PSMD3 4078.0 157.0
PSMD4 3582.0 -1267.0
PSMD5 4489.0 -2216.0
PSMD6 3031.0 -4213.0
PSMD7 4280.0 5170.0
PSMD8 4998.0 -1500.0
PSME2 3072.0 -3228.0
PSME3 3713.0 5601.0
PSME4 -3812.0 5257.0
PSMF1 4976.0 229.0



Recognition of DNA damage by PCNA-containing replication complex

Recognition of DNA damage by PCNA-containing replication complex
metric value
setSize 18
pMANOVA 4.75e-05
p.adjustMANOVA 0.000368
s.dist 0.607
s.rna 0.596
s.meth 0.114
p.rna 1.19e-05
p.meth 0.404




Top 20 genes
Gene rna meth
RFC3 4802 4586
RFC1 4516 4869
USP1 3973 5286
RBX1 2144 5045
POLE2 3151 3358
RPA1 4240 2412
POLD3 3311 2655
POLE 3539 2109
PCNA 4757 1003
CUL4A 4450 765

Click HERE to show all gene set members

All member genes
rna meth
CUL4A 4450 765
CUL4B -3359 -934
DDB1 2931 -3209
PCNA 4757 1003
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
RBX1 2144 5045
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685
USP1 3973 5286



Cyclin A/B1/B2 associated events during G2/M transition

Cyclin A/B1/B2 associated events during G2/M transition
metric value
setSize 12
pMANOVA 0.00136
p.adjustMANOVA 0.00681
s.dist 0.605
s.rna 0.524
s.meth 0.301
p.rna 0.00167
p.meth 0.0709




Top 20 genes
Gene rna meth
CDK1 4481 4276
PPP2R1B 4160 4434
PPP2R1A 2925 5110
CCNB1 3469 3871
PPP2CA 3993 3289
CCNA2 3657 2423
CDC25A 3079 2868
PPP2CB 1799 626

Click HERE to show all gene set members

All member genes
rna meth
CCNA2 3657 2423
CCNB1 3469 3871
CCNH 2610 -2081
CDC25A 3079 2868
CDC25B 2937 -1883
CDK1 4481 4276
FOXM1 4854 -4930
PPP2CA 3993 3289
PPP2CB 1799 626
PPP2R1A 2925 5110
PPP2R1B 4160 4434
XPO1 -52 4216



Assembly of the pre-replicative complex

Assembly of the pre-replicative complex
metric value
setSize 46
pMANOVA 1.49e-11
p.adjustMANOVA 9.77e-10
s.dist 0.602
s.rna 0.601
s.meth 0.0304
p.rna 1.78e-12
p.meth 0.722




Top 20 genes
Gene rna meth
PSMD1 5507 5589
MCM5 5383 4599
E2F1 5236 4409
PSMD7 4280 5170
ORC2 4242 4997
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
ORC1 3704 4008
PSMD14 3173 4254
PSMB8 3444 3538
E2F2 2767 3317
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
GMNN 4342 710
E2F3 816 2112
PSMF1 4976 229
PSMD3 4078 157

Click HERE to show all gene set members

All member genes
rna meth
CDC6 3792 -4341
CDT1 4701 -922
E2F1 5236 4409
E2F2 2767 3317
E2F3 816 2112
GMNN 4342 710
MCM2 5363 -3563
MCM3 5094 -5013
MCM5 5383 4599
MCM6 4995 -2391
ORC1 3704 4008
ORC2 4242 4997
ORC3 -515 2150
ORC4 -3477 2024
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



Resolution of AP sites via the multiple-nucleotide patch replacement pathway

Resolution of AP sites via the multiple-nucleotide patch replacement pathway
metric value
setSize 17
pMANOVA 9.68e-05
p.adjustMANOVA 0.000701
s.dist 0.602
s.rna 0.573
s.meth 0.183
p.rna 4.29e-05
p.meth 0.193




Top 20 genes
Gene rna meth
LIG1 4370 5174
RFC3 4802 4586
RFC1 4516 4869
POLE2 3151 3358
RPA1 4240 2412
POLD3 3311 2655
PARP1 2392 3245
POLE 3539 2109
PCNA 4757 1003
POLB 378 5291

Click HERE to show all gene set members

All member genes
rna meth
LIG1 4370 5174
PARG -2691 -1172
PARP1 2392 3245
PCNA 4757 1003
POLB 378 5291
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685



DNA Replication Pre-Initiation

DNA Replication Pre-Initiation
metric value
setSize 58
pMANOVA 3e-14
p.adjustMANOVA 2.66e-12
s.dist 0.599
s.rna 0.597
s.meth 0.0469
p.rna 3.7e-15
p.meth 0.537




Top 20 genes
Gene rna meth
PSMD1 5507 5589
MCM5 5383 4599
E2F1 5236 4409
PSMD7 4280 5170
ORC2 4242 4997
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
ORC1 3704 4008
POLA2 4488 3152
PSMD14 3173 4254
PSMB8 3444 3538
POLE2 3151 3358
RPA1 4240 2412
POLA1 4369 2250
E2F2 2767 3317
POLE 3539 2109
PRIM2 4573 1436
PSMD11 3386 1762

Click HERE to show all gene set members

All member genes
rna meth
CDC6 3792 -4341
CDC7 1248 687
CDT1 4701 -922
DBF4 3123 -1454
E2F1 5236 4409
E2F2 2767 3317
E2F3 816 2112
GMNN 4342 710
MCM10 3817 572
MCM2 5363 -3563
MCM3 5094 -5013
MCM5 5383 4599
MCM6 4995 -2391
ORC1 3704 4008
ORC2 4242 4997
ORC3 -515 2150
ORC4 -3477 2024
POLA1 4369 2250
POLA2 4488 3152
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
PRIM1 4113 -1972
PRIM2 4573 1436
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229
RPA1 4240 2412
RPA2 4244 -2685



Formation of a pool of free 40S subunits

Formation of a pool of free 40S subunits
metric value
setSize 34
pMANOVA 1.41e-08
p.adjustMANOVA 2.83e-07
s.dist 0.595
s.rna 0.575
s.meth 0.155
p.rna 6.72e-09
p.meth 0.117




Top 20 genes
Gene rna meth
RPL11 5637 5596
RPS9 4671 5151
RPL38 3889 5651
RPS6 3660 5059
RPL23A 4758 3359
RPL5 5219 2810
EIF3G 3436 3889
EIF3B 3906 3162
RPL37 4161 2628
RPS26 3887 2685
RPL14 1794 5403
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
RPL15 1498 1903
RPL7 4102 307
EIF3H 4788 140

Click HERE to show all gene set members

All member genes
rna meth
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
FAU 3058 -2417
RPL10 4070 -226
RPL11 5637 5596
RPL14 1794 5403
RPL15 1498 1903
RPL22 2609 -1826
RPL22L1 -3752 3443
RPL23A 4758 3359
RPL26 4540 -4716
RPL28 5332 -1109
RPL3 4305 -1627
RPL31 5358 -3687
RPL34 4708 -1609
RPL37 4161 2628
RPL38 3889 5651
RPL3L -5130 3767
RPL5 5219 2810
RPL7 4102 307
RPL8 3994 -291
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



SCF-beta-TrCP mediated degradation of Emi1

SCF-beta-TrCP mediated degradation of Emi1
metric value
setSize 37
pMANOVA 3.85e-09
p.adjustMANOVA 9.6e-08
s.dist 0.591
s.rna 0.591
s.meth 0.0127
p.rna 4.88e-10
p.meth 0.893




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
FBXO5 4672 3485
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
CUL1 2299 5154
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CDC20 4871 -306
CUL1 2299 5154
FBXO5 4672 3485
FZR1 3434 -264
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229
SKP1 -2794 -2858



Ubiquitin-dependent degradation of Cyclin D

Ubiquitin-dependent degradation of Cyclin D
metric value
setSize 35
pMANOVA 1.64e-08
p.adjustMANOVA 3.25e-07
s.dist 0.585
s.rna 0.584
s.meth 0.0255
p.rna 2.22e-09
p.meth 0.794




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
CDK4 4765 3169
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
CCND1 2293 1143
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CCND1 2293 1143
CDK4 4765 3169
GSK3B -2933 2793
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



L13a-mediated translational silencing of Ceruloplasmin expression

L13a-mediated translational silencing of Ceruloplasmin expression
metric value
setSize 38
pMANOVA 3.58e-09
p.adjustMANOVA 9.1e-08
s.dist 0.584
s.rna 0.552
s.meth 0.19
p.rna 3.93e-09
p.meth 0.0424




Top 20 genes
Gene rna meth
RPL11 5637 5596
RPS9 4671 5151
RPL38 3889 5651
RPS6 3660 5059
EIF4G1 3535 5052
RPL23A 4758 3359
RPL5 5219 2810
EIF3G 3436 3889
EIF3B 3906 3162
RPL37 4161 2628
RPS26 3887 2685
RPL14 1794 5403
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855
RPL15 1498 1903
RPL7 4102 307

Click HERE to show all gene set members

All member genes
rna meth
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4G1 3535 5052
EIF4H 3553 1782
FAU 3058 -2417
RPL10 4070 -226
RPL11 5637 5596
RPL14 1794 5403
RPL15 1498 1903
RPL22 2609 -1826
RPL22L1 -3752 3443
RPL23A 4758 3359
RPL26 4540 -4716
RPL28 5332 -1109
RPL3 4305 -1627
RPL31 5358 -3687
RPL34 4708 -1609
RPL37 4161 2628
RPL38 3889 5651
RPL3L -5130 3767
RPL5 5219 2810
RPL7 4102 307
RPL8 3994 -291
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Regulation of activated PAK-2p34 by proteasome mediated degradation

Regulation of activated PAK-2p34 by proteasome mediated degradation
metric value
setSize 33
pMANOVA 5.07e-08
p.adjustMANOVA 7.99e-07
s.dist 0.583
s.rna 0.583
s.meth 0.0204
p.rna 6.97e-09
p.meth 0.84




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
PSMD14 3173 4254
PSMB8 3444 3538
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
PAK2 -3101 5492
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1

Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
metric value
setSize 13
pMANOVA 0.00139
p.adjustMANOVA 0.0069
s.dist 0.58
s.rna 0.552
s.meth 0.179
p.rna 0.000571
p.meth 0.263




Top 20 genes
Gene rna meth
E2F1 5236 4409
RBL1 4359 5290
CDK1 4481 4276
CCNA2 3657 2423
TFDP2 2194 2836
LIN37 2600 2106

Click HERE to show all gene set members

All member genes
rna meth
CCNA2 3657.0 2423.0
CDK1 4481.0 4276.0
E2F1 5236.0 4409.0
E2F4 5040.0 -592.0
E2F5 -2164.0 4282.0
LIN37 2600.0 2106.0
LIN54 2430.0 -198.0
LIN9 4624.0 -850.0
MYBL2 4902.0 -3159.0
RBL1 4359.0 5290.0
RBL2 389.0 -1117.0
TFDP1 5290.5 -4292.5
TFDP2 2194.0 2836.0



Hh mutants that don't undergo autocatalytic processing are degraded by ERAD

Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
metric value
setSize 35
pMANOVA 2.31e-08
p.adjustMANOVA 4.28e-07
s.dist 0.579
s.rna 0.579
s.meth -0.0034
p.rna 3.03e-09
p.meth 0.972




Top 20 genes
Gene rna meth
PSMB7 4175 -4520
PSMA7 5337 -3323
PSMB9 4631 -3753
PSMD2 3397 -4943
PSMB6 4575 -3607
PSMD6 3031 -4213
PSMD5 4489 -2216
PSME2 3072 -3228
PSMD8 4998 -1500
PSMC4 4381 -1547
PSMD4 3582 -1267
PSMC3 4518 -761
PSMB10 3033 -979
PSMB2 3836 -514
PSMC2 5346 -32

Click HERE to show all gene set members

All member genes
rna meth
OS9 2822 1024
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229
SEL1L -231 -4891
SYVN1 595 5448



CDT1 association with the CDC6:ORC:origin complex

CDT1 association with the CDC6:ORC:origin complex
metric value
setSize 39
pMANOVA 3.13e-09
p.adjustMANOVA 8.22e-08
s.dist 0.579
s.rna 0.578
s.meth 0.0262
p.rna 4.08e-10
p.meth 0.777




Top 20 genes
Gene rna meth
PSMD1 5507 5589
PSMD7 4280 5170
ORC2 4242 4997
PSME3 3713 5601
PSMA1 4448 4295
PSMB4 4220 4097
PSMA6 5492 2708
ORC1 3704 4008
PSMD14 3173 4254
PSMB8 3444 3538
PSMD11 3386 1762
PSMA8 5181 1056
PSMD13 3352 1458
GMNN 4342 710
PSMF1 4976 229
PSMD3 4078 157
PSMC1 4461 112

Click HERE to show all gene set members

All member genes
rna meth
CDC6 3792 -4341
CDT1 4701 -922
GMNN 4342 710
ORC1 3704 4008
ORC2 4242 4997
ORC3 -515 2150
ORC4 -3477 2024
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



Regulation of ornithine decarboxylase (ODC)

Regulation of ornithine decarboxylase (ODC)
metric value
setSize 35
pMANOVA 2.34e-08
p.adjustMANOVA 4.28e-07
s.dist 0.579
s.rna 0.579
s.meth -0.000584
p.rna 3.07e-09
p.meth 0.995




Top 20 genes
Gene rna meth
PSMB7 4175 -4520
PSMA7 5337 -3323
PSMB9 4631 -3753
PSMD2 3397 -4943
PSMB6 4575 -3607
PSMD6 3031 -4213
PSMD5 4489 -2216
PSME2 3072 -3228
PSMD8 4998 -1500
PSMC4 4381 -1547
PSMD4 3582 -1267
PSMC3 4518 -761
PSMB10 3033 -979
PSMB2 3836 -514
OAZ2 207 -2830
PSMC2 5346 -32

Click HERE to show all gene set members

All member genes
rna meth
AZIN1 -63 4868
NQO1 3001 80
OAZ2 207 -2830
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229



Activation of the pre-replicative complex

Activation of the pre-replicative complex
metric value
setSize 23
pMANOVA 9.82e-06
p.adjustMANOVA 9.76e-05
s.dist 0.578
s.rna 0.575
s.meth 0.0574
p.rna 1.78e-06
p.meth 0.634




Top 20 genes
Gene rna meth
MCM5 5383 4599
ORC2 4242 4997
ORC1 3704 4008
POLA2 4488 3152
POLE2 3151 3358
RPA1 4240 2412
POLA1 4369 2250
POLE 3539 2109
PRIM2 4573 1436
GMNN 4342 710
MCM10 3817 572
CDC7 1248 687

Click HERE to show all gene set members

All member genes
rna meth
CDC6 3792 -4341
CDC7 1248 687
CDT1 4701 -922
DBF4 3123 -1454
GMNN 4342 710
MCM10 3817 572
MCM2 5363 -3563
MCM3 5094 -5013
MCM5 5383 4599
MCM6 4995 -2391
ORC1 3704 4008
ORC2 4242 4997
ORC3 -515 2150
ORC4 -3477 2024
POLA1 4369 2250
POLA2 4488 3152
POLE 3539 2109
POLE2 3151 3358
POLE4 503 -201
PRIM1 4113 -1972
PRIM2 4573 1436
RPA1 4240 2412
RPA2 4244 -2685



Telomere C-strand (Lagging Strand) Synthesis

Telomere C-strand (Lagging Strand) Synthesis
metric value
setSize 25
pMANOVA 3.65e-06
p.adjustMANOVA 3.88e-05
s.dist 0.578
s.rna 0.578
s.meth 0.0242
p.rna 5.77e-07
p.meth 0.834




Top 20 genes
Gene rna meth
LIG1 4370 5174
RFC3 4802 4586
RFC1 4516 4869
POLA2 4488 3152
RPA1 4240 2412
POLA1 4369 2250
POLD3 3311 2655
PRIM2 4573 1436
PCNA 4757 1003
ACD 160 975

Click HERE to show all gene set members

All member genes
rna meth
ACD 160 975
CHTF18 4890 -1868
CTC1 4390 -1355
DNA2 3164 -2748
DSCC1 3420 -184
LIG1 4370 5174
PCNA 4757 1003
POLA1 4369 2250
POLA2 4488 3152
POLD1 4996 -608
POLD2 5448 -3613
POLD3 3311 2655
POT1 -1451 -318
PRIM1 4113 -1972
PRIM2 4573 1436
RFC1 4516 4869
RFC3 4802 4586
RFC4 5403 -4135
RFC5 4881 -1846
RPA1 4240 2412
RPA2 4244 -2685
TEN1 666 -3651
TERF1 -281 3727
TERF2 -27 2965
TINF2 2751 -1802



Metabolism of polyamines

Metabolism of polyamines
metric value
setSize 40
pMANOVA 2.19e-09
p.adjustMANOVA 6.64e-08
s.dist 0.577
s.rna 0.577
s.meth -0.0115
p.rna 2.71e-10
p.meth 0.9




Top 20 genes
Gene rna meth
AMD1 5691 -4327
PSMB7 4175 -4520
PSMA7 5337 -3323
PSMB9 4631 -3753
PSMD2 3397 -4943
PSMB6 4575 -3607
PSMD6 3031 -4213
PSMD5 4489 -2216
PSME2 3072 -3228
SMOX 3861 -2367
PSMD8 4998 -1500
PSMC4 4381 -1547
PSMD4 3582 -1267
PSMC3 4518 -761
PSMB10 3033 -979
PSMB2 3836 -514
OAZ2 207 -2830
PSMC2 5346 -32

Click HERE to show all gene set members

All member genes
rna meth
AMD1 5691 -4327
AZIN1 -63 4868
NQO1 3001 80
OAZ2 207 -2830
PAOX 5683 732
PSMA1 4448 4295
PSMA3 -537 -2323
PSMA6 5492 2708
PSMA7 5337 -3323
PSMA8 5181 1056
PSMB10 3033 -979
PSMB11 -67 -1629
PSMB2 3836 -514
PSMB4 4220 4097
PSMB6 4575 -3607
PSMB7 4175 -4520
PSMB8 3444 3538
PSMB9 4631 -3753
PSMC1 4461 112
PSMC2 5346 -32
PSMC3 4518 -761
PSMC4 4381 -1547
PSMD1 5507 5589
PSMD11 3386 1762
PSMD13 3352 1458
PSMD14 3173 4254
PSMD2 3397 -4943
PSMD3 4078 157
PSMD4 3582 -1267
PSMD5 4489 -2216
PSMD6 3031 -4213
PSMD7 4280 5170
PSMD8 4998 -1500
PSME2 3072 -3228
PSME3 3713 5601
PSME4 -3812 5257
PSMF1 4976 229
SMOX 3861 -2367
SMS -3956 4163
SRM 5491 428



Phase 2 - plateau phase

Phase 2 - plateau phase
metric value
setSize 17
pMANOVA 0.000213
p.adjustMANOVA 0.00138
s.dist 0.575
s.rna -0.535
s.meth -0.213
p.rna 0.000136
p.meth 0.129




Top 20 genes
Gene rna meth
CACNA2D4 -4950 -4179
CACNB1 -3979 -3669
CACNA2D3 -4031 -3366
CACNG3 -2761 -4830
KCNE4 -2735 -4406
CACNA1C -5019 -2147
CACNA1D -4232 -407
CACNG4 -641 -2176
CACNA2D2 -82 -607

Click HERE to show all gene set members

All member genes
rna meth
AKAP9 -3504 866
CACNA1C -5019 -2147
CACNA1D -4232 -407
CACNA1S 1874 -4310
CACNA2D2 -82 -607
CACNA2D3 -4031 -3366
CACNA2D4 -4950 -4179
CACNB1 -3979 -3669
CACNB2 -4896 2960
CACNB3 2547 -1656
CACNB4 -1724 1546
CACNG2 -1336 4247
CACNG3 -2761 -4830
CACNG4 -641 -2176
KCNE3 -5030 3270
KCNE4 -2735 -4406
KCNQ1 -4201 2587



Digestion

Digestion
metric value
setSize 11
pMANOVA 0.00437
p.adjustMANOVA 0.0201
s.dist 0.574
s.rna -0.572
s.meth 0.0546
p.rna 0.00103
p.meth 0.754




Top 20 genes
Gene rna meth
AMY1A -5144 3022
AMY1B -5144 3022
AMY2A -5144 3022
AMY2B -5144 3022
CEL -4433 1647

Click HERE to show all gene set members

All member genes
rna meth
AMY1A -5144 3022
AMY1B -5144 3022
AMY2A -5144 3022
AMY2B -5144 3022
CEL -4433 1647
GUCY2C -3337 -5047
LCT 905 -3333
MGAM 130 3426
PIR 4857 -2828
PNLIP -4390 -185
PNLIPRP2 -4332 -233



Cap-dependent Translation Initiation

Cap-dependent Translation Initiation
metric value
setSize 45
pMANOVA 2.26e-10
p.adjustMANOVA 1.08e-08
s.dist 0.574
s.rna 0.557
s.meth 0.139
p.rna 1.05e-10
p.meth 0.108




Top 20 genes
Gene rna meth
RPL11 5637 5596
EIF2B3 5490 4863
RPS9 4671 5151
RPL38 3889 5651
RPS6 3660 5059
EIF4G1 3535 5052
RPL23A 4758 3359
RPL5 5219 2810
EIF3G 3436 3889
EIF3B 3906 3162
RPL37 4161 2628
EIF4EBP1 4082 2624
RPS26 3887 2685
RPL14 1794 5403
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855

Click HERE to show all gene set members

All member genes
rna meth
EIF2B1 5046 17
EIF2B2 3421 -3204
EIF2B3 5490 4863
EIF2B4 3754 -4571
EIF2B5 2722 -2647
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4EBP1 4082 2624
EIF4G1 3535 5052
EIF4H 3553 1782
EIF5B -313 -1081
FAU 3058 -2417
RPL10 4070 -226
RPL11 5637 5596
RPL14 1794 5403
RPL15 1498 1903
RPL22 2609 -1826
RPL22L1 -3752 3443
RPL23A 4758 3359
RPL26 4540 -4716
RPL28 5332 -1109
RPL3 4305 -1627
RPL31 5358 -3687
RPL34 4708 -1609
RPL37 4161 2628
RPL38 3889 5651
RPL3L -5130 3767
RPL5 5219 2810
RPL7 4102 307
RPL8 3994 -291
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Eukaryotic Translation Initiation

Eukaryotic Translation Initiation
metric value
setSize 45
pMANOVA 2.26e-10
p.adjustMANOVA 1.08e-08
s.dist 0.574
s.rna 0.557
s.meth 0.139
p.rna 1.05e-10
p.meth 0.108




Top 20 genes
Gene rna meth
RPL11 5637 5596
EIF2B3 5490 4863
RPS9 4671 5151
RPL38 3889 5651
RPS6 3660 5059
EIF4G1 3535 5052
RPL23A 4758 3359
RPL5 5219 2810
EIF3G 3436 3889
EIF3B 3906 3162
RPL37 4161 2628
EIF4EBP1 4082 2624
RPS26 3887 2685
RPL14 1794 5403
EIF4H 3553 1782
EIF3K 4368 1438
EIF3I 3878 1541
EIF3F 5240 970
RPS24 2515 1670
RPS27 3357 855

Click HERE to show all gene set members

All member genes
rna meth
EIF2B1 5046 17
EIF2B2 3421 -3204
EIF2B3 5490 4863
EIF2B4 3754 -4571
EIF2B5 2722 -2647
EIF2S2 2196 95
EIF3B 3906 3162
EIF3D 4386 -3212
EIF3F 5240 970
EIF3G 3436 3889
EIF3H 4788 140
EIF3I 3878 1541
EIF3K 4368 1438
EIF3L 5227 -4139
EIF4B -304 4545
EIF4EBP1 4082 2624
EIF4G1 3535 5052
EIF4H 3553 1782
EIF5B -313 -1081
FAU 3058 -2417
RPL10 4070 -226
RPL11 5637 5596
RPL14 1794 5403
RPL15 1498 1903
RPL22 2609 -1826
RPL22L1 -3752 3443
RPL23A 4758 3359
RPL26 4540 -4716
RPL28 5332 -1109
RPL3 4305 -1627
RPL31 5358 -3687
RPL34 4708 -1609
RPL37 4161 2628
RPL38 3889 5651
RPL3L -5130 3767
RPL5 5219 2810
RPL7 4102 307
RPL8 3994 -291
RPS14 457 -707
RPS19 2645 -81
RPS24 2515 1670
RPS26 3887 2685
RPS27 3357 855
RPS6 3660 5059
RPS9 4671 5151



Here is the session info with all the versions of packages used.

sessionInfo()
## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.4 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## attached base packages:
## [1] stats     graphics  grDevices utils     datasets  methods   base     
## 
## other attached packages:
##  [1] pkgload_1.1.0   GGally_2.0.0    ggplot2_3.3.2   reshape2_1.4.4 
##  [5] beeswarm_0.2.3  gplots_3.0.3    gtools_3.8.2    tibble_3.0.1   
##  [9] dplyr_1.0.0     echarts4r_0.3.2 mitch_1.0.6    
## 
## loaded via a namespace (and not attached):
##  [1] Rcpp_1.0.4.6       assertthat_0.2.1   rprojroot_1.3-2    digest_0.6.25     
##  [5] mime_0.9           R6_2.4.1           plyr_1.8.6         backports_1.1.8   
##  [9] evaluate_0.14      highr_0.8          pillar_1.4.4       rlang_0.4.6       
## [13] gdata_2.18.0       rmarkdown_2.3      desc_1.2.0         labeling_0.3      
## [17] stringr_1.4.0      htmlwidgets_1.5.1  munsell_0.5.0      shiny_1.5.0       
## [21] compiler_4.0.2     httpuv_1.5.4       xfun_0.15          pkgconfig_2.0.3   
## [25] htmltools_0.5.0    tidyselect_1.1.0   gridExtra_2.3      reshape_0.8.8     
## [29] crayon_1.3.4       withr_2.2.0        later_1.1.0.1      MASS_7.3-51.6     
## [33] bitops_1.0-6       grid_4.0.2         jsonlite_1.7.0     xtable_1.8-4      
## [37] gtable_0.3.0       lifecycle_0.2.0    magrittr_1.5       scales_1.1.1      
## [41] KernSmooth_2.23-17 stringi_1.4.6      farver_2.0.3       promises_1.1.1    
## [45] testthat_2.3.2     ellipsis_0.3.1     generics_0.0.2     vctrs_0.3.1       
## [49] pbmcapply_1.5.0    RColorBrewer_1.1-2 tools_4.0.2        glue_1.4.1        
## [53] purrr_0.3.4        parallel_4.0.2     fastmap_1.0.1      yaml_2.2.1        
## [57] colorspace_1.4-1   caTools_1.18.0     knitr_1.29

END of report